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Abstract 
Trypanosomiasis is still prevalent in endemic areas despite the recently reported 
gains in control of the disease. A major setback to disease control is the 
emergence and spread of strains of the parasites that are resistant to available 
anti-Trypanosoma drugs, in addition to the toxicity and difficulty in the 
administration of the drugs. In Trypanosoma brucei, drug sensitivity and 
resistance depend on transporters mediating the uptake and efflux of 
chemotherapeutic agents. A typical example is the aminopurine transporter, 
TbAT1/P2, which is involved in the uptake of diamidines and arsenical drugs 
including pentamidine, diminazene aceturate and melarsoprol. A loss of 
TbAT1/P2, and of the High Affinity Pentamidine Transporter, HAPT1, gives a 
high pentamidine-melarsoprol cross-resistance phenotype. The related parasite 
T. congolense has a major amplification of the Equilibrative Nucleoside 
Transporter (ENT) family, but phylogenetically most of these cluster as 
nucleobase transporters rather than nucleoside transporters (P1-cluster) and has 
no members in the nucleoside/nucleobase transporter part of the tree (P2 
cluster). As such, T. congolense does not have a counterpart with similar 
functionality to TbAT1, and as a result, it is less sensitive to diminazene, the 
main drug for the treatment of T. congolense infection. However, another 
important class of potential drug transporters in chemotherapy, the Major 
Facilitator Superfamily (MFS), present in T. congolense, is suspected to mediate 
both the import and efflux of metabolites and quite possibly drugs, contributing 
to drug resistance phenotypes.  
The efflux-associated functions of MFS and similar transporters could include the 
extrusion of cAMP, which is known to be released from trypanosomes. This helps 
to control the level of cAMP in the cell, along with the Phosphodiesterases 
(PDEs), which catalyse the breakdown of cAMP to AMP. T. brucei PDEB1/B2 has 
for some time been considered as a drug target since inhibition of their activity 
prevents cAMP degradation, leading to toxic levels of the compound in the cell 
and eventual death. However, results from various experiments indicate that the 
effectiveness of this phenomenon is limited by a mechanism involving the 
exportation of excess cAMP from the cell. Thus, the efflux transporters of cAMP 
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have become an important and interesting topic in the pharmacology of PDE 
inhibitors as a potential drug target. Unfortunately, details of the mechanisms of 
this process are not available. 
Eight T. congolense genes of some MFS, Multidrug and Toxic Compound Extrusion 
(MATE) and related transporter family members were cloned and expressed in 
various T. brucei lines in order to assess their ability to affect drug sensitivity, 
either in the direction of sensitisation or resistance. Next, the T. brucei 
orthologues of several of these transporter genes were manipulated by RNA-
interference, single or double knock out, and the specific gene-nulled 
phenotypes were used in carefully designed experiments to investigate some of 
the issues aforementioned.  
The expression of the T. congolense transporters in drug-sensitive and resistant 
T. brucei, showed that three T. congolense transporter proteins (MF5.2, MF7.1 
and MF18.8) caused significant increases in resistance to Pentamidine in T. 
brucei clone ISMR1, a clone adapted to high levels of resistance to 
isometamidium (ISM) but sensitive to pentamidine. Careful analysis of the 
observations made in these experiments suggests that at least some of these 
transporters could be involved in the efflux of drugs from the cell. We can also 
confirm that some of the genes investigated, especially MF5.2, are essential for 
the long-term survival of the parasites. MF5.2-null T. brucei cell lines, 
constructed by the introduction of an inducible copy of TcoMF5.2 prior to 
deletion of both TbrMF5.2 alleles, showed a significantly increased sensitivity to 
ISM, and CpdA, a potent inhibitor of TbPDEB1/B2. The cell line was also found to 
be significantly resistant to suramin. Indeed, the data indicate that the 
transporter protein encoded by MF5.2 could be involved in efflux rather than 
uptake of ISM and CpdA whilst also influencing the uptake of (or sensitivity to) 
suramin.  
Single or double knockout of the MF7.1 gene resulted in a significant reduction in 
the uptake of ISM when compared with uptake of the compound into the wild-
type (WT s427) parasites. Parasites with null MF18.8 gene were also seen to 
exhibit lower sensitivity to ISM, suggesting that the transporter protein encoded 
by this gene could be involved in the efflux of the drug, or perhaps its 
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intracellular sequestration. The same phenomenon could explain the response of 
these gene-edited parasites to ethidium, and CpdA. In order to understand and 
assess the involvement of some of the MF genes in transportion of compounds in 
the parasite, one allele of TbrMF5.2 was deleted from null TbrMF7.1 parasites to 
generate a null MF7.1+heterozygote MF5.2 cell line. Deleting a single MF5.2 
allele from a null MF7.1 parasite causes these parasites to be significantly 
resistant to diminazene and isometamidium, with a Resistance Factor in one 
clone reaching 6.0 for isometamidium. Similarly, deleting a single MF7.1 allele 
from null MF18.8 parasites drives the ISM EC50 to approximately 3.5-fold the 
value of wild-type T. brucei s427. Collectively, this work is the first to address, 
describe and confirm the activity of MATE and MFS genes as a transporter for 
important compounds or drugs used in the current and/or experimental 
treatment of both human and animal trypanosomiasis and previously un-
discovered basis of resistance to these compounds. The cellular localisation of 
the genes, mostly in the plasma membrane, support the potential for these 
proteins to be involved in the suggested functions, and makes them easier to be 
targeted by newly designed trypanocides. Finally, we describe here the first 
transporter/symporter for cAMP, which is potentially very important, especially, 
in the quest to use PDEs as new therapies in the treatment of trypanosomiasis. 
The development of specific inhibitors for some of these transporters will allow 
the possibility of the application of combination therapy, and to reverse 
developed resistance. 
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Definitions/Abbreviations 
3H  Tritium 
AAT Animal African Trypanosomiasis  
AATr  Amino acid transporter  
AB  Assay buffer 
AC  Adenylyl Cyclase 
AMP Adenosine monophosphate 
ATP  Adenosine triphosphate 
BSA Bovine serum albumin 
BSF  Bloodstream form 
cAMP Cyclic adenosine monophosphate 
CpdA  tetrahydrophthalazinone compound A  
dH2O  
DIM 
distilled water 
Diminezene 
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DMSO Dimethyl sulphoxide 
dNTP  Deoxynucleotide triphosphates  
EC50 Effective concentration inhibiting 50% cell proliferation 
ELISA 
ENT 
Enzyme-linked immunosorbant assay 
Equilibrative Nucleoside Transporter 
EPAC 
ETH 
Exchange Protein Activated by cAMP 
Ethidium 
F Flagellum 
FBS/FCS Foetal Bovine Serum/Foetal Calf Serum FP Flagellar Pocket 
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GAF -domain Allosteric binding domain named after cGMP-specific and 
binding phosphodiesterases adenylyl cyclase of Anabaena and FhlA of 
E. coli GC Guanylyl cyclase 
gDNA Genomic DNA  
GFP Green Flouresence Protein 
GPCR G-Protein Coupled Receptors 
GPI Glycophosphatidylinositol 
HAPT  High affinity pentamidine transporter  
HAT Human African trypanosomiasis 
HMI-9 Hirumi's medium 9 
IBMX Isobutylmethylxanthine 
IFA 
ISM 
Immunoflouresence assay 
Isometamidium 
K 
K/O 
Kinetoplast 
Knock out 
L Litre 
LB Luria broth 
MATE Multidrug and toxin extrusion  
MFS  The major facilitator superfamily  
mRNA Messenger-ribonucleic acid 
MS Mass Spectrometry 
N Nucleus 
o.e 
O/N 
Overexpression 
Over Night 
ORF Open reading frame 
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PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDE 
PEN 
Phosphodiesterase enzyme 
Pentamidine 
PFR Paraflagellar rod 
PK Protein kinase 
PKA Cyclic adenosine monophosphate-specific protein kinase 
PKA-C Catalytic subunit of PKA 
PKA-R Regulatory subunit of PKA 
PKC Calcium/calmodulin-specific protein kinase 
QRT-PCR 
RF 
Quantitative Reverse Transcription PCR 
Resistance Factor 
RNAi RNA interference 
rpm Revolutions per minute 
RT Reverse transcriptase 
SDS Sodium dodecyl sulphate 
SEM Standard error of mean 
sKO 
SUR 
Single knockout 
Suramin 
Tb427 Trypanosoma brucei strain 427 
TbAT Trypanosoma brucei adenosine transporter 
TbrPDEB Trypanosoma brucei phosphodiesterase enzyme B  
TcrPDEB Trypanosoma cruzi phosphodiesterase enzyme B 
Tet  Tetracycline 
TPR Tetratricopeptide Repeats 
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TM  Trans-membrane 
UTRs Untranslated regions 
UV  Ultraviolet 
VSG  Variant surface glycoprotein 
WHO World Health Organization 
WT  wild type 
  
  
General Introduction 
 
1.1 General Introduction 
African Trypanosomiasis, caused by certain species of trypanosomes 
(Trypanosoma spp), is a zoonotic disease which affect significant number of 
humans (Human African Trypanosomiasis, HAT) and animals (Animal African 
Trypanosomiasis, AAT) living in disease-endemic areas of the world. 
Trypanosomiasis derives its name from the genus of the causative parasite, 
Trypanosoma, which is a member of the order of Trypanosomatids, and belongs 
to the kinetoplastid class of protozoa. These protozoa are motile due to their 
flagellum and are unicellular members of Eukaryota (Seebeck et al., 2011). 
The disease poses a significant threat to human lives and is a big challenge to 
agriculture development in these areas. Trypanosoma brucei species include the 
causative agents of sleeping sickness, Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense, in addition to the livestock-pathogenic, 
Trypanosoma brucei brucei. Reports indicate that there have been a significant 
decrease in the incidence of the human disease (Morrison et al., 2016; Isaac et 
al., 2017). However, it must be emphasised that the animal disease still poses a 
huge problem. AAT has a significant impact on agricultural production in Africa 
(Shaw et al., 2015), being responsible for the death of about three million cattle 
every year, with fifty-five million cattle, thirty million sheep and forty million 
goats at risk of the disease (Giordani et al., 2016). In sub-Saharan Africa, where 
the greatest burden of AAT is felt, most infections are caused by Trypanosoma 
vivax, Trypanosoma congolense and Trypanosoma brucei brucei; with 
Trypanosoma congolense causing the most severe forms of AAT. T. brucei 
gambiense, which is endemic in more than 20 west and central African 
countries, is responsible for over 95% of the reported instances of sleeping 
sickness (WHO, 2018). T. b. rhodesiense which is present in 13 eastern and 
southern Africa countries accounts for under 3% of currently reported cases 
(WHO, 2018).  
Trypanosomiasis is transmitted to humans through the bites of the tsetse fly, 
which includes the Glossina palpalis and Glossina morsitans species (WHO, 
2013). It is important to note that through effective efforts of control of tsetse 
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ﬂies and prompt diagnosis and management of patients, the disease burden has 
declined to less than 10,000 cases per year (WHO, 2017). 
Unlike most other parasitic protozoa, African trypanosomes proliferate in the 
extracellular blood of the mammalian host (Vickerman, 1985). They escape the 
host’s immune response by means of their variant surface glycoprotein (VSG) 
coat. This dense coat is frequently switched and serves as an effective barrier to 
both the innate and adaptive immune system (Engstler, 2004; Horn, 2014). “The 
active VSG gene is transcribed in one of approximately 20 telomeric expression 
sites (ESs)”. 
HAT manifests itself clinically in two stages. The first stage comprises of fever, 
headaches, and joint pains or itching. In the second or late stage the nervous 
system is affected, resulting in a disorganised sleep-wake pattern and motility 
dysfunctional. In most of the cases involving T. b. gambiense infections, there 
are usually no symptoms of the disease for several months before the parasites 
progresses and attack the nervous system. However, T. b. rhodesiense causes 
acute infections with rapid invasion of the central nervous system.  
An effective animal vaccine would be the much-needed strategy to eliminate the 
disease. However, there is no imminent prospect of developing one due to the 
afore-mentioned antigenic variation of the highly variable variant surface 
glycoprotein (VSG) of trypanosomes. Consequently, chemotherapy and 
chemoprophylaxis remain the main resort for disease control. Five drugs are 
currently being used to treat the disease in humans, of which suramin and 
pentamidine are employed for the ﬁrst, hemolymphatic stage of the disease 
whilst melarsoprol, and the combination of eﬂornithine and nifurtimox, are used 
for the second stage when the central nervous system has been attacked (Brun 
et al., 2010). However, the parasites have developed resistance to these anti-
trypanosomal drugs. It is also worth noting that some of the antitrypanosomal 
drugs are difficult to administer as they require lengthy parenteral 
administration protocols (Fairlamb and Horn, 2018). Again, Most drugs are 
associated with a high level of toxicity (Fairlamb and Horn, 2018). This situation 
calls for the discovery and development of novel anti-trypanosomal drugs, 
particularly those that target the unique metabolic system of the parasite. In 
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this regard transporters of nutrients and ions in the parasite can be an excellent 
target. Indeed, trypanosomes, like all parasites depend on the import of 
nutrients and ions from their host milieu and as such require speciﬁc 
transporters and channels for translocation of these substances. Therefore, 
detailed knowledge and understanding of the function of the parasite’s transport 
system will not only illuminate its metabolic adaptations to parasitism, but will 
also disclose vulnerable points for chemotherapeutic attack (Schmidt et al., 
2017). Recent whole genome sequencing analysis identified a viable triploid 
strain of Trypanosoma congolense. The group of Tihon demonstrated the 
presence of this triploidy at all stages of parasite life cycle and they showed 
these to be stable over time (Tihon et al., 2017). They firmly conjectured that 
the presence of viable field-isolated triploid parasites is an indication of a 
possible layer of genetic diversity in natural T. congolense populations. 
The sequence and annotation of the genome of the trypanosome parasite have 
been completed and this has, among other things, revealed the presence of 
hundreds of genes that appear to encode for transporters in the parasite. The 
majority of these transporters, however, remains uncharacterized hence their 
exact functions are largely unknown. These annotated transporters are 
reportedly involved in essential functions including nutrient uptake, release of 
waste products, ion balance and metabolite exchange between organelles 
(Schmidt et al., 2017). They also play key roles in chemotherapy, often 
mediating drug uptake and resistance. Apart from nutrient uptake, transporters 
of trypanosomes are also involved in cellular signalling (Schmidt et al., 2017). 
The major facilitator superfamily (MFS) is one of the two biggest families of 
membrane transporters ubiquitously present in bacteria, archaea, and eukaryote 
(Pao et al., 1998). Members of the MFS transport proteins are reported to be 
involved in the movement of an extensive variety of substrates crossing 
biomembranes (Quistgaard et al., 2016). Despite this knowledge, MFS 
transporters in protozoa, specifically in T. brucei species, have barely been 
studied and so their function in the parasite is very poorly understood. It has 
been speculated that MFS transporters may play a major role in cyclic Adenosine 
Monophosphate (cAMP) efflux from the parasite cells, diminishing the 
effectiveness of cAMP phosphodiesterase (PDE) inhibitors. This speculated 
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function of the MFS transporters in cAMP efflux is interesting, in that, although 
an accumulation of cellular cAMP through inhibition of phosphodiesterases 
(PDEs) is lethal to the cells, some protozoa appear to overcome this by 
regulation of their cAMP levels through efflux of excess cAMP. It must be noted 
that when a genetic change occurs in the parasite, a drug resistant phenotype 
may likely emerge with the ability to alter nutrient and ion uptake, drug 
metabolism, drug-target interaction or efflux. 
Another transporter worth studying in trypanosome is the multidrug and toxin 
extrusion (MATE) protein which are reportedly involved in translocation of 
substances in various organisms. The MATE proteins can function as molecular 
pumps to flush different drugs out of cells and confer multidrug resistance 
(Brown et al., 1999; Omote et al., 2006). 
In this project some of the genes encoding the MFS and MATE transporters in 
trypanosomes would be selected, disrupted and interrogated in order to 
understand their functions in this parasite. This thesis reports on the outcome 
and discussion of a series of experiments carried out to identify the functions of 
MFS and MATE transporters in trypanosomes and their possible involvement in 
the action of current trypanocidal drugs. Each experimental theme is reported in 
separate chapter which is preceded by a review of literature of the subject 
area. 
 
1.2 Life cycle of African trypanosomes 
Basically, two subspecies of the parasite’s complex, T. brucei gambiense and T. 
b. rhodesiense, which are morphologically indistinguishable from each, cause 
the disease in humans. The life cycle of the parasite is summarised in Figure 1.1 
followed by description of the various stages. 
The trypanosome life cycle is shown in Figure 1.1. The cycle is in two parts, one 
in the mammalian host and the other in the vector. The vector, tsetse fly, 
becomes infected with the parasite in the bloodstream trypomastigote form 
when obtaining a blood meal from an infected mammal. The parasite moves into 
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the tsetse flies midgut where they transform into procyclic trypomastigotes. 
They multiply by binary fission and leave this location as they transform into 
epimastigotes. The epimastigotes then migrate to the salivary glands multiplying 
by binary fission as it progresses to form trypomastigotes. Metacyclic 
trypomastigotes are introduced into skin tissue of an uninfected mammal when 
an infected tsetse fly attempts to obtain a blood meal. These transform into the 
replicative human infective long slender (LS) bloodstream form trypanosomes, 
which then immediately enter the lymphatic system and progress more into the 
main bloodstream of the host. Some proportion of the LS trypanosomes 
continues to the non-replicative insect-infective short stumpy (SS) stage. The LS 
trypanosomes cause the disease symptoms, however the transition from LS to SS 
has been thought to be responsible in part for the observed instances of 
prolonged infection by reducing the parasite burden on the host, and therefore 
increasing the chances of transmission (Seed and Wenck, 2003). As the 
bloodstream trypomastigotes migrate to other parts of the body (the lymph and 
spinal fluids etc) they continuously replicate by binary fission. For the lifecycle 
to continue, a tsetse fly ingests some of the SS form trypanosomes while taking a 
blood meal. 
 
Figure 1.1: The life cycle of Trypanosoma brucei.  
Reproduced from (Bonnet et al., 2015) 
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1.3 Disease burden and distribution of trypanosomiasis 
Human African trypanosomiasis is considered a neglected tropical diseases by 
the World Health Organization (WHO, 2015). Human African trypanosomiasis, 
which affects a significant number of people, is endemic in sub-Saharan Africa 
countries where an estimated 60 million people are at risk (WHO, 2010; Brun et 
al., 2010; Simarro et al., 2011). Distribution of the disease is shown in Figure 
1.2. 
According to Molyneux and colleagues, trypanosomiasis occurs amongst the 
world’s poorest populations, in regions where there are often no doctors, 
medications and sometimes insufficient food (Molyneux et al., 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Disease distribution and burden of the Human African Trypanosomiasis. 
Source: Adapted from Simarro et al., 2011 
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It must be emphasised that reasons for the continuous presence of 
trypanosomiasis in these areas is multifactorial: deteriorating economic 
conditions with its attendant funding crisis, combined with the outbreak of a 
number of wars and the AIDS epidemic in the continent (Barrett and Fairlamb, 
1999). In addition to these are the favourable environmental conditions for the 
vector responsible for transmission of the parasites to thrive. 
It has also been documented that the cost of the disease in terms of disability 
adjusted life years (DALY's) lost to HAT is around 1.5 million, making it the 
seventh in ranking compared to other diseases (Fèvre et al., 2008). In monetary 
terms, up to US$1.5 billion has been estimated to be lost annually as a 
consequence of the disease (WHO, 2017). Reports also indicate that the disease 
decreases labour resources and prevents growth of the livestock industry given 
that high yielding animals are less likely to survive the disease (FAO, 2008). The 
effect on the availability of meat and milk put deep financial burdens on farmers 
and affects the food security of sub-Saharan populations (FAO, 2008). A study by 
the group of Bukachi concluded that ‘Sleeping sickness patients and their 
households spent a lot of money seeking treatment, besides facing challenges of 
disruption of daily activities, food insecurity, neglect of homesteads, poor 
academic performance as well as school drop-outs and death’(Bukachi et al., 
2017). 
 
1.3.1 T. congolense and African animal trypanosomiasis 
Trypanosoma congolense is a species of trypanosomes that is responsible mainly 
for African animal trypanosomiasis, nagana in cattle and other animals. African 
animal trypanosomiasis causes serious economic losses in livestock from anemia, 
loss of condition and effects on reproduction. Other animals besides livestock 
that are affected include dogs. If left untreated, the infection can be fatal, and 
the mortality rate high. T. congolense are extracellular and intravascular blood 
parasites and causes this disease mainly in East and West Africa (Naylor, 1971). 
co-localisation of West & East African trypanosomiasis considered a potential 
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problem because that need different treatments for the two species and if both 
infections exist in the same area we can’t know which treatment to give without 
first doing a molecular characterisation of the trypanosome species. 
The life cycle of this parasite is complex and divided into two phases, one in the 
tsetse fly vector and one in the bloodstream of the mammalian host. Infections 
with T. congolense are more chronic than T. b. rhodesiense. In such situation 
the parasitaemia is usually low and are difficult to detect using parasitological 
methods. Anemia, which is usually present, progresses with mucous membranes 
becoming pale. Most often the infected animals lose weight and become 
extremely weak and show signs of ataxia. The subcutaneous oedema may extend 
to the head with features of severe emaciation. 
A small number of drug has been licensed for the treatment of the African 
animal trypanosomiasis. Diminazene aceturate and isometamidium chloride are 
used most often despite reported parasite resistance to these drugs. 
Compared to T. brucei, T. congolense is a strict intravascular parasite whereas 
the former can leave blood vessels and invade tissues (but not cells). This 
suggests the presence of differences in virulence mechanisms between them.  
Trypanosoma brucei (T.b.) gambiense and T.b. rhodesiense are pathogenic to 
human as they are able to infect humans and cause Human African 
Trypanosomiasis (HAT) or sleeping sickness. However, T.b. brucei is non-
pathogenic to human and only causes Animal African Trypanosomiasis (AAT) in 
wild or farm animals. It must be understood that these trypanosomes species are 
extremely closely related. According to a review by (Bonnet et al., 2017), T.b. 
brucei is not pathogenic for humans because it exists as a trypanolytic complex, 
in human serum, with a haptoglobulin and an apolipoprotein which lyse the 
parasites (Nath Baral, 2010)  . It need be emphasized that Normal human serum 
lyses T. b. brucei, while T. b. rhodesiensae is unharmed, although it quickly 
loses this serum resistance if passaged in vitro without serum. According to 
(Oethinger and Campbell, 2009), ‘the substance in serum associated with 
trypanosomal lysis, Trypanosomal Lytic Factor (TLF), is associated with HDL, and 
has been identified as apolipoprotein L-I (apoL-I)’. This substance has been 
identified as a human-specific apolipoprotein of recent evolutionary origin. This 
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protein coded by a highly modified VSG gene which binds to and inactivates 
apoL-I (Oethinger and Campbell, 2009).For this reason T. brucei is unable to 
infect humans. 
 
1.4 Symptoms of trypanosomiasis 
After being infected through the bite of the tsetse fly, the trypanosome 
multiplies in the lymph and the blood of the victim resulting in unspecific 
symptoms and signs such as fever, headache, weakness, joint pain and 
lymphadenopathy among others. Serious signs of illness may be delayed; 
however, after some time the parasite crosses the blood-brain barrier and 
transfers to the central nervous system, causing various neurological changes 
which include sleep disorder, abnormal tone and mobility, deep sensory 
disturbances, psychiatric disorders, ataxia and seizures etc (Boatin et al., 1986). 
At this stage the condition is very serious as it could results in coma and an 
eventual death. Since there are two phases of the disease, determination of the 
stage of the disease is crucial for an effective treatment. 
Generally, an infection with T. b. rhodesiense leads to an acute manifestation of 
the disease, ongoing from a few weeks to several months while in T. b. 
gambiense infections, the disease is chronic and generally progresses slowly over 
several years. 
 
1.5 Diagnosis of trypanosomiasis 
A major diagnosis requires the detection of parasites in body fluid, usually in the 
blood and lymph systems. Lack of specific signs or symptoms during the first 
stage of the disease makes early diagnosis of the disease difficult. This situation 
is compounded by the unavailability of very sensitive parasitological methods. 
Since HAT occurs in regions where there are other disease with similar clinical 
symptoms it is important to rule out other diseases such as malaria, HIV, 
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tuberculosis and various helminthic and viral infestations. Differentiating 
between acute and chronic stages of the disease is very important. This is 
because drug treatment regimens differ for the different stages of the disease. 
Examination of cerebrospinal fluid (CSF) is normally used for differentiation 
between the two forms of the disease when there are strong indications of 
infection (WHO, 1983). In the case of T. b. rhodesiense infection, this 
examination is usually performed after a dose of suramin has been administered, 
as blood parasitaemia need to be cleared before a lumbar puncture is 
performed. This is done to avoid the risk of introducing the parasite into CSF in 
cases of traumatic lumbar puncture (WHO, 1983).  
Serological screening for the presence of T. b. gambiense can also be performed 
using the Card Agglutination Test for Trypanosomiasis (CATT). Infection is then 
confirmed through parasitological tests using any body fluid to demonstrate the 
presence of trypanosomes in the patient. It is however worth stating that the 
number of parasites in body fluid can be very low and may not be easily 
detected. Therefore, a negative parasitological result in the presence of a 
positive serological test does not necessarily indicate absence of infection. The 
tests may have to be repeated over time to achieve diagnosis (www.who.int). 
The WHO diagnostic criteria for late stage HAT require the detection of 
trypanosomes in the CSF or a WBC count of more than 5 cells per μL, or both 
(Bonnet et al., 2015). Detection of HAT infection can also be performed using 
polymerase chain reaction (PCR), increased CSF proteins and EEG abnormalities. 
However, such tests are not easily applicable in the field and as such are not 
convenient methods of diagnosis. 
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1.6 Treatment of Human African Trypanosomiasis 
Chronology of arsenical and diamidine used for treatment of trypanosomiasis is 
presented in Figure 1.3. The diamidines and the arsenicals are two main classes 
of drugs used to treat trypanosomiasis in humans and Nagana in livestock (Baker 
et al., 2013). Melarsoprol and pentamidine represent the former and later 
classes of drugs respectively. 
 
 
 
 
 
Figure 1.3: History of trypanosomiasis treatment with arsenical and 
diamidine. 
Source: Adapted from Baker et al., 2013 
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Arsenicals used for trypanosomiasis treatment are organo-arsenic molecules 
containing a melamine ring that target the trypanosomes cytosol. Trypanothione 
is a primary target for aromatic arsenical derivatives against African 
trypanosomes. Melarsoprol is an arsenical and is the drug of choice specifically 
used to treat the second-stage of the disease caused by T. b. rhodesiense, when 
the central nervous system is involved. It is also used as second line drug for the 
advanced stage of T. b. gambiense infections. Unfortunately, melasoprol is 
known to contain arsenic, a highly poisonous heavy metal. Consequently the 
safety profile for the drug is unimpressive, as it is reported to cause post 
treatment reactive encephalopathy's (PTRE) in up to 10% of patients, with a 
significant mortality rate (Docampo and Moreno, 2003). Another downside of 
melarsoprol is its poor solubility in aqueous solutions, hence requires 
administeration in propylene glycol. The later compound destroys tissue and 
veins at the injection site (Legros et al., 2002). It has been suggested that 
melarsoprol acts primarily by forming a toxic adduct with trypanothione, known 
as Mel T (Alsford et al., 2012). This is achieved because melarsoprol is a 
prodrug, which is metabolized to melarsen oxide (MelOx) as its active form. 
Being an arsenic oxide, Mel Ox irreversibly binds to vicinal sulfhydryl groups on 
pyruvate kinase and thus interrupt energy production in the parasite. MelOx also 
reacts with trypanothione (a spermidine-glutathione adduct that replaces 
glutathione in trypanosomes) to form a melarsen oxide-trypanothione adduct 
(Mel T) that competitively inhibits trypanothione reductase, effectively killing 
the parasitic cell. 
Diamidines are chemical compounds that contain two cationic amidine 
(C(NH)NH2) groups. They are typical nucleic acid-binding drugs (Edwards et al., 
1992) with the ability of becoming highly concentrated within the 
mitochondrion, and destroying this organelle. Pentamidine, an aromatic 
diamidine that is administered by intramuscular injection once a day over a 
seven day treatment period (Jannin and Cattand, 2004), has been used since the 
1930s to treat human African trypanosomiasis. The drug is most effective against 
the early stage of T. b. gambiense infections, and it is thought to exert its effect 
through multiple cellular targets (Damper and Patton, 1976a; b). Pentamidine 
binds strongly to the minor groove of DNA, where, in combination with type II 
topo-isomerases, it forms mini-circle protein complexes. Such complexes occur 
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only with kinetoplast DNA (kDNA) and not genomic DNA (Shapiro and Englund, 
1990). Therefore, this drug and other diamidines are thought to kill 
trypanosomes mostly through disruption of the kinetoplast (Thomas et al., 
2018). Conversely, partly because of it serum binding and tissue retention which 
leads to reduction in blood-brain barrier traversal, pentamidine is not used for 
treatment of the advanced stage of the disease (Barrett et al., 2011). Even the 
amount that is able to traverse the blood-brain barrier faces clearance by efflux 
transporters such as P-glycoprotein and multidrug resistance-associated protein 
(Sanderson et al., 2009). It must be emphasized that through a major research 
effort, many novel diamidines have been designed and developed, including 
some with the ability to penetrate the CNS (Paine et al., 2010).  
The diamidine, 2,5-bis(4-amidinophenyl)-furan called DB75 or furamidine has 
been reported to be effective against trypanosomes (Thuita et al., 2008). DB75 
which was the first orally administered trypanocide that showed activity superior 
to that of pentamidine at comparable doses when tested against three mouse 
models. It was shown that uptake of DB75 into T. brucei occurs mainly through 
P2 transporter (Lanteri et al., 2006). In confirmation, trypanosomes lacking the 
TbAT1 gene that encodes the P2 transporter exhibited an 11-fold reduction in 
sensitivity to DB75 when measured under controlled in vitro conditions. 
Diminazene aceturate (Berenil) is a di-amidine formulated as its aceturate salt. 
It has been used as an anti-trypanosome in livestock since 1955 and has proven 
to be an effective anti-trypanosome drug. For instance changes in testicular 
morphology and function in dogs caused by an infection with T. brucei were 
reversed by treatment with diminazene aceturate (Obi et al., 2013). Diminazene 
aceturate was shown to be exclusively accumulated by the T. brucei P2 
transporter (de Koning et al., 2004). It was demonstrated that loss of this single 
transport activity is associated with high levels of parasite resistance. Since 
1955, diminazene aceturate has been widely used as a chemotherapeutic agent 
for treatment of trypanosomiasis in livestock. 
The general structures of some of the trypanocides are shown in Figure 1.4. 
Current drugs that are used to treat human African trypanosomiasis: 
pentamidine, DB75, suramin, melarsoprol and eflornithine. In addition 
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nifurtimox is utilized in combination with eflornithine. Unfortunately all the 
drugs have a certain level of toxicity and are complex to administer. 
Pentamidine and suramin are usually used to treat the first stage of T. b. 
gambiense and T. b. rhodesiense infections respectively. Eflornithine has been 
found ineffective against T. b. rhodesiense infection but can be used in 
monotherapy in the second stage of T. b. gambiense infection (Milord et al., 
1992), but this is believed to rapidly lead to resistance (Munday et al., 2014). 
Since 2009, the combination of eflornithine and nifurtimox has taken over as 
first line treatment for second stage gambiense human African trypanosomiasis 
in all disease-endemic countries (Alirol et al., 2013). The combination drastically 
decreases the required dose and duration of eflornithine administration and this 
nifurtimox-eflornithine combination therapy has enjoyed rapid implementation 
(Barrett et al., 2011). The chance for parasites to develop resistance for 
monotherapy is higher than combination therapy. Therefore, combination 
therapy is now being considered for treatment for parasitic diseases. 
Eflornithine acts on the trypanosomes through inhibition of its target enzyme, 
ornithine decarboxylase (Vincent et al., 2010), whereas nifurtimox is a prodrug 
activated by a type 1 nitroreductase, leading to the production of free radicals 
that kill the parasite (Wyllie et al., 2016).  
 
The future of HAT treatment looks promising as two new anti-trypanosomal 
drugs, oral fexinidazole and SCYX-7158, are in development (ClinicalTrials.gov, 
2015; Mesu et al., 2017). Oral fexinidazole which has undergone clinical trial, 
was found to be effective and safe for the treatment of T. b. gambiense 
infection compared with nifurtimox-eflornithine combination therapy in late-
stage HAT patient (Mesu et al., 2017). Fexinidazole is metabolised into sulfoxide 
and sulfone derivatives, both of which have strong activity against trypanosomes 
(Torreele et al., 2010).The suitability of SCYX-7158 (a benzoxaborole derivative) 
administration as a capsule was also assessed 
(https://clinicaltrials.gov/ct2/show/NCT01533961). It is indeed the first orally 
active drug treatment developed for sleeping sickness. 
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Figure 1.4: Structures of some of the trypanocides. 
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Amani S. Alhejely   Chapter 1,39 
 
1.6.1 Overview of the Diagnostic Methods Used in the Field for 
HAT 
Procedure for diagnosing both the first and second stage of HAT based on active 
screening in the field is summarized in Figure 1.5. The drugs used to treat each 
stage of the disease once diagnosis has been done are also presented in the 
figure. 
 
 
 
 
  
Figure 1.5: Diagnosis and treatment of HAT. 
Adapted from Bonnet et al., 2015 
CSF= cerebrospinal fluid CATT= Card Agglutination Test for Trypanosomiasis CTC= 
capillary tube centrifugation 
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1.7 Transporters of nutrients and ions in trypanosomes 
All parasites including trypanosomes salvage nutrients from their host milieu. 
This makes transporters of these nutrients important for the parasite physiology. 
Detail study of the parasite’s transport system will enable insight into the 
characteristics of the transporters which could be exploited further as drug 
target. Nutrient and ion transporters are therefore potential drug targets. At 
least three general types of transporters may exist in Trypanosome brucei, 
namely channels, carriers and ATPases (see  
Figure 1.6). 
 
 
 
Figure 1.6: The different types of transporters that may exist in trypanosomes. 
Source: (Schmidt et al., 2017)  
 
The various transporters that have been found to be involved in drug uptake in 
trypanosomes are shown in Table 1.1 and discussed in the subsequent sub-
section. Table 1.2 also highlights the annotated transporters that were found to 
be essential for bloodstream-form T. brucei through a genome-wide RNAi screen 
(Schumann Burkard et al., 2011). 
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Table 1.1: Transporters of Trypanosoma brucei which are involved in drug uptake 
Source: Reproduced from (Schmidt et al., 2017) 
 
Protein 
name 
Natural 
substrate(s) 
Drug 
substrate(s) 
TriTrypDB 
accession 
AT1/P2 Adenosine, 
adenine 
Melarsoprol, 
pentamidine, 
diminazene, 
cordycepin 
Tb927.5.286b 
AQP2 Water, 
glycerol, 
urea 
Melarsoprol, 
pentamidine 
Tb927.10.14170 
AAT6 Neutral 
amino acids 
Eflornithine Tb927.8.5450 
NT11.1/ATT Adenine, 
xanthine, 
hypoxanthine 
Pentamidine Tb927.9.15980 
NT12.1/ATE Adenine Pentamidine Tb927.3.590 
 
 
Table 1.2: Bloodstream‐form Trypanosoma brucei transporters and their predicted 
functions. 
These were found to be essential for the parasite through a genome‐wide RNAi screen. 
Accession Name Predicted 
function 
RNAi  
phenotype 
Tb927.4.4820 AATP10/AAT4.1 Amino acid 
transporter 
0-0-0-0 
Tb927.11.15960 AAT17.2 Amino acid 
transporter 
0-0-1-0 
Tb927.10.10880 ABCF1 ABC transporter 0-0-1-0 
Tb927.10.2880 FS179 Ca2+ channel 0-0-0-0 
Tb927.9.15460 - P-type Ca2+ 
ATPase 
0-0-0-0 
Tb927.10.12500 - P-type H+ ATPase 0-0-0-0 
Tb927.10.12510 - P-type H+ ATPase 0-0-0-0 
Tb927.9.4310 - Tricarboxylate 
carrier 
0-0-1-0 
Tb927.10.200 - Vacuolar ATP 
synthase 
0-0-0-0 
 
 
NB: RNAi phenotype is binary encoded for four conducted experiments: 0= signiﬁcant loss-
of ﬁtness, 0-0-0-0= signiﬁcant loss of ﬁtness in all tested life-stages, 0-0-1-0 = signiﬁcant 
loss of ﬁtness in bloodstream forms only. Source: reproduced from (Schmidt et al., 2017) 
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1.7.1 TbAT1 
AT1 is an aminopurine permease present in trypanosomes which mediate the 
uptake of adenine and adenosine. The transporter also facilitates the transport 
of trypanocidal substrates that are ‘adenosine-like’ (analogues) and other 
amidine motif-containing drugs such as diamidines or melamine-based arsenicals 
(Carter and Fairlamb, 1993; Geiser et al., 2005). TbAT1 is a single copy gene 
that encodes a protein of 463 amino acids containing eleven transmembrane 
domains. This transporter protein belongs to the equilibrative nucleoside 
transporter (ENT) family (Mäser et al., 1999). 
Genetic deletion of TbAT1 in T. brucei conferred resistance not only to 
adenosine analogues such as cordycepin or tubercidin but also to the diamidines, 
pentamidine and diminazene, and to melaminophenyl arsenicals such as 
melarsoprol (Matovu et al., 2003; Geiser et al., 2005; Bridges et al., 2007).  
1.7.2 TbAAT6 
AAT6 is an amino acid permease, whose physiological substrates are neutral 
amino acids (Mathieu et al., 2014). It also transports the trypanocidal amino acid 
derivative eﬂornithine (diﬂuoromethylornithine) (Vincent et al., 2010; Schumann 
Burkard et al., 2011; Baker et al., 2011).  
It has been demonstrated that TbAAT6 is not essential for the growth of 
procyclic form of trypanosomes when glucose or proline is present (Vincent et 
al., 2010). TbAAT6-RNAi lines of both bloodstream and procyclic form 
trypanosomes were observed to exhibit some resistance to eflornithine 
indicating that the drug enters the parasite through this transporter. 
1.7.3 TbAQPs 
AQPs are major intrinsic proteins (MIPs) that comprise of a superfamily of 
aquaporins and aquaglyceroporins. As reviewed by Benga in 2009, these are 
channels that facilitate the passive transport of water and small neutral solutes 
across cell membranes in organisms from bacteria to humans (Benga, 2009). 
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With regard to the T. brucei aquaglyceroporins, AQP1, AQP2, and AQP3, they 
have been reported to transport water, glycerol, urea, dihydroxyacetone 
(Uzcategui et al., 2004) , and ammonia (Zeuthen et al., 2006). AQP1 and AQP3 
have been reported in trypanosomes as flagellar membrane and plasma 
membrane proteins, respectively (Bassarak et al., 2011). 
AQP2 has been established as a High Affinity Pentamidine transporter (HAPT1), 
mediating the uptake of pentamidine (but not diminazene) and melarsoprol, 
with high affinity (Baker et al., 2012). The AQPs have also been reported to play 
a major role in melarsoprol/pentamidine cross-resistance (MPXR) (Baker et al., 
2012). Baker and colleagues first reported that AQP2 and/or AQP3, were 
associated with MPXR in a high-throughput loss-of-function screen. Graf and 
colleagues review also provided evidence implicating AQP2 in clinical cases of 
resistance (Graf et al., 2015). 
1.7.4 NT11.1 / NT12.1 
These transporters which are closely related to TbAT1, have been reported to 
mediate the uptake of pentamidine when expressed in Xenopus laevis oocytes 
(Ortiz et al., 2009). However, these results and conclusions could not be 
reproduced, despite intense efforts, in the de Koning laboratory (Munday and 
de Koning, unpublished data). 
1.8 Anti-trypanosomal drug resistance 
Drug resistance has been defined as ‘the heritable, temporary or permanent loss 
of the initial sensitivity of the population of microorganisms against the active 
substance’ (Schnitzer and Grunberg, 1957). From this definition, it can be said 
that drug resistance in T. brucei may not necessarily be indefinite. The 
emergence of parasite strains that are resistant to the anti-trypanosoma drugs 
has rendered the treatment and management of both human and animal African 
trypanosomiasis difficult. 
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In part, the indiscriminate use of the drugs has resulted in the development of 
resistance to drugs used in the treatment of trypanosomiasis: the parasites are 
able to survive in high concentrations of the drug that may not even be tolerable 
to the host. Host, vector or parasite-related factors among others may cause 
natural resistance to the drug in certain situations (Matovu et al., 2001). 
Moreover, exposure of parasites to sub-optimal anti-trypanosome drug levels 
may enhance the selection and development of true drug resistance (Burri and 
Keiser, 2001; Brun et al., 2001). Other mechanisms of parasites resistance to 
anti-trypanosoma drugs are discussed in the section below. 
 
1.8.1 Mechanism of Anti-Trypanosoma Drug Resistance 
Using in vivo and in vitro methods, trypanosomes resistant to each of the 
licensed HAT disease monotherapies have been derived through selection in the 
laboratory. Apart for that of suramin resistance (Scott et al., 1996), the 
underlying mechanisms in the others have been defined (Table 1.3). Biochemical 
assays linked with the chemistry of the compounds have enabled the 
establishment of the character of resistance mechanism in the parasite. Also, 
using various genetic approaches, it has been possible to identify the gene 
products responsible for some of the observed resistance phenotypes. “This 
broad approach was used to identify the genes encoding the trypanosome P2 
adenosine transporter, AT1” (Carter and Fairlamb, 1993; Mäser et al., 1999), 
and the amino acid transporter, AAT6 (Vincent et al., 2010), as key 
determinants of melarsoprol and eflornithine uptake, respectively, in T. brucei. 
The use of candidate-based reverse genetic approaches has enabled the 
identification of potential drug resistance determinants, such as the 
melarsoprol-trypanothione (Mel-T) transporter, multidrug resistance protein A 
(MRPA) (Shahi et al., 2002), and some nucleobase transporters related to AT1, 
NT11·1 and NT12·1, reportedly capable of taking up pentamidine (Ortiz et al., 
2009). Additionally, the trypanosome nitroreductase (NTR) has been identified as 
the activator of the pro-drugs nifurtimox and benznidazole in T. cruzi (Wilkinson 
et al., 2008). Many of these studies were made possible by the sequencing of the 
trypanosome genomes (Berriman et al., 2005; El-Sayed et al., 2005), the 
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development of reverse genetic tools, such as stable transfection, inducible 
protein expression and RNA interference (RNAi) systems (Lee and Van der Ploeg, 
1990; Lee and Van Der Ploeg, 1990; Wirtz and Clayton, 1995; Wirtz et al., 1999; 
LaCount et al., 2000; Wang et al., 2000; Alsford et al., 2005; Taylor and Kelly, 
2006; Alsford and Horn, 2008) and early forward genetic tools, such as 
trypanosome cDNA and genomic DNA libraries (Mäser et al., 1999; Shahi et al., 
2002). 
 
Table 1.3: Current drugs – their application, and resistance mechanisms identified by low 
throughput analysis of laboratory-derived and clinical resistant isolates. 
(Adopted from Alsford S et al., 2013) 
Drug Stage/Trypanosome Resistance determinant(s) 
laboratory 
Clinical 
Berenil 
(diminazene) 
T. congolense, T. vivax, 
T. b. brucei 
• adenosine transporter 1 
(AT1) 
AT1 
Isometamidium T. congolense • nda nd 
Homidium T. congolense • nd nd 
Suramin Stage 1 T. b. 
rhodesiense 
• bloodstream form-specific 
factorb 
ndc 
Pentamidine Stage 1 T. b. gambiense • AT1 
• high affinity pentamidine 
transporter (HAPT (AQP2)) 
ndd 
Melarsoprol Stage 2 T. brucei spp. • AT1 
• multidrug resistance 
protein A (MRPA) 
AT1e 
Eflornithine Stage 2 T. b. gambiense • amino acid transporter 6 
(AAT6) 
ndf 
Nifurtimox T. cruzi, stage 2 T. b. 
gambiense 
• nitroreductase (NTR) NTR 
Benznidazole T. cruzi • NTR NTR 
Notes 
aNot determined. 
bFollowing selection, a suramin-resistant phenotype was expressed in bloodstream but not insect 
stage parasites (Scott et al. 1996). 
cTreatment failures reported in west Africa in the 1950s (Pépin and Milord, 1994). 
dPentamidine resistant T. brucei can be generated in the laboratory, but they have not been 
reported in the field (Barrett et al. 2011). 
eMutation or loss of AT1 renders T. brucei less sensitive to melarsoprol, however not all resistant 
clinical isolates have modified this locus (Matovu et al. 2001). 
fEflornithine monotherapy treatment failures reported in some foci (Barrett et al. 2011), as well as a 
limited number of NECT relapses (Franco et al., 2012). 
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1.9 Major Facilitator Superfamily Transporter (MFS) 
The major facilitator superfamily (MFS) are membrane proteins expressed in 
many organisms for the transport of various substrates. The major facilitator 
superfamily (MFS) are sometimes referred to as the uniporter-symporter-
antiporter family (Baldwin, 1993; Goswitz and Brooker, 1995), illustrating their 
functional diversity. This transporter family was initially thought to be only 
involved in the translocation of sugars but subsequent studies showed that they 
play major roles in the transportation of various nutrients as well as drugs 
(Marger and Saier, 1993). The major facilitator superfamily is thought to be 
made up of more than 15000 members as new transporters are sequenced and 
added to the family (Finn et al., 2014). They are present in a wide range of 
organisms including bacteria, archaea, and eukaryotes. Families in the MFS, 
their characteristics and some of the compounds they transport in specified 
organism are presented in Table 1.4.  
All the members of the family possess a structure of either 12 or 14 putative or 
established transmembrane α-helices. Phylogenetic analyses have revealed the 
existence of 17 distinct families within the MFS family (Pao et al., 1998). It has 
been established that all the 17 families exhibit the common feature of a well-
conserved motif, present in the loop between transmembrane domains 2 and 3 
(Pao et al., 1998). These transporters perform their function by utilizing the 
electrochemical gradient of the target substrate (uniporter) or act as a 
cotransporter where transport is coupled to the movement of a second 
substrate. MFS transport varieties of compounds such as amino acids, 
nucleosides, sugars and drugs. 
MFS are made up of facilitators, symporters and antiporters, that are able to 
move substrate across membranes using varied methods such as facilitated 
diffusion, cotransport, or exchange (Yan, 2013). Using these means they are able 
to move organic and inorganic ions, nucleosides, amino acids, short peptides and 
lipids into the cells. 
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Table 1.4: Structural information for MFS transporters*TCDB 
 # is the transporter classification number obtained from the Transporter Classification 
Database, http://www.tcdb.org/.Source: Table reproduced from (Madej, 2014) 
Subfamily TCDB #* Protein Function PDB code 
Resolution 
(Rfree) Organism 
Oligosaccharide: H+ 
symporter (OHS) 2.A.1.5.1 LacY 
Lactose: H+ 
symport 
1PV6, 1PV7, 
2CFP, 2CFQ, 
2V8N, 2Y5Y, 
4OAA 
2.95 Å 
(0.298) E. coli 
Organophosphate: Pi 
antiporter (OPA) 2.A.1.4.3 GlpT 
Glycerol-3-
phosphate: 
PO4−3 antiporter 
1PW4 
3.30 Å 
(0.325) E. coli 
Drug: H+ antiporter 
(DHA1) 2.A.1.2.9 EmrD 
Multidrug 
transporter 2GFP 
3.50 Å 
(0.35) E. coli 
Fucose: H+ symporter 
(FHS) 
2.A.1.7.1 FucP 
L-Fucose: H+ 
symporter 
3O7Q, 3O7P 
3.14 Å 
(0.273) 
E. coli 
H+-dependent 
oligopeptide 
transporter (POT) 
2.A.17 PepT Peptide: H
+ 
symporter 
4IKV, 4IKW, 
4IKX, 4IKY, 
4IKZ, 4APS, 
2XUT, 4LEP 
1.90 Å 
(0.216) 
G. 
kaustophilus 
St. 
thermophiles 
Sh. oneidensis 
Sugar porter (SP) 2.A.1.1.3 XylE D-Xylose: H
+ 
symporter 
4GBY, 
4GBZ, 4GC0, 
4JA3, 4JA4 
2.60 Å 
(0.246) 
E. coli 
Solute carrier family 
(SLC22) 
2.A.1.9.10 PiPT PO4
−3 : H+ 
symport 
4J05 2.90 Å 
(0.259) 
P. indica 
Sugar porter (SP) 2.A.1.1.3 GlcP D-Glucose: H
+ 
symporter 
4LDS 3.20 Å 
(0.341) 
S. epidermidis 
Nitrate: nitrite porter 
(NNP) 2.A.1.8.10 NarU 
NO3-/NO2-/ 
exchanger 4IU8, 4IU9 
3.01 Å 
(0.316) E. coli 
Nitrate: nitrite porter 
(NNP) 
2.A.1.8.1 NarK 
NO3-/H+  
symporter (K1); 
NO3-/NO2- 
antiporter (K2) 
4JR9, 4JRE 2.60 Å 
(0.261) 
E. coli 
Glycoside-pentoside-
hexuronide: cation 
symporter (GPH) 
2.A.2.1.1 MelB 
Melibiose: Na+, 
Li+, or H+ 4M64 
3.35 Å 
(0.359) 
S. 
typhimurium 
NRT1/PTR family 2.A.17.3 NRT1.1 Low affinity 
NO3- transporter 
4CL4, 4CL5, 
4OH3 
3.25 Å 
(0.307) 
A. thaliana 
Solute carrier family 
(SLC2A1) 2.A.1.1.28 GLUT1 
D-Glucose 
uniport 4PYP 
3.17 Å 
(0.278) Homo sapiens 
The MFS transporters have been shown to be important in the uptake of 
nutrient, metabolites and multidrug resistance. These essential roles make these 
proteins essential for growth, metabolism, and homeostasis (Yan, 2013). Due to 
their importance in these biological functions, they could be employed for drug 
delivery as well as could make for drug targets (Rask-Andersen et al., 2013). 
Gene deletions, mutations and aberrations in MFS have been associated to a 
plethora of diseases which includes but not limited to gout, cancer, epileptic 
seizures and Alzheimer's disease among others (El-Gebali et al., 2013; Rask-
Andersen et al., 2013; Reimer, 2013). 
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1.9.1 Representative Structure of MFS transporter 
LacY, a lactose permease for Escherichia coli, has been used as a model for MFS. 
The structure of the transporter is shown in Figure 1.7. This permease is 
reported to mediate the transportation of a galactopyranoside and a 𝐻𝐻+ across 
the cytoplasmic membrane (Pao et al., 1998). The model transporter has been 
used to demonstrate the mechanism of translocation by members of the MFS. 
 
1.9.2 Possible Transport Mechanisms of MFS 
Because of their properties, certain protein can present as molecular tools 
through cycles of conformational changes to one energy form to another. 
Symporters, antiporters, transporters, carriers, or permeases act in this manner 
(see Figure 1.8). Symporter are integral membrane proteins that translocate 
compound across cell membranes together with a secondary substrate, usually 
Figure 1.7: Structure of LacY 
showing: (a) Side view of the inward-facing conformation of LacY; (b) Cytoplasmic 
view; (c) Topology of the internal structural repeats in the LacY. Source: reproduced 
from Madej, 2014. 
 
  
(a) (b) 
(c) 
Cytoplasmic view 
K358 
E126 D237 
D240 
R144 
90∘ 
W151 
E325 
R302 
H322 
E269 
K319 
Cytoplasmic side 
E126 
R144 
E325 
E269 D237 
H322 
W151 
D240 
R302 
K319 
 
Periplasmic side 
C 
N 
III II I 
Central 
cavity VII VIII IX 
IV V VI XII XI X 
Amani S. Alhejely Chapter 1,49 
an ion such as H+ or Na+. Thus, they achieve a more efficient and unidirectional 
transport of their substrates by translocating the ion together (at the same time) 
across the cell membrane in a direction that generates energy for the 
translocation of the main substrate, even against the concentration gradient. 
Antiporters also generate the energy for substrate translocation by co-
transporting an ion, but in the opposite direction. This is shown as an example 
for LacY and GlpT, respectively, in Figure 1.8. A final category of transporter is 
the uniporter, in which only the principal substrate is transported (e.g. GLUT1); 
these are usually equilibrative, meaning that a bidirectional exchange is being 
facilitated.  
Figure 1.8: Types of transport involving MFS. 
(I) active transports (symport, e.g., LacY, and antiport, e.g., GlpT) and facilitated diffusion 
(e.g., GLUT1). The red and green arrows shows the direction of translocation of substrate 
and co-substrate; (II) Uphill substrate (S) accumulation in response to an efflux; (III) Uphill 
transport in response to an influx. (IV) Uphill transport which depends upon the direction 
of the substrate concentration gradient. Source: Reproduced from Madej, 2014.
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Some members of MFS means of translocation of compounds in specific 
organisms can be seen in Table 1.4. The figure shows that MFS are involved in 
transport of varieties of substances including simple sugars, ions, proteins and 
many others. The transporter family are present in many organisms some of 
which are mentioned. in Table 1.4. 
1.9.3 Phylogenetic tree for the MFS 
Phylogenetic tree has been described as a hypothetical diagram showing 
evolutionary relationships among organisms. According to Bear and colleagues, 
the pattern of branching in a phylogenetic tree indicates the evolvement of a set 
of species or other groups from a series of common ancestors (Bear et al., 2016). 
As shown in Figure 1.9, it is generally assumed that two species are more related 
if they have a more recent common ancestor, and vice versa, that is, less 
related if they have a less recent common ancestor. 
 
 
Figure 1.9: Features of a phylogenetic tree. 
Source: Adapted from Bear et al., 2016 
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A phylogenetic tree for the MFS, which includes representative proteins from 
most of the families listed in Table 1.4 is shown in Figure 1.10. From the 
diagram, it can be deduced that some of the members of MFS are more related 
to each other than to others. 
 
Figure 1.10: The relatedness of the MFS including representative members of most of the 
currently recognized constituent families listed in Table 1.1. 
Source: Adapted from Pao et al., 1998 
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The relatedness of MFS in some organisms including trypanosomes is also shown 
in Figure 1.11. 
Figure 1.11: Phylogenetic tree for MFS in organisms including trypanosome. 
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1.9.4 Does MFS play any functional role in trypanosome? 
The role played by MFS transporters in trypanosoms is not clear. However, one 
MFS transporter has been shown to be present in the lysosomal membrane is 
believed to facilitate the exit of suramin from the endocytic-lysosomal system 
(Zoltner et al., 2016).  
New drug targets are being investigated in the T. brucei signal transduction 
pathway based on cyclic Adenosine Monophosphate (cAMP), which is the common 
signal transduction pathway in eukaryotes. Phosphodiesterases (PDEs) have been 
validated as possible drug targets, and inhibitors of these enzymes prevent cAMP 
degradation. Other components of the cAMP-based signal transduction include 
adenylate cyclase and protein kinase A, which would appear to be potential drug 
targets, but are yet to be validated. GAF-domains for activity and the N-
terminus for localization have been identified for several different Trypanosoma 
phosphodiesterases (Oberholzer et al., 2007; de Koning et al., 2012). The 
activities of MFS in trypanosomes, especially the possible role it play in signal 
transduction was investigated in this study. This effort constitutes the first 
attempt to determine functions of some of the MFS transporters expressed by 
trypanosomes. 
1.10 Multidrug and Toxic Compound Extrusion (MATE) 
Multidrug resistance has emerged as a major obstacle to the effective treatment 
of communicable and non-infectious diseases. Two transporter families, ATP-
binding cassette (ABC) proteins and Multidrug and Toxin Extrusion proteins 
(MATE) proteins have been shown to be involved in the excrusion of compounds 
from the cell to extracellular fluids (Lončar et al., 2016). Whilst ABC proteins 
are a large superfamily of ATP-dependent proteins that mediate the active 
transport of substrates across compounds, MATEs on the other hand functions as 
bidirectional transporters that efflux using a proton pump (Omote et al., 2006; 
Tsuda et al., 2007). Some integral membrane proteins acting as transporters are 
capable of removing toxic substances from the cell. Some of these multidrug 
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transporters constitute the Multidrug and Toxin Extrusion proteins (MATE). 
Acting as a molecular pump, they are able to extrude various drugs out of the 
cell and confer multidrug resistance (Brown B. and Williams, 1999; Omote et al., 
2006). MATE transporters constitute a family of cation antiporters (see Figure 
1.12) which naturally occur in most organisms (reviewed by (Takanashi et al., 
2014)). Members of the MATE family are involved in a wide variety of 
physiological functions, transporting a broad range of substrates. 
 
The MATE proteins which are also involved in multidrug efflux (Hvorup et al., 
2003) are predicted to have 12 alpha-helical transmembrane regions (Morita et 
al., 1998) and they contribute to multidrug resistance by exporting a wide 
variety of therapeutic drugs across cell membranes. MATE proteins are 
conserved from human to bacteria and can be categorized into the NorM, DinF 
(DNA damage-inducible protein F) and eukaryotic subfamilies (Lu, 2016). 
Members of the NorM and DinF subfamilies can utilize either the H+ or Na+ 
electrochemical gradient, while the eukaryotic MATE proteins appear to be H+-
dependent (Morita et al., 2000; Chen et al., 2002; Long et al., 2008). An 
example of a MATE structure, the substrate-bound NorM-NG is shown in Figure 
Figure 1.12: A scheme describing facilitated diffusion proteins. 
Source: reproduced from Pak et al., 2013 
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1.13 and a proposed mechanism underlining the function is shown in Figure 1.14 
Detailed understanding of the characteristic of MATE transporters is crucial as 
they hold great appeal as potential therapeutic targets for curbing multidrug 
resistance (Lu, 2016). 
 
 
 
 
 
 
 
 
 
Figure 1.13: Structure of substrate-bound NorM-NG. 
The structure is viewed from the membrane plane, and the views in (A) and (B) are 
related by 180° rotation around the membrane normal. The N and C domains of NorM-NG 
are colored cyan and yellow respectively. Monobody, a crystallization chaperone, is 
drawn as a magenta ribbon. Bound substrate is shown as magenta sticks. 
NB: C-terminus represent the end of an amino acid chain terminated by a free carboxyl 
group (-COOH) whilst the N-terminus indicate the start of a protein referring to the free 
amine group (-NH2). 
Source: Reproduced from (Lu, 2016). 
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Figure 1.14: Antiport mechanism for NorM-NG proposed by Lu is reproduced here. 
Briefly, Na+ (green circle) binds to a cation-free, drug-bound, extracellular-facing NorM-NG 
(pink) and triggers the movement of TM7 and TM8 (red arrow) in the cation-bound, drug-
bound state, causing the drug (red) to be dissociated from NorM-NG. The cation-bound, 
drug-free NorM-NG then switches to an intracellular-facing conformation (gray) to intercept 
another drug from the cytoplasm. Drug binding subsequently induces the release of Na+ 
into the cytoplasm, and the protein returns to the drug-bound, extracellular-facing state. The 
known structures (specified by their PDB codes) correspond to the 3 extracellular-facing 
states. TM1 and TM2 are simplified as a thick cyan stick, TM7 and TM8 as a thick yellow 
stick, and TM10 as a thin yellow stick, respectively. Source: (Lu, 2016) 
 
 
 
 
 
Amani S. Alhejely Chapter 1,57 
1.11 Drug uptake through nutrient and ion transporters in 
trypanosomes 
The ability of nutrient transporters in trypanosomes to also translocate 
trypanocides has been thoroughly examined (Barrett and Gilbert, 2006). As 
supported by Schmidt and colleagues, it is important to state that we could 
exploit the difference in nutrient transporters between host and parasite to 
deliver antimetabolites into the parasites to cause their death (Schmidt et al., 
2017). One consideration for exploitation of nutrient transport systems for 
delivery of novel antitrypanosome drug is that the transporter should be 
selective for the compound. Ideally, the particular transporter should have high 
affinity for the trypanocide, whereas any mammalian counterpart should 
preferably have low affinity and/or low capacity for the drug. Additionally, 
these transporters should have low abundance of competing substrates and 
uptake of compounds should be concentrative rather than equilibrative (de 
Koning and Jarvis, 1999; Hasne and Barrett, 2000).  
The P2 purine transporter in T. brucei is reportedly involved in transportation of 
anti-trypanosome drugs (Carter and Fairlamb, 1993; Carter et al., 1995; Barrett 
and Gilbert, 2006). The P2 transporter, which is encoded by the gene TbAT1 has 
been shown to mediate the uptake of melaminophenyl arsenicals and diamidines 
(Mäser et al., 1999; Matovu et al., 2003). This is also evident by the fact that 
mutation of TbAT1 results in reduced P2 uptake of the drugs and is thus 
associated with drug resistance (Carter and Fairlamb, 1993; Mäser et al., 1999). 
Diamidine and melaminophenyl arsenical entry into the cell, via this transporter, 
according to several reports, is due to the similarity in recognition motifs 
between diamidines and arsenicals and the transporter’s normal amino purine 
substrates (Tye et al., 1998; Barrett and Fairlamb, 1999; de Koning and Jarvis, 
1999; Munday et al., 2015a). It must be emphasized that the parasite can lose 
this transporter without compromising viability. This situation could result in the 
development of drug resistance without loss in virulence. Hence, new routes of 
drug delivery are essential in order to avoid cross-resistance. 
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Trypanosoma brucei also exhibit an eflornithine transporter AAT6, which could 
be described as a low-affinity low-selective transporter for neutral amino acids 
(Baker et al., 2013). Since trypanosomes salvage amino acid from exogenous 
transporters for their survival, such transporters can be considered as potential 
drug target. 
Melarsoprol and diamidine resistance to trypanosomes have been studied and 
linked the loss of certain proteins localized to the plasma membrane responsible 
for the transport of certain specific nutrients. For example, P2, mediate the 
transport adenosine and can also transport both diamidines and melarsoprol into 
the parasite. Moderate resistance has been found associated with mutations in 
P2 but high levels of resistance occurs upon the further loss of a second 
transport protein, HAPT. It has also been reported that some diamidines are 
substrates for another transporter, LAPT. 
Another nutrient transporter in trypanosome which is also involved in mediation 
of drug is TbMRPA. It has been shown that overexpression of TbMRPA led to over 
10-fold increase in the IC50 of melarsoprol (Shahi et al., 2002).
1.12 The cAMP signalling system in trypanosomes 
Cyclic adenosine monophosphate (cAMP, or 3',5'-cyclic adenosine 
monophosphate) is a second messenger that plays an important role in many 
biological processes (Figure 1.15). cAMP-dependent pathways are involved in 
signal transduction in numerous organisms. cAMP is reported to be a universal 
regulator of cellular function in many living organisms, from mammals to 
protozoa and prokaryotes (Hofer and Lefkimmiatis, 2007). In higher eukaryotes 
its formation is promoted by adenylyl cyclase activation after ligation of G 
protein–coupled receptors by ligands including hormones, autocoids, 
prostaglandins, and pharmacologic agents (reviewed by (Serezani et al., 2008). 
Protozoa do not contain any G-proteins and their adenylyl cyclases are directly 
activated by various stimuli (Gould and de Koning, 2011).  
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Figure 1.15: Formation of cAMP from ATP catalysed by Adenyl cyclase. 
Source: (Cyclic AMP and Its Action) 
 
As reviewed by Patel and colleagues, adenylyl cyclases, the enzymes that 
stimulate the synthesis of cAMP, can be classified according to their biochemical 
and structural properties into different families (Patel et al., 2001). The 
mammalian adenylyl cyclases according to the review present 12 transmembrane 
domains (families I–IX). All the isoforms involved share a conserved structure 
with two domains of six transmembrane helices (MI1 and MII) and two 
intracellular catalytic domains (CI and CII) which are highly homologous but not 
identical, both are required to achieve maximal catalytic activity (Patel et al., 
2001).  
In comparison, trypanosomatid adenylyl cyclases share little sequence homology 
with their mammalian counterparts as they present a completely different 
structure. The proteins involved have been described to have a unique 
intracellular catalytic domain, which is highly conserved, one transmembrane 
domain, and a large extracellular variable N-terminal domain, a structure that 
looks like that of guanylyl cyclase receptors (Lucas et al., 2000; Seebeck et al., 
2001).  
In T. brucei cAMP is a major trigger of the differentiation process. Bieger and 
Essen determined the high-resolution X-ray structures of the catalytic domains of 
two trypanosomal adenylate cyclase, ACs (tACs), GRESAG4.1 and GRESAG4.3 
(Bieger and Essen, 2001). The tAC domains are structurally very closely related 
to the AC domains of higher eukaryotes, but also comprise a highly conserved 
structural element near the active site, the Δ-subdomain. 
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Generally, the cAMP formed goes on to activate specific proteins such as protein 
kinase A, which goes on to phosphorylate certain cellular proteins (Figure 1.16). 
Figure 1.16: Activation of protein kinase by cAMP. 
Source (Reece et al., 2011) 
The adenylate cyclase gene (ESAG4) and probably other members of the large 
family of adenylate cyclases, encode the enzyme which plays crucial functions in 
T. brucei. Extracellular cAMP may be produced as part of the parasite's
mechanism to circumvent the host innate immunity upon infection (Salmon et
al., 2012b). It has been shown that changes in intracellular cAMP concentration
impact on trypanosomes as evidenced by the severe phenotypes upon altered
expression of enzymes involved in cAMP metabolism (Gould et al., 2013).
Phosphodiesterases (PDEs) consist of four distinct families in T. brucei (Kunz et 
al., 2006; Gould and de Koning, 2011) degrade elevated cAMP to AMP (Seebeck 
et al., 2004). This phenomenon has been studied thoroughly, resulting in the 
validation of cAMP-specific PDEs, genetically and pharmacologically, as excellent 
drug targets in the parasite (Oberholzer et al., 2007; de Koning et al., 2012). 
The combined activities of two members of the PDE family have been shown to 
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be essential in bloodstream form trypanosomes (Oberholzer et al., 2007). 
Simultaneously disrupting of both PDEB genes in T. brucei blood stream forms 
using RNAi technique resulted in an uncontrolled and sustained increase in cAMP 
concentration. This further led to cytokinesis defects which eventually produced 
multinuclear and multiflagellated cells leading to their death (Oberholzer et al., 
2007). The group of Salmon also reported a similar impaired-cytokinesis 
phenotype produced by repression of adenylate cyclase activity (Salmon et al., 
2012a). Indeed, these findings suggests that fine-tuning of cAMP levels plays a 
role in regulation of cell division, with extreme or deregulated concentrations in 
either direction being detrimental (Salmon et al., 2012a). The unique structural 
differences between the trypanosomal PDEs and the equivalent human PDEs are 
being exploited in order to increase selectivity (Orrling et al., 2012). Surface-
induced social behaviour, termed social motility, characterized by single cells 
assembling into multicellular groups that coordinate their movements in 
response to extracellular signals has been found to be an important occurrence 
in T. brucei. Oberholzer and colleagues in 2015 demonstrated that T. brucei 
social motility depends on cAMP signalling systems in the parasite's flagellum 
(Oberholzer et al., 2015). Pharmacological inhibition of cAMP-specific PDEB1 and 
B2 completely blocks social motility without impacting the viability or motility of 
individual cells (Oberholzer et al., 2015).  
New drug targets are being investigated in the T. brucei cAMP signal 
transduction pathway based on PDEs have already been validated as possible 
drug targets, and inhibitors of these enzymes have been shown to prevent cAMP 
degradation (Tagoe et al., 2015). Other components of the cAMP-based signal 
transduction involve adenylate cyclase and protein kinase A and the newly 
identified CARP proteins, whose RNAi knockdown causes resistance to PDE 
inhibitors (Gould et al., 2013). Some of these components of the cAMP signalling 
pathways may well prove to be drug targets, but have not been validated yet 
(Oberholzer et al., 2007; de Koning et al., 2012; Gould et al., 2013; Tagoe et 
al., 2015) 
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1.13 The nuclear genome of T. brucei 
There is a significant difference in many aspects of the genomes of T. brucei and 
their modes of gene expression compared to other eukaryotic model organisms 
(Daniels et al., 2010). The complete sequence of T. brucei genome, which was 
made available to the scientific community, has enabled the comprehensive 
understanding of the parasite’s behaviour from a genome-wide perspective. As 
reviewed by (Daniels et al., 2010), T. brucei are diploid and their nuclear 
genome is encompassed by 11 pairs of megabase-size chromosomes (MBCs) per 
genome as shown in Figure 1.17. The entire gene of T. brucei is ∼35 Mb per 
haploid genome and is enclosed in a nucleus with a diameter of ∼2.5 μm (Ersfeld 
et al., 1999). According to Campbell and colleagues, many aspects of the T. 
brucei genome organization and nuclear gene expression regulation are unusual 
compared to those of other eukaryotic model organisms (Campbell et al., 
2003).Reports indicate that nuclear functions such as replication and translation 
are not homogeneously distributed but compartmentalized in the parasite’s 
nucleus, and that the most distinctive nuclear compartment, the nucleolus, is 
sub structured into fibrillar and granular components (Daniels et al., 2010). 
When the cytoskeleton and endocytic trafficking systems of the parasite was 
compared with those of eukaryotes, a major difference was seen to exist among 
the two. Additionally comparison of the metabolic pathways encoded by the 
genomes of T. brucei, T. cruzi, and Leishmania major also indicated that the 
least overall metabolic capability could be found in T. brucei and the greatest in 
L. major (Berriman et al., 2005). 
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Figure 1.17: Map of the T. brucei genome showing the organization of genes according to 
their class and transcribing polymerase. 
The map is based on the v4 annotation available at www.genedb.org. Coloured bars indicate 
the positions and lengths of different genetic elements relative to the chromosome backbone 
(black line). Bars above the lines indicate transcription toward the right; bars below the lines 
indicate transcription toward the left. When a number of a similar elements are present in 
close proximity in the genome, this is indicated by n× next to bar (where n is the number of 
elements). Noncoding RNA genes have been given a minimum bar length to facilitate 
visualization. Only the largest assembled contig is represented for each chromosome. 
Chromosomes 9 to 11 have been split across two lines. Source of Figure and legend: 
(Daniels et al., 2010) 
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1.13.1 Amenability of trypanosome genome for genetic 
manipulation 
Sequencing of the trypanosome genome was completed in 2005 (Barry et al., 
2005). Detailed information on the genome is available at http://tritrypdb.org. 
The genome of T. brucei has about 9000 protein-coding genes 
(http://tritrypdb.org). Availability of the genome sequence data makes the 
search and manipulation of genes encoding specific proteins in the parasite 
possible. Various techniques are currently being used for the genetic 
manipulation of trypanosomes. Gene knockout by homologous recombination or 
RNAi-mediated silencing of gene expression can be employed to disrupt the 
normal function of selected genes in trypanosomes (Rusconi et al., 2005). 
Inducible RNAi libraries have been established to perform genome-wide screens 
for loss of function mutations (Alsford et al., 2012). 
The CRISPR/Cas9 technology of gene editing has become available for 
trypanosomatids as well, which will greatly facilitate many different forms of 
genetic modification. In this the Cas9 endonuclease can be set by guide RNA to 
introduce sequence-specific breaks in genomic DNA. “Genome modification, 
exploiting the native homologous recombination machinery, has been 
important for studies on trypanosomes but often requires multiple rounds of 
transfection using selectable markers that integrate at low efficiency” (Rico et 
al., 2018). It is worth noting that in T. brucei, DNA constructs, typically 
introduced by electroporation, can be used for gene knockout and gene 
knockdown. This is achieved by exploiting the native RNA interference 
machinery as in this study, tagging native alleles or by inducing the expression 
of recombinant products. The T. brucei core genome being diploid means that 
the gene disruption in the parasite would typically require two rounds of 
electroporation and selection (Rico et al., 2018). 
Genetic analysis indicated that except for two genes, T. brucei genes do not 
contain introns, have no strong codon bias, and can easily be expressed in 
heterologous systems such as Xenopus laevis oocytes or Saccharomyces 
cerevisiae (Schmidt et al., 2017). Since all T. brucei mRNAs carry the same 39 
nucleotide leader sequence which is spliced in trans to the 5′ end it makes the 
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cloning of cDNAs and mapping of transcription start sites very easy. Being 
unicellular and strictly extracellular parasites, as well as easily cultured in large 
quantities, T. brucei have simple topology making it suitable for the study of 
transporters of the plasma membrane or intracellular membranes using classical 
transport assays. 
Transfection is a deliberate effort of introducing nucleic acid into cells. This 
involves creating a transient pore or a ‘hole’ in the cells for the introduction of 
the DNA. Transient pores can be created using various methods including 
electroporation. In this project, different plasmids were introduced into the 
parasite using electroporation, which induces efficient transient transfection of 
the parasites and, consequently, the introduced DNA can be transcribed into 
RNA.  
1.13.2 RNAi machinery in T. brucei 
RNA interference (RNAi) refers to the introduction of homologous double 
stranded RNA (dsRNA) to specifically target a gene product of interest, resulting 
in a parasite lacking that gene caused by the ablation of mRNA. RNAi studies can 
be performed both in vitro and in vivo and this makes it a powerful means for 
the study of protein function in situ. Several trypanosomatids, including those 
organisms responsible for human and animal diseases, naturally possess the 
conditions necessary for RNAi manipulations. This allows for the use of RNAi in 
unravelling many of the pressing questions regarding the parasite's unique 
biology.  
RNA interference (RNAi) was discovered in 1998 and was immediately recognized 
as a powerful tool to study gene function and dissect the biology of organisms 
that possesses them (Fire et al., 1998). Immediately, after this discovery, T. 
brucei was found to be the first protozoan parasite to have a functional RNAi 
system. 
Experimental evidence confirms the down-regulation of mRNA as well as the 
identification of classical proteins that are required for RNAi function: TbAGO1, 
a member of the Argonaute family of proteins and two Dicer-like 
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homologues, TbDCL1 and TbDCL2 (Ngo et al., 1998; Djikeng et al., 2001, 2004; 
Durand-Dubief and Bastin, 2003; Shi et al., 2006; Patrick et al., 2009).  
However, it was discovered that the RNAi machinery in trypanosomes lack RNA-
dependent RNA polymerase (RdRp) activity neither do they harbor a potential 
gene that will code for RdRp in the genome (Siomi and Siomi, 2009). The lack of 
RdRp results in only a transient down regulation of target messenger RNA 
(mRNA) which is quite different in C. elegans where RNAi was first discovered 
(Fire et al., 1998).  
T. cruzi lacks the RNAi pathway which is attributed to the loss of the machinery 
during the evolution of the trypanosomatid lineage retention and loss of RNA 
interference pathways in trypanosomatid protozoans (Lye et al., 2010).  
A tetracycline-regulated expression dsRNA was employed to exploit the full 
potential of RNAi using vectors that allow for inducible and heritable expression 
of toxic gene products (Wirtz and Clayton, 1995; Kolev et al., 2011). 
Since then RNAi has been used extensively in trypanosomes especially in T. 
brucei as a reverse genetic method to query trypanosome biology with 
outstanding discoveries and insights that is shaping our understanding as well as 
guiding the identification of potent therapy. 
1.14 Specific aims of this investigation 
1. To identify and clone potential drug transporters from Trypanosoma 
species. 
2. To investigate whether expression of these transporters correlates 
with drug resistance. 
3. To investigate their role in drug sensitivity and cAMP efflux. 
4. To explore whether (some of) these transporters are essential, by 
creating genetic knockouts. 
  
Materials and Methods 
Here, the materials used and as well as the various techniques applied to 
research the question and provide answers are described. The techniques 
include molecular cloning and gene manipulation, drug sensitivity assays, drug 
uptake assays, immunofluorescence assays, Enzyme Linked Immunosorbant 
Assays (ELISA) and growth assays. 
2.1 Materials used in this project 
Hirumi's modified Iscove‘s (HMI-9) (Hirumi and Hirumi, 1989) (Gibco (Life 
Technologies, Paisley, UK) supplemented with 10% heat Inactivated Fetal Bovine 
Serum Gold (FBS) (PAA Laboratories Linz, Austria) was used for culturing T. b. 
brucei bloodstream forms. [3H]-Thymidine (56.6 Ci/mmol) and Scintillation fluid 
[Optiphase HiSafe III] (Perkin-Elmer, Waltham, MA, USA) were used in the uptake 
assays. In this study, all antibodies, chemicals and compounds were obtained 
from Sigma Aldrich®. Go-Taq polymerase and the dNTPs were purchased from 
Promega (Madison, WI, USA). Primers were synthesized by Eurofins MWG Operon 
(Ebersberg, Germany). The High-fidelity proofreading polymerase Phusion and 
restriction enzymes were purchased from New England Biolabs (Hitchin, UK) 
whilst Nucleospin Gel and PCR extraction kits from Macherey-Nagel® (Düren, 
Germany) were used for PCR gel and plasmid purification respectively. Nanodrop 
ND 1000 spectrophotometer (Thermo Scientific®, UK) was used for measuring 
DNA concentration. The XL1-Blue competent cells of Escherichia coli was 
purchased from Agilent Technologies® (UK) and and DH5α was a gift from the 
group of Professor Mike Barret of the University of Glasgow. CpdA was a kind gift 
from Geert Jan Sterk of Mercachem, The Netherlands.  
2.1.1 Bacterial Strains used in this project 
For all genetic cloning and plasmid construction, XL1 blue competent E. coli 
(Agilent Technologies®) and DH5α were used. A frozen sample was thawed and 
made competent using an inhouse protocol for making competent (see Appendix 
C.1 for recipe for making competent cells).  
Amani S. Alhejely   Chapter 2,69 
 
2.1.2 Trypanosoma brucei brucei lines used in this project 
Four different published strains of T. b. brucei (BSF) were used in this project. 
The foundational strain was the standard T. b. brucei strain Lister 427 
(Wildtype) from George Cross. Secondly, A multi-drug resistant B48 line created 
by deletion of the gene encoding the drug transporter TbAT1 (Matovu et al., 
2003) and further adapting to high levels of diamidine and arsenical resistance 
(Bridges et al., 2007). Thirdly, T. b. b. MITat1.2, clone 221a (2T1) strain (Alsford 
et al., 2005), generously donated by Prof. David Horn (University of Dundee). 
Finally, resistant strain ISMR1 (isometamidium resistant clone 1) derived by 
exposing the wild-type T. brucei s427 to increasing doses of isometamidium (Eze 
et al., 2016). Through genetic manipulations (gene knockouts, knockdowns, 
overexpression, among others), several mutant lines of these strains were 
generated (See Appendix B.2). 
2.1.3 Culturing of T. b. brucei lines 
Culturing of bloodstream form (BSF) trypanosomes was performed in HMI-9 
medium from Gibco supplemented with 15 g sodium hydrogen carbonate, 71.5 μl 
2-mercaptoethanol and 500 ml of FBS (PAA Laboratories Linz, Austria) per 5 
litres. The parasites were incubated at 37°C in a 5% (v/v) CO2 atm and were 
passaged twice weekly in vented flasks. To retain the tetracycline promoter, BSF 
Lister 427 cells clone 221a (2TI) were placed under phleomycin (0.5 µg/ml) and 
puromycin (0.2 µg/ml). Antibiotics were used to keep selection pressure in 
parasites that have been genetically manipulated. Blasticidin (5µg/ml), 
Hygromycin (2µg/ml) and Neomycin (0.5µg/ml) were used to select after 
transfection of plasmids into parasites. After stable transfection ans selection of 
clones, half concentrations of antibiotics were used to keep the pressure.  
2.1.4 Nucleic acid Extractions 
Extractions of DNA from plasmid and parasite (genomic DNA) was performed 
following manufactures protocol  
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(https://www.mn-net.com/tabid/1310/default.aspx, 10-10-2015). Similarly, 
extraction of RNA for cDNA and subsequent qRT-PCR was also performed just as 
indicated in the manufacturers protocol  
(https://www.mn-net.com/tabid/1311/default.aspx: 10-10-15) 
2.1.5 Nucleic acid manipulation 
Primers designed based on the Coding Sequences (CDS) of desired genes or based 
on Untranslated Regions (UTRs) were amplified in a PCR reaction using extracted 
genomic DNA (gDNA) following the PCR reaction condition below:  
Hot lid on 112 
Temperature step: 95°C for 3 minutes 
Cycle starts 35 cycles: 
Temperature step 95°C for 30 seconds 
Temperature step 55°C for 30 seconds 
Temperature step 72°C for 1.5 minutes (1 min/kb of DNA of interest) 
Cycle ends  
Temperature step 72°C for 5 minutes  
Storage at 10°C 
 
DNA from PCRs are purified following manufacturers protocol (https://www.mn-
net.com/tabid/1310/default.aspx, 10-10-2015)  
Restriction digest to free a backbone, digest an Open Reading Frame (ORF) or 
UTR for ligation to generate a plasmid construct or to confirm correctly made 
constructs were performed following this reaction steps: 
2 µg PCR product/plasmid DNA 
5 µl 10X reaction buffer 
2.5 µl enzyme A 
2.5 µl enzyme A 
X ddH2O 
Total volume 50 µl 
Amani S. Alhejely   Chapter 2,71 
 
The reaction is incubated for 1 h at 37 °C or other temperature depending on 
the enzyme. 
Ligation of ORFs and UTRs into plasmid backbones to generate complete 
constructs for transfection was performed as described below:  
150 ng of backbone DNA 
50 ng of digested inset DNA 
1 µl 10X DNA ligase buffer 
1 µl T4 DNA ligase  
X ddH2O 
Total volume 10 µl 
Reaction is allowed to ligate at room temperature (RT) for 3 h 
Completed plasmid constructs were sent for sequencing with appropriate 
primers that will allow for the complete sequencing of integrated UTR and ORF. 
Sequencing was performed by Source Bioscience, Glasgow, UK.  
To perform Quantitative Reverse-Transcriptase (qRT-PCR) 200 ng concentration 
of extracted RNA from each test and control cell lines were converted into 
Complementary DNA (cDNA) using a Reverse-Transcriptase (RT) kit 
(Primerdesign®) following manufacturers protocol  
(http://www.primerdesign.co.uk/products/9605-precision-nanoscript2-reverse-
transcription-kit?: 10-10-15). The cDNA for each sample was subsequently 
diluted with RNase free water to a concentration of 20 ng/µl for Real Time-PCR.  
Amplification of cDNA was performed in a 7500 Real Time PCR System (Applied 
Biosystems®) under these conditions:  
Anneling step 65°C for 5 min 
Extension step  42 °C for 20 mins 
Extension step 75 °C for 10 mins 
Store    10 °C/infinity 
Complementary DNA (cDNA) samples were either used immediately or stored at -
80 °C.  
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2.1.6 Bacterial transformation 
In making plasmids for genetic manipulation of parasites, ligated ORFs and UTRs 
are transformed in XL1 competent E. coli to make more plasmid DNA copies for 
subsequent transfection. The transformation process involves adding the ligated 
mix to a 50 µl XL1 blue competent cell allowed to thaw on ice. The ligated mix 
and thawed XL1 blue competent cells were mixed by flicking the tube with the 
finger 3X after which the mixture was left on ice for 30 mins. This was followed 
by heat shock in a water bath at 42 °C for 45 S and back to the ice for 3 mins. 
150 µl of Luria Broth (LB) was added after the 3 mins on ice and the mixture 
allowed to shake for 45 mins to an hour on a shaker at 37°C to activate the 
ampicillin resistance of the bacteria. A 100 µl of the transformation was then 
plated on a dry an ampicillin agar plate which was subsequently incubated 
overnight at 37°C. process described above have been also used when DH5α was 
used in RNAi.  
2.1.7 T. brucei transfections 
In preparing for transfection, generated constructs were digested using the 
appropriate enzyme in a reaction mix of 20 µg construct, 1.1 µl enzyme, 20 µl 
10X enzyme buffer topped to 200 µl with ddH2O. Digestion was performed for 4 h 
or O/N at 37 °C. The digests were cleaned using a DNA cleaning kit and following 
manufacturers protocol (https://www.mn-net.com/tabid/1313/default.aspx) 
and ethanol precipitated.  
For transfection, Bloodstream form parasites of T. b. brucei WT s427 strains, 
2TI, B48, ISMR1 cell lines were cultured to mid-log phase with a density of 1 x 
106 cells/ml. About 5 x 106 cells of culture for each transfection were 
transferred into a 15 mL centrifuge tube (Corning®) and centrifuged at 2600 rpm 
for 10 minutes at 22°C in a Heraeus Biofuge centrifuge. The supernatant was 
decanted off, and the pellet washed into 100 µl cytomix (0.01 M 
K2HPO4/KH2PO4(pH 7.6), 0.12 M KCl, 0.00015 M CaCl2, 0.005 M MgCl2, 0.025 M 
Hepes (pH 7.6), 0.002 M EDTA, adjust with 10 mol/L KOH to pH 7.6, then filter 
with 0.22 μm filter and aliquoted) solution for transfection. Ethanol-precipitated 
vector (20 µg) was mixed with the parasite in cytomix and electroporated with 
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Amaxa Nucleofector™ II electroporator (Amaxa Biosystems) with program X-001. 
Immediately after electroporation, the transfections were transferred into pre-
warmed HMI-9 with 10% FBS medium and allowed to recover for 8 – 16 hours at 
37°C and 5% CO2. Selection for clonal lines and integration was undertaken after 
recovery until the parasite was at mid-log phase. 
2.2 Bioinformatics 
An article from (Mazurkiewicz et al., 2005), proved that bacterial transporters 
have a high affinity for ethidium bromide which is structurally related to ISM. 
This alerted our collaborator Vincent Delespaux, (Vrije Universiteit Brussel, 
Belgium) who performed further literature searches (Neyfakh, 2002; Couto et 
al., 2008; Paixão et al., 2009; Coleman and Mylonakis, 2009; Lee et al., 2009) 
leading to the identification of several of these transporters (see appendix A.5). 
Through data mining he identified genes coding for these transporters and 
performed a BLAST search of the T. congolense genomic database 
(https://tritrypdb.org/tritrypdb/) with this set of transporters. See Table 2.1 for 
list of genes. 
To study the importance of these proteins on cellular activities, the encoding 
genes were genetically manipulated in these parasites. This was then followed 
with various biochemical methods to characterize the mutant parasites.  
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Table 2.1: List of MFS genes and their source. 
T congolense gene IDs, their T. brucei annotation, the names used in this thesis and their 
weblink. 
Gene ID (T. 
congolense) 
Gene ID (T. 
brucei brucei) 
Name in 
thesis 
TriTrypDB. source 
TcIL3000.0.56990 Tb927.5.2430 
 
 MF 1.1 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_0_56990 
 
TcIL3000.9.4800 Tb927.9.11810 
 
MF 2.2 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_9_4800 
 
TcIL3000.10.10620 Tb427.10.12400 
 
MF 3.1 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_10_10620 
 
TcIL3000.9.5420 Tb927.9.12960 
 
MF 4.1 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_9_5420 
 
TcIL3000.10.11980 Tb927.10.14090 
 
MF 5.2 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_10_11980 
 
TcIL3000.10.13270 Tb927.10.15480 
 
MF 6.3 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_10_13270 
 
TcIL3000.5.90 Tb927.5.470 MF 7.1 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_5_90 
 
TcIL3000.8.5380 Tb927.8.5570 
 
MF 18.8 https://tritrypdb.org/tritry
pdb/app/record/gene/TcIL3
000_8_5380 
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2.3 Generation of trypanosomal DNA constructs 
Plasmids used in this thesis is found tabulated below: 
Table 2.2: Plasmids and their sources used in generating constructs for genetic 
manipulation of trypanosomes. 
 
 
Primers used in making constructs, checking for integration, sequencing etc. is 
found in Appendix B (Primers used in research methodology in this thesis).  
Plasmid 
Name 
Description of plasmid  Propose to use in this project  
pHD1336 To do TcoMF 
expression, with PARP 
promoter  
expression of TcoMF 
1.1,2.2,3.1,4.1,5.2,6.3,7.1,18.8 
in B48, ISMR and s427WT. 
(Biebinger et 
al., 1997; 
Munday et 
al., 2013; 
Munday et 
al., 2015)  
pRPaGFP
 
 To do gene expression 
and has the Tet-
promoter for 
tetracycline induction  
The MF5.2 plasmid was 
transfected into the TbrMF5.2-/- 
to integrate into the tubulin 
locus making a TbrMF5.2-/--
TcoMF5.2e  
(Alsford et 
al., 2005)  
pGL2084 For RNAi To generate a loop that will 
interfere with the expression 
on the TbrMF5.2 (TbrMF5.2RNAi) 
(Jones et al., 
2014). 
PGL2308-
6HA 
This is a c-terminal 6x 
hemmaglutinin (HA) 
tagged 
6xHA tag was added to the C-
terminus of TcoMF5.2, 7.1 and 
18.8 expressed in B48 
(TcoMF6HA) 
Donated from 
Jeremy 
Mottram 
group. 
 
MB95  The plasmid was used 
to knockout the gene 
and replaced with 
blasticidin resistance 
marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
based on 
pTBT (Cross 
et al., 2002),  
MB96  The plasmid was used 
to knockout the gene 
and replaced with 
hygromycin as a 
resistance marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
based on 
pTBT (Cross 
et al., 2002), 
MB97  The plasmid was used 
to knockout the gene 
and replaced with 
neomycin as a 
resistance marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
 
based on 
pTBT (Cross 
et al., 2002), 
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2.3.1 Design of trypanosomal expression constructs 
The table below shows all constructs that were made and used in this thesis. 
Table 2.3: Plasmids generated for genetic manipulation of trypanosomes. 
 
 
Genomic DNA from T. b. brucei was isolated with Nucleospin tissue extraction 
kit Macherey-Nagel® (Düren, Germany) according to the manufacturer’s protocol 
(https://www.mn-net.com/tabid/1310/default.aspx, 10-10-2015) after which 
the NanoDrop ND 1000 spectrophotometer (Thermo Scientific®) was used to 
measure DNA concentrations. Extracted DNA sample was stored at –20 °C until 
use. 
Using the open reading frames (ORFs) of the MF genes found in T. congolense in 
Table 2.3, specific primers were designed for the ORFs. A forward primer from 
the start codon (ATG) and a reverse primer from each gene was designed using 
CLC Genomic workbench version 7.0. Specificity of primers were confirmed using 
BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). To allow for making 
of constructs, specific restriction sites unique to the plasmid and flanking the 
ORF were added to the forward and reverse primers to allow for insertion into 
parent plasmid pHD1336 (Biebinger et al., 1997; Munday et al., 2013, 2015b) and 
pRPaGFP (Alsford et al., 2005) (Figure 2.1 A&B). Whenever possible, primer 
sequences were designed to have between 50 to 60% GC content and to have a G 
or C at both ends. For list of all primers used in this thesis (See Appendix: Table 
B.1). 
Gene Plasmid source Constructs made 
TcoMF 1.1,2.2,3.1, 
4.1,5.2,6.3,7.1,18.8  
pHD1336  pHD1336 expressing TcoMF 1.1, 
2.2, 3.1, 4.1, 5.2, 6.3, 7.1, 18.8 
TcoMF 5.2, 7.1, 18.8 PGL2308-C- 
Terminal 
PGL2308-6xHA expressing TcoMF 
5.2,7.1,18.8 
TbrMF,5.2, 7.1, 18.8 MB95 H MB96 B 
MB97 N 
MB95, MB96, MB97 expressing 
UTRs of TbrMF,5.2, 7.1, 18.8 
TcoMF5.2  
 
pRPaGFP pRPa expressing TcoMF5.2  
TbrMF5.2 pGL2084  pGL2084 expressing TbrMF5.2 
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Figure 2.1 A&B: Trypanosomal expression vectors used in this study: 
Plasmid maps of pHD1336 and pRPaGFP showing the restriction sites, GFP and region for 
expression cassette. 
 
Amani S. Alhejely   Chapter 2,78 
 
The melting temperatures of the primers were obtained by performing a 
gradient PCR with primer pairs of each ORFs and 200 ng of isolated DNA. For PCR 
conditions see Appendix A. The PCR products were individually cleaned using 
PCR cleaning kit (https://www.mn-net.com/tabid/1313/default.aspx, and the 
fragments digested with  HindIII and BamHI for 4 hours at 37 °C using a CutSmart 
buffer (NEB®) for pHD1336 or xbaI and HindIII for pRPaGFP using cut smart buffer 
too (Neb®) in a 50 µl total reaction volume. The reaction mix was made up of 2 
µg PCR product, 5 µl 10X reaction buffer, and 2.5 µl enzyme brought to a total 
volume of 50 µl with double deionised H2O (ddH2O) and incubated for 1 h at 37 
°C. Similarly, pHD1336 plasmid DNA was digested with the same enzymes and 
same reaction mix. The digest was run on a 1% agarose gel, to separate 
backbone from inset. Backbones of pHD1336 and pRPaGFP were excised and gel 
purified following manufacturers protocol (https://www.mn-
net.com/tabid/1452/default.aspx). Ligations of DNA fragments and backbones of 
pHD1336 and pRPaGFP were performed in a 10 µl reaction (50 ng of fragment and 
150 ng of pHD1336 and pRPaGFP, one µl 10X ligase buffer and one µl T4 ligase, X 
µl ddH2O) incubated at room temperature (RT) for 3 h. 
 
The ligation mix was transformed into XL1 blue (Agilent Technologies®) 
competent E. coli (see Appendix C.1 for recipe for making competent cells) cells 
using the following procedure: 5 µl of ligation reaction was pipetted into a 
sterile 1.5 ml Eppendorf tube (Eppendorf®) tube and a 50 µl aliquot of XL1-blue 
cells defrosted on ice was then added; the mixture was incubated on ice for 30 
minutes, heat-shocked for 45 seconds at 42°C and then incubated on ice for 
another 2 minutes. 200 µl of LB broth was added and incubated at 37 °C for 1 
hour with shaking. Finally, 50 µl of the transformation reaction was spread on an 
Luria agar (LA) plates supplemented with 100 µg/ml Ampicillin (AMP-Agar plates) 
(Sigma-Aldrich®) and incubated at 37 °C overnight (O/N).  
Transformed colonies from O/N cultures were screened to check for integration 
of individual DNA fragments. For pHD1336, a forward primer (HDK429) from the 
plasmid and a reverse primer of the individual DNA fragments whilst in pRPaGFP 
HDK535 was the forward primer and reverse HDK713 (see appendix B, Table 
B.1). About ten colonies from each plate of the different MF genes were 
screened with digested plasmid and no DNA serving as controls. Positive colonies 
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corresponding to the flanking length of MF gene fragment in plasmid were grown 
O/N in 10 mL Luria broth (LB) supplemented with 100 µg/ml Ampicillin and 
plasmid extracted following manufacturers protocol (https://www.mn-
net.com/tabid/1315/default.aspx). Primers binding pre-ATG and post TAG were 
used to sequence (Source Bioscience, Glasgow, UK), correct plasmids to ensure 
correct nucleotide sequence and plasmid integration. Plasmids PHD 1336 with MF 
DNA fragments meeting the above criteria were linearized with NotI before 
transfection into trypanosomes (Figure 2.2). 
T. congolense MF5.2 (TcoMF5.2) was used to rescue T. bruce bruei MF5.2-/- 
(TbrMF5.2-/-) through the tetracycline induction system using the pRPaGFP 
plasmid. Using the procedure described above for making of MF expressing 
genes, DNA fragment of TcoMF5.2 was ligated into backbone of pRPaGFP making 
pRPaTcoMF5.2. The construct was then digested with AscI before transfection into 
TbrMF5.2-/- parasites (Figure 2.3). 
 
 
 
Figure 2.2: An example of a linearized plasmid (pHD1336) showing MF gene. After 
linearization with NotI, the plasmid integrates in the RNA spacer (sprRNA). 
The expression of the gene is under the PARP promoter (pPARP). The MF DNA fragment is 
followed by 3’ Actin-PARP (3’ ACT-PARP) and 5’ Actin (5’ACT) and Blasticidin the antibiotic 
resistance gene. The green arrows indicate primers used for the amplification of the MF 
gene whilst the purple primers check for the integration of the plasmid into the trpanosome 
 
 
 
 
 
Figure 2.3: AscI Digested pRPaGFP expression construct with TcoMF5.2 DNA 
fragment. The plasmid integrates into the ribosomal RNA fragment. 
The GFP tag and MF5.2 are under a Ribosomal RNA promoter. The hygromycin 
resistant cassette is under EP procyclin promoter. 5’ UTR and 3’ UTR are T. brucei 
aldolase mRNA processing fragments 
sprRNA 
pPARP 
MF(s) 
3’ ACT-PARP 
Linker 5’ ACT Blasticidin 
Hygromycin 
MF5.2 3’UTR 
RRNA  
promoter 
EP procyclin 
promoter 5’UTR 
GFP 
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2.3.2 Design of MF C-terminal-6x HA (TcoMF6HA) constructs 
To determine the localisation of MF genes the ORF of TcoMF5.2, TcoMF7.1 and 
TcoMF18.8 were cloned into plasmid pGL2308-6HA to generate TcoMF5.26HA, 
TcoMF7.16HA and TcoMF18.86HA constructs (Figure 2.4). The design and making of 
these constructs follow the same PCR, digestion, ligation, transformation and 
sequencing process described above for expressing TcoMF in pHD1336 and 
pRPaGFP.  
 
Figure 2.4: Plasmid map of pGL2308-6HA. 
The plasmid map showing the restriction sites, 6-HA, expression cassette (MCM8) and 
Ampicillin Resistance gene (AmpR). 
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In making TcoMF5.16HA, TcoMF7.26HA and TcoM18.86HA, the primers for 
amplification were designed to eliminate the stop codon. This allowed for a C-
terminal fusion of the 6x HA ensuring that both gene and tag are under the same 
promoter. The various DNA fragments ligated into the plasmid using XbaI and 
BamHI restriction sites. To allow for integration into the tubulin locus, the 
plasmid was digested with AscI (Figure 2.5). Parasites with integrated plasmids 
were selected using blasticidin (BSD) antibiotic.  
 
 
 
2.3.3 Design of MF knockout (MF-/-) constructs.  
The Untranslated regions (UTRs) flanking the open reading frames (OFRs) of the 
TbrMF genes were identified from the TriTrypDB 
(http://tritrypdb.org/tritrypdb/). A 5’ UTR forward and reverse primer were 
designed to amplify about 700 bp of that UTR whilst a 3’ UTR forward and 
reverse primer was designed to amplify a 700 bp region of that UTR. Forward 
and reverse primers were checked for specificity to the UTRs of these genes 
using the nucleotide BLAST feature 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). NotI and Xbal restriction 
sites were added to the forward and reverse primers of the 5’ UTRs whilst Nsil, 
and Xhol were added to the 3’ UTRs of each MF gene. This was then cloned into 
the parent vector pMB-G97 following similar cloning strategy as described above 
for making pHD1336 and pRPaGFP constructs (Figure 2.6). 
Figure 2.5: pGL2308-6HA expression constructs with the TcoMF. 
The expression of the MF-6x HA genes is driven by an actin promoter. (Actin IR). Resistance 
is driven by a Blasticidin gene. AmpR_promoter is the ampicillin promter for Ampicillin 
resistance gene  
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2.3.4 Making of TbrMF-/- constructs 
Making of TbrMF KO construct follows the same PCR, digestion, ligation, 
transformation and sequencing process described above for expressing TcoMF in 
pHD1336 and pRPaGFP. The only difference is that the steps of PCR, digestion, 
ligation and transformation and sequencing were repeated to clone in both the 
5’ and 3’ UTRs to flank the antibiotic resistance gene. The amplified 5’ UTR was 
digested with NotI and Xbal similar to the parent plasmid pMB-G97. The digested 
DNA fragments was cloned into the backbone of pMB-G97 making 5’ UTR-pMB-
G97. DNA fragments from the 3’ UTRs was amplified and also digested with NsiI 
and XhoI. The generated 5’ UTR-pMB-G97 was also digested with NsiI and XhoI. 
The 3’ UTR DNA fragments was cloned into the backbone making MF 5’ UTR-pMB-
G97Hygromycin-3’ UTR. Due to the presence of EcoRI restriction enzymes 
flanking the gene encoding for hygromycin resistance, the resistance cassette 
was digested out and replaced with genes encoding for Blasticidin and Neomycin 
Figure 2.6: Plasmid map of pMB-G97 showing 5’ and 3’ UTRs with hygromycin 
antibiotic cassette.  
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resistance to generate MF 5’ UTR-pMB-G97Blasticidin-3’ UTR and MF 5’ UTR-pMB-
G97Neomycin-3’ UTR. This resulted in 3 KO plasmids with three different 
antibiotic resistance cassettes (Figure 2.7).  
  
Figure 2.7: KO constructs designed with the various resistant cassettes to replace MF 
genes. 
The P(no.) corresponds to primer used to check for loss of gene and also the 
integration of construct into the genome of the parasite. 
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2.3.5 Making TbrMF5.2RNAi construct  
For making TbrMF5.2RNAi plasmid, the GatewayTM (Invitrogen) cloning method 
was used. Here a reaction was performed, using the attB TbrMF5.2 product, 
pGL2084 vector, TE buffer and BP Clonase II (Invitrogen) incubated at 16 oC O/N. 
Proteinase K was added to terminate the reaction, with further incubation for 10 
mins at 37 oC. TbrMF5.2 was amplified and cleaned yielding an attB MF5.2 
product (Jones et al., 2014). Heat shock and transformation in DH5α cells were 
performed as described previously. Overnight cultures from transformed colonies 
were cultured in LB broth + 100 mg/ml ampicillin in an incubator at 37 oC O/N. 
Plasmid DNA was extracted as described previously. Confirmation test digests for 
the presence of stem-loop RNAi attB MF5.2 was performed using BamHI and XBaI, 
ClaI, StuI and AscI (Figure 2.8). For list of plasmids made, see Appendix B: Table 
B.2. 
 
Figure 2.8: RNAi constructs with the attB sites for integration of MF 5.2 gene 
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2.3.6 Transfection and generation of mutant MF cell lines  
The designed constructs for generating TbrMF-/-,TcoMFe, TcoMF6HA and TbrMFRNAi 
mutant trypanosomal lines were prepared for transfection by either digestion or 
linearization with appropriate enzymes to allow for stable integration into the 
genome of the trypanosome. TbrMF-/- constructs were digested with NotI and 
XhoI generating a linear vector that can undergo homologous integration into 
UTRs of respective MF and in the process deleting the genes whilst integrating a 
gene encoding an antibiotic resistance. For TcoMFoe, plasmids were linearized 
with NotI which enables the vector to integrate into the ribosomal RNA locus 
whilst TbrRNAi was digested with AscI freeing a linearised vector that can 
integrate to replace an in-house puromycin cassette in the 2T1 parasite allowing 
selection with hygromycin. TcoMF6HA vector was also digested with AscI to 
release a linearised vector that integrates into the tubulin locus.  
In preparing for transfection, generated constructs were digested using the 
appropriate enzyme in a reaction mix of 20 µg construct, 1.1 µl enzyme, 20 µl 
10X enzyme buffer topped to 200 µl with ddH2O. Digestion was performed for 4 h 
or O/N at 37 °C. The digests were cleaned using a DNA cleaning kit and following 
manufacturers protocol 
(https://www.mn-net.com/tabid/1313/default.aspx) and ethanol precipitated. 
MF 5.2, 7.1 and 18.8 constructs with 5’ and 3’ UTRs and either Blasticidin, 
Hygromycin and Neomycin resistance cassettes were transfected into WT s427 
parasites. Expression vectors of all the TcoMF selected genes were prepared for 
transfection individually into B48 and ISMR1 parasites. TcoMF5.1, TcoMF7.1 and 
TcoMF18.8 and TcoMF3.3 vectors were also transfected into WT s427 parasites. 
MF 5.2, 7.1 and 18.8 -6x HA vectors were transfected into B48. TcoMF5.2RNAi and 
MF 5.2 knockout vectors were transfected into 2TI cell line.  
Cells were kept under selection until they were at mid-log phase. Parasites 
expressing TcoMFe were selected with Blasticidin (5 µg/ml) whilst those 
expressing TbrRNAi were selected with Hygromycin (2 µg/ml). TbrMF-/- parasites 
encoding Neomycin resistance gene were selected using 0.5 µg/ml. Transfected 
cells were cloned out using limiting dilution into 96 well plates with 3 dilutions 
(plate 1=1/24 dilution, plate 2=1/288 and plate 3=1/576). Three clones were 
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selected for each gene with preference for clones from lower dilutions. For 
TcoMFe, TcoMF6HA and TbrRNAi, integration is achieved with a single transfection. 
A single transfection of one of the KO vectors only deletes a single MF gene 
resulting in a heterozygote parasite (TbrMF+/-) expressing the resistance encoding 
gene in transfected vector. Thus, in order to generate a null MF parasite (TbrMF-
/-), additional transfection of a vector with a different resistance encoding gene 
was performed on the heterozygote TbrMF+/- parasites to generate a homozygote 
TbrMF-/- parasite expressing 2 different resistance encoding genes.  
Since the target was to generate TbrMF-/-, WT s427 parasites were transfected 
with pMB-G97 plasmids having respective UTRs and Blasticidin (B) or Hygromycin 
(H) resistance cassettes resulting in TbrMF+/B and TbrMF+/H. After selection and 
cloning out, TbrMF+/B parasites were transfected with the pMB-G97 plasmids with 
Hygromycin (H) resistance cassette whilst TbrMF+/H was transfected with pMB-
G97 plasmid with Blasticidin resistance cassette. This generated TbrMF7.1-/- and 
TbrMF18.8-/- mutant parasites. Similarly, pMB-G97 plasmids with Neomycin (N) 
resistance cassette was used in MF gene deletion making TbrMF+/N and in 
combination with either of the antibiotic resistance encoding genes to make 
TbrMF7.1-/-. 
2.3.7 Rescuing TbrMF-/- with pRPaTcoMF5.2  
The inability to obtain a double gene deletion after several attempts with the 
appropriate controls necessitated the use of alternative methods to attempt a 
double gene manipulation of TbrMF5.2. One of those methods uses the 
tetracycline (Tet) gene induction system to introduce an ectopic copy of the 
gene to rescue the phenotype (but only in the presence of Tet) when both native 
genes have been deleted. 
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To rescue TbrMF-/-, TbrMF-/B was generated in 2T1 parasites as described 
previously (2.3.5). This was followed with transfection of pRPaTcoMF5.2 plasmid 
ectopically to make TbrMF-/B-TcoMF5.2. After selection and cloning out, TbrMF-
/B-TcoMF5.2, expression of TcoMF5.2 was induced with Tetracycline to keep the 
expression of an ectopic copy of MF5.2. The second copy of TbrMF5.2 was then 
deleted using pMB-G97 with a Neomycin resistance cassette replacing this copy 
resulting in TbrMF-/--TcoMF5.2 parasites. These parasites were selected with 
Neomycin and cloned out for characterization (Figure 2.9). 
Figure 2.9: Illustrates the stages involved in the creation of a double knock out with 
rescue copy. 
The first TbrMF5.2 allele will be replaced with blasticidin, then a rescue copy 
construct of TcoMF5.2 was added in an alternative location, followed by neomycin 
replacing the second TbrMF5.2 allele. 
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For list of mutant cells generated see table below:  
Table 2.4: Cell lines generated from genetic manipulation of trypanosomes. 
 
 
2.3.8 PCR confirmation of KO, expression and RNAi plasmid 
integration generating mutant MF parasites 
Transfected mutant parasites were checked for proper integration of plasmids 
using PCR. DNA was extracted from parasites (WT s427, B48, ISMR1) transfected 
with TcoMF. A forward primer binding to a region in the plasmid before the ORF 
and a reverse primer binding to and the resistant cassette (see appendix B 
,Table B.1)were used to confirm correct integration of plasmid (Figure 2.2 and 
Figure 2.3). For TbrMF+/- TbrMF-/- (5.2, 7.1 and 18.8), confirmation of integration 
of resistant cassettes and consequently loss of genes were performed. Here 5’ 
integration was confirmed using a forward primer (see appendix B , Table B.1) 
designed to bind to a region before the 5′ UTRs and a reverse primer binding to 
the antibiotic resistance cassette whilst 3’ integration confirmation was with a 
forward primer binding to the antibiotic resistance cassette and a reverse primer 
Gene Plasmid source Cell line created 
TcoMF 1.1,2.2,3.1, 
4.1,5.2,6.3,7.1,18.8  
pHD1336  TcoMF in  B48, TcoMFin ISMR 
TcoMF 5.2,7.1,18.8 pHD1336 TcoMFKin 
TcoMF 5.2,7.1,18.8 PGL2308-C- 
Terminal 
TcoMF6HA 
TbrMF,7.1,18.8 MB95 H MB96 B 
MB97 N 
TbrMF-/- 
 TbrMF5.2 MB95 
MB96 
MB97 
TbrMF5.2+/- 
TbrMF5.2  MB95 
MB96 
MB97 
TbrMF5.2+/- 
TcoMF5.2  pRPaGFP TbrMF5.2-/--TcoMF5.2e  
TbrMF5.2 MB95 
MB96 
MB97 
TbrMF5.2-/- 
TbrMF5.2 pGL2084  TbrMF5.2RNAi 
TcoMF7.1 pHD1336 TbrMF7.1-/-- TcoMF7.1e 
TbrMF5.2 MB95 
MB96 
MB97 
TbrMF7.1-/-- TbrMF5.2+/- 
TbrMF 7.1 MB95 
MB96 
MB97 
TbrMF18.8-/-- TbrMF7.1+/- 
Amani S. Alhejely   Chapter 2,89 
 
binding after the 3′ UTRs (Figure 2.7). Further confirmation of gene deletion was 
performed by attempting to PCR the ORF. In these reactions, Wild type s427, 
B48, ISMR1 and 2TI cells were used as controls for the respective experiments. 
2.3.9 Confirmation of changes in gene expression by Quantitative 
Real Time-PCR (qRT-PCR) of mutant MF parasites 
Confirmation of knock in, RNAi knockdown, and KO of MF genes using qRT-PCR 
was carried out by measuring the changes in mRNA levels in comparison to their 
controls as previously described (Ali et al., 2013). Primers for qRT-PCR were 
designed using Primer3® (Table B.1). The constitutively expressed gene GPI8 
was used as an endogenous control (Wilson et al., 2012). To ensure proper and 
efficient binding of primers, an initial primer efficiency qRT-PCR was undertaken 
for each of the primers and the endogenous control (GPI8). This was then 
plotted using the previously described method of Pfaffl (Pfaffl, 2001) which is 
used in calculating the gene expressions.  
Firstly, Ribonuclei Acid (RNA) was extracted from transfected parasites and their 
respective control cell lines (non-transfected WT cell lines). Here, parasites 
were allowed to grow until log phase densities in HMI-9 with 10% FBS medium. 
Cells were counted, and a total concentration of 2 x 106 cells was pelleted at 
800 g for 10 minutes. The supernatant was discarded. The RNA Extraction kit 
(Machery and Nagel®) was used to extract RNA following manufacturer’s 
protocols (https://www.mn-net.com/tabid/1311/default.aspx). Extracted RNA 
was quantified using a Nanodrop (Thermo Scientific). 200 ng concentration of 
RNA from each test and control cell lines were converted into Complementary 
DNA (cDNA) using a Reverse-Transcriptase (RT) kit (Primerdesign®). The cDNA 
for each sample was subsequently diluted with RNase free water to a 
concentration of 20 ng/µl for Real Time-PCR. Amplification of cDNA was 
performed in a 7500 Real Time PCR System (Applied Biosystems®) under these 
conditions (Anneling step: 65 °C/5 min; Extension step: 42 °C/20 mins followed 
by 75 °C/10 mins and then Store 10 °C/infinity). To ensure that only single 
strand of DNA is being amplified, a dissociation curve was used. Controls include 
no cDNA and samples that have not been reversed transcribed. The entire 
experiment was performed on three independent occasions, starting from cell 
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culture and RNA isolation of the different cell lines. Fold change was calculated 
using the determined primer efficiency in a spreadsheet (Pfaffl, 2001).  
2.4 Analysis of recombinant parasites 
2.4.1 Growth curve of TbrMF5.2 RNAi cell line. 
A study of the growth phenotype of TbrMF5.2 RNAi cell line and its 2T1 control 
was performed to determine the effect of knockdown of TbrMF5.2 on cell growth 
and gene essentiality. Bloodstream cells of the test and control cells were 
seeded at 2 × 104 cells ml-1 in 24-well plates with and without tetracycline 
added. The plates were incubated at 37 °C and 5% CO2. Cells were counted 
every 24 h using a haemocytometer. Cells were diluted to the initial starting 
concentration of 2 × 104 when they get to a log phase every 48 h. A technical 
replicate was set up for each condition whilst the entire experiments were 
performed on three independent occasions to obtained three biological 
replicates. GraphPad® Prism 5 software was used to generate linear regression 
curves. 
2.4.2 The effect of expression, RNAi and deletion of MF genes on 
their sensitivities to common trypanosomal compounds. 
Drug sensitivity assays for ISM, pentamidine, diminazene, ethidium and CpdA (de 
Koning et al., 2012) were performed using the dye Alamar blue dye (Resazurin 
sodium salt, 0.0125% w/v solution in PBS). The assay will indicate whether cells 
are dead or alive, as the metabolism of live cells will turn the non- fluorescent 
blue dye into fluorescent pink. The drugs were serially diluted in 100 μl of HMI-9 
media across two rows on a 96 wells plate, with one plate for each cell line. 
Three clones of each line under investigation were diluted to a density of 2 x 105 
cells/ml, and then 100 μl (2 x104 cells) were added to all wells containing 100 µl 
of HMI-9 media, giving a final density of 1 x 104 cells/well. The plates were 
incubated at 37 °C, 5% CO2 for 48h after which Resazurin blue dye was added to 
all the wells followed by additional incubation at 37 °C, 5% CO2 for 24 h., After 
the final incubation, the plates were read using a fluorescent plate reader 
FLUOstar Optima (BMG Labtech) fluorimeter at 530 nm and 590 nm, excitation 
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and emission respectively. EC50 values were subsequently determined using the 
GraphPad® Prism 5 software. No drug and no cell controls were performed for 
each cell line and clone. 
2.4.3 Measurement of Cyclic AMP levels in MF overexpressing 
cell lines 
CpdA a phosphodiesterase inhibitor has been shown to increase cAMP 
concentration is in trypanosomes (de Koning et al., 2012; Gould et al., 2013) 
synonymous to RNAi inhibition of TbPDEB1 (Oberholzer et al., 2007). 
Intracellular and extracellular levels of cAMP in MF mutants were measured 
following the protocol described in (de Koning et al., 2012; Gould et al., 2013) 
with minor modifications.  
To determine the concentration of extracellular cAMP levels in MF mutants, 
these parasites and their controls were grown to log-phase concentrations from 
an overnight (O/N) incubation of about 2 x 106. The parasite from the O/N 
incubation was then split into 2 or 3 flasks with 2x and 5x EC50 concentration of 
CpdA added to 2 of the flasks (CpdA +) whilst the other was retained as a control 
(CpdA -). All were further incubated for a further 3 h after which a total of 5 x 
106 parasites was counted for both sets of flasks and then separated by 
centrifugation at 800 g, 10 minutes at 4 ºC. 1 ml of the supernatant was 
carefully removed into labelled eppendorfs and kept at -80 °C for extracellular 
cAMP assay. To obtained intracellular cAMP samples, the rest of the supernatant 
was discarded, and the cell pellet resuspended in 100 µl 0.1 M HCl and left on 
ice for 20 minutes to complete cell lysis. The samples were centrifuged at 
16,000 g for 10 minutes at 4 ºC and the supernatant transferred to newly 
labelled eppendorf and stored in a freezer at -80 ºC.  
To assay for cAMP concentrations, the instructions from Cyclic AMP ELISA 
Immunosorbent Assay (EIA) Kit (Cayman Chemical Company, Missouri, USA) 
(https://www.caymanchem.com/Search?q=cAMP) was strictly followed as briefly 
described. Firstly, assay specific buffers, standards and samples were prepared 
according to recommended protocols (intracellular samples were diluted 1 in 
two with EIA buffer). The Non-acetylated cAMP assay protocol was performed in 
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96 well plates pre-coated with mouse monoclonal cAMP-specific rabbit 
antiserum. Standards (double wells), blanks, buffer, tracer and cAMP-specific 
rabbit antiserum, were prepared and added to 96 well plates. This was followed 
by samples after which the plate was incubated for 18 hours. This was followed 
by washing and developing with Ellman’s reagent for two hours. The plates were 
read on Dynex® Technologies Revelation plate reader to detect absorbance at 
450 nm . Each sample was assayed in duplicate whilst the whole experiment 
from sample preparation to cAMP measurement was performed independently on 
at least three occasions. cAMP was measured in pmol/ml. Graphs are a plot of 
Mean and SE of 3 to 6 independent biological replicates 
2.4.4 Transport Assays: 
Using the standard uptake technique as described for T. b. brucei (Wallace et 
al., 2002; Al-Salabi and de Koning, 2005; Gudin et al., 2006), the time-
dependent uptake of radiolabelled compounds was investigated. Trypanosomes 
were washed by mixing with Assay Buffer, (AB) made of (33 mM HEPES, 98 mM 
NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM 
MgCl2, 23 mM NaHCO3 and 14 mM glucose, pH 7.3). After allowing it to stand for 
a brief period, the cells were pelleted by centrifugation at 1,000 g for 10 min. 
The washing was repeated after which the cell pellet was resuspended at a 
density of 108 cells /ml in AB for the designated experiment. The cells left for 
20–30 minutes at room temperature to recover from centrifugation stress. 100 μl 
of cell suspension were incubated at ambient temperature for a predetermined 
time with 100 μl radiolabelled test compound, in the presence or absence of 
unlabelled substrate or other competitive inhibitors before transferring to a 
sterile 1.5 ml microfuge tube containing 300 μl of oil mix (1:7 mixture of light 
mineral oil and di-n-butylphthalate). An ice-cold stop solution (AB containing 
saturating levels, usually 10 mM, of unlabelled permeant) was added to the 
mixture of radiolabeled test compound and cells to terminate the assay followed 
by centrifugation through oil for 1 min at 13,000 g. The microfuge tubes were 
then frozen in liquid nitrogen and the cell pellets in the bottom of the tube were 
cut off and collected in scintillation vials containing 300 μl of 2% sodium dodecyl 
sulphate. The scintillation vials were left at room temperature with shaking (50 
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rounds per minutes (RPM)) for 30 minutes to solubilise the pellets. A volume of 3 
ml scintillation fluid (Optiphase HiSafe III) was added to each vial and left 
overnight at room temperature. Trapped extracellular radioactivity was 
determined as the amount of radiolabel associated with the cell pellet in the 
presence of 1 mM permeant (i.e. saturation of all high affinity transport 
activities) and subtracted. Radioactivity was determined by liquid scintillation 
counting in a Beckman LS6000 TA scintillation counter. Saturation data, 
inhibition data, and time courses were plotted to equations for linear or non-
linear regression (hyperbolic or sigmoid curves), as appropriate using GraphPad 
prism 5 software. All experiments were performed in triplicate and on at least 
three independent occasions.  
Transport of ISM into T. b. brucei was investigated using the classical uptake 
technique previously described by Eze and colleagues (Eze et al., 2016). Cells of 
the trypanosomes were washed by mixing with assay buffer (AB). After allowing 
it to stand for a brief period, the cells were harvested by centrifugation at 1,000 
g for 10 min. The washing was repeated after which the cell pellet was re-
suspended to a concentration of 1 × 107 cells /ml in AB for the designated 
experiment. For the uptake assay, 100 µl of the re-suspended cells were 
incubated with 100 µl 20uM ISM for 600 seconds on top of an oil mix (7:1 
dibutylphthalate/mineral oil (v/v); Sigma- Aldrich) in an eppendolf tube. After 
the period of incubation, uptake of the permeate into the cells was terminated 
by centrifugation at 13,000 × g for 1 minute to pellet the cells. The pellet was 
then retrieved by capillary suction of the top layer of AB and oil-mix. The cell 
pellets were then solubilised in 50 µl of a 0.1 N HCl/methanol (1:8 v/v) mixture 
for an hour at room temperature. Solubilised cells samples were transferred into 
a 96-well plate and the fluorescence determined. Fluorescence of accumulation 
of ISM in the cells was measured using a FLUOstar Optima plate reader (λem 620 
nm; λexc 355 nm and quantified by extrapolation from a standard curve of 
known ISM concentrations. 
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2.5 Statistics: 
In Drug sensitivity assays and Quantitative RT-PCR Statistical significance was 
determined using Unpaired t-test significance indicated by *, P<0.05; **, P<0.01; 
***, P<0.001. However, in cAMP measurement Statistical significance was 
determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001. 
  
  
Expression of T. congolense transporter genes in 
T. brucei cell lines 
 
3.1 MFS and MATE transporters in T. congolense: 
Presence and functions  
T. congolense is one of the main causes of animal trypanosomiasis in sub-Saharan 
Africa, with an enormous impact on livestock in the affected areas. 
Unfortunately, parasites have become resistant to most of the classical anti-
trypanosomal drugs used for treatment of the disease. Although parasite 
resistance to the anti-trypanosomal drugs is well known and documented, yet, as 
reported by Delespaux and colleagues, detailed explanation of the molecular 
basis of the resistance is limited (Delespaux et al., 2005).  
Trypanosomes take up nutrients such as purine and certain anti-trypanosomal 
drugs through membrane transporters. Therefore, deletion of the genes 
encoding these transporters is likely to result in suppression of parasite growth 
or resistance to these anti-trypanosomal drugs, although there is some 
redundancy in at least some nutrient transporters. It is also worth noting that 
some transporters mediate the efflux rather than the uptake of drugs, and in 
such situations the expression of the transporter would cause the parasites to 
become resistant to such drugs. These phenomena have not been well studied in 
some of the trypanosome species especially T. congolense. Therefore, a major 
objective of this part of the study is to decipher at the molecular level the 
potential links between certain transporter proteins of T. congolense and the 
uptake of ISM, ethidium or diminazene among others. 
To carry out this investigation, eight T. congolense transporter genes (Table 3.1) 
(see Table A.5) donated by Dr. Vincent Delespaux (Institute for Tropical 
Medicine in Antwerp) were individually expressed in ISM- or pentamidine-
resistant T. brucei strains that were described previously by Bridges and 
colleagues (Bridges et al., 2007) and Eze (Eze et al., 2016), respectively. The 
resultant transfectants were then tested for their sensitivity to ISM, ethidium, 
diminazene and suramin in comparison with that of the un-transfected ISM 
resistant strain and B48. The assumption is that, if indeed some of these 
transporters encoded by the genes are involved in anti-trypanosomes drug 
resistance, then their expression in a resistant strain will rather make them 
comparably sensitive to the drugs. Expressing the transporter genes in a drug-
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sensitive strain will however show their drug efflux ability, indicated by the 
occurrence of resistance to the drug.  
This section of the study also ascertained whether any of the MFS and MATE 
transporters described earlier in this thesis are involved in the transport of 
cAMP. This was done by investigating the effect of an inhibitor of T. brucei 
phosphodiesterase, CpdA, on cAMP mediation. When CpdA inhibits T. brucei 
phosphodiesterases, a decrease in cAMP breakdown in the cell leads to elevated 
levels of cAMP in the cell and extracellular medium as observed and reported by 
the group of de Koning (de Koning et al., 2012). Here, cAMP levels in the media 
used to cultivate the transfected lines was measured using an ELISA method, in 
the presence and absence of CpdA. The outcome of these investigations is herein 
reported. 
Table 3.1: Identification number and annotation of T. congolense MFS and MATE genes 
used in this study. 
Numbering MF Gene Family T.brucei gene ID T. congolense gene ID
1.1 MF1.1 MATE family Tb927.5.2430 TcIL3000.0.56990 
2.2 MF2.2 MATE family Tb927.9.11800 (11790-810) TcIL3000.9.4800 
3.1 MF3.1 MATE family Tb927.10.12400 TcIL3000.10.10620 
4.1 MF4.1 MFS Tb927.9.12960 TcIL3000.9.5420 
5.2 MF5.2 MFS Tb927.10.14090 TcIL3000.10.11980 
6.3 MF6.3 Not MFS Tb927.10.15480 TcIL3000.10.13270 
7.1 MF7.1 MFS Tb927.5.470 TcIL3000.5.90 
18.8 MF18.8 UNKOWN Tb927.8.5570 TcIL3000.8.5380 
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3.1.1 Expression of T. congolense transporter genes in 
isometamidium (ISMR1) and pentamidine (B48) resistant cell 
lines  
As aforementioned, an important aim of this project is to identify transporters 
involved in drug uptake in trypanosomes, understand their uptake mechanism as 
well as to elucidate drug resistance mechanism involved if any. To address this 
goals eight T. congolense transporter genes were individually expressed in ISM 
and B48 resistant T. brucei strains exactly as described by Bridges and 
colleagues (Bridges et al., 2007; Eze et al., 2016).  
To generate knock-in vectors, genes amplified from T. congolense genomic DNA 
in TOPO vectors (supplied by Dr. Vincent Delespaux of the Institute for Tropical 
Medicine in Antwerp, Belgium) were digested with appropriate restriction 
enzymes and ligated into the pHD1336 backbone to create the required 
pHD1336-MF plasmid. 
3.1.2 Expression of T. congolense transporter genes in 
isometamidium (ISMR1) cell line  
The pHD1336-MF plasmids created above and designated 1.1, 2.2, 4.1, 5.2, 7.1 
and 18.8 were transfected into ISMR1 cell lines. Quantitative Reverse 
Transcriptase Polymerase Chain Reaction (qRT-PCR) was then performed on the 
T. brucei ISMR1 cells expressing the heterologous genes and the expression level 
was compared with ISMR1 which had been transfected with just pHD1336 
containing no insert (pHD1336-empty: referred to as the control). As shown in 
Figure 3.1, MF7.1 exhibited the highest fold-change expression of 17.2, followed 
by MF5.2 (17.0). MF2.2 and MF4.1 had the least expression of 3.6 and 3.7 
respectively.  
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Figure 3.1: Quantitative RT-PCR confirmation of TcoMF genes expression in ISMR1 cells. 
20 ng/µl cDNA was used as template and quantification was done using the generated CT 
values. The average of 3 replicate determinations is shown. The housekeeping gene GPI8 
was used as control. [Note: the experiment was performed by Dr Daniel Tagoe before the 
start of work on the current thesis]  
3.1.3 Drug sensitivity of parasites expressing T. congolense 
transporter genes in ISMR1 cell line 
Test of sensitivity of parasites expressing T. congolense transporter genes in 
ISMR1 cell line to Pentamidine (PEN), isometamidium (ISM), diminazene (DIM), 
Ethidium (ETH), Suramin (SUR) and CpdA were performed using the classical 
Alamar blue dye assay as previously described (de Koning et al., 2012). Clones 
expressing TcoMF 5.2, 7.1, 18.1 in ISMR1, were all tested in parallel in a series of 
experiments. The results shown in Figure 3.2 indicate significant resistance to 
PEN by these clones, whilst only those expressing TcoMF1.1 showed significant 
resistance to ISM, ETH (NB: The RF value of 1.3 indicates that it may be a 
spurious association) and DIM. Tests with CpdA (which in later literature has 
been renamed NPD-001), showed significant sensitisation in parasites expressing 
TcoMF 1.1, 5.2, 7.1 and 18.8. Tests with suramin showed no significant 
differences (Figure 3.2). 
In a separate series of assays, parasites expressing TcoMF6.3 in ISMR1 showed no 
significant differences in sensitivity to ISM, PEN, ETH, and DIM when expressed in 
ISMR1 (Figure 3.3). Note that TcoMF6.3 was generated in ISMR1 separately long 
after the other TcoMF were generated. 
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Figure 3.2: Drug sensitivity assays of selected trypanocides against ISMR1 cell lines 
expressing TcoMF genes. 
The trypanocides tested in this work are pentamidine, diminazene, ethidium, 
isometamidium, CpdA/NPD-001 and sSuramin. Untransfected ISMR1 was used as control 
cell line. Using the standard alamar blue assay, the cells (2 x 105 cells per mL corresponding 
to 2 x 104 cells per well) were incubated with serially diluted drugs in a 96 well plate for a 
total of 72 hours at 37 oC, and 5% CO2. The result shows TcoMF 5.2, 7.1, 18.1 in ISMR1 
showed significant resistance to PEN, whilst only parasites expressing TcoMF1.1 showed 
significant resistance to ISM, ETH and DIM. Also, TcoMF 1.1, 5.2, 7.1 and 18.8 showed 
significant sensitivity to CpdA. Values are means derived from multiple (n=3 to 6) 
experiments + standard error of mean (SEM). Unpaired t-test showing significance is 
indicated by *P<0.05; **P<0.01; ***P<0.001. RF=Resistance Factor defined as the ratio of 
EC50 of the transgene parasite to that of the control (ISMR) 
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Figure 3.3: Drug sensitivity assays of selected trypanocides against ISMR1 cell lines 
expressing TcoMF 6.3 gene. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium, 
isometamidium, CpdA/NPD-001 and Suramin. ISMR1 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per 
well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 
oC, and 5% CO2. The result shows no significant differences of TcoMF6.3 in ISMR1 
compared with the control. Values are means derived from multiple (n=3 to 6) experiments + 
standard error of mean (SEM). Unpaired t-test showed no significance at P<0.05; P<0.01; 
P<0.001. RF=Resistance Factor defined as the ratio of EC50 of the transgene parasite to that 
of the control (ISMR) 
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3.1.4 Drug sensitivity assays of cells expressing T. congolense 
transporter genes in the B48 cell line 
T. congolense transporter genes were also expressed in the B48 cell line. Drug 
sensitivity assays using PEN, ISM, DIM and ETH were undertaken in parasites 
expressing T. congolense genes compared with untransfected B48 parasites. For 
PEN and DIM, MF2.2 was significantly sensitised to both drugs (Figure 3.4). 
TcoMF1.1 showed significant resistance to ISM and DIM (Figure 3.4).  
 
Figure 3.4: Drug sensitivity assays of selected trypanocides against B48 cell lines 
expressing TcoMF genes. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium, B48 was used as control cell line. Using the standard alamar blue assay, 
the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) were incubated with 
serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, and 5% CO2. The 
result shows TcoMF2.2 was significantly sensitive to PEN and DIM. Also, TcoMF1.1 showed 
significant resistance to ISM and DIM. Values are means derived from multiple (n=3 to 6) 
experiments + standard error of mean (SEM). Unpaired t-test showed significance indicated 
by *P<0.05; **P<0.01; P<0.001. RF=Resistance Factor defined as the ratio of EC50 of the 
transgene parasite to that of the control (B48) 
 
Amani S. Alhejely   Chapter 3,103 
 
3.2 Expression of T. congolense MF3.1 genes in ISMR1, 
B48 and WT s427 cell lines 
ISMR1 cell line, B48 and s427WT were transfected with pHD1336-TcoMF3.1 
leading to the generation of parasites expressing the TcoMF3.1 gene. This was 
followed by PCR to confirm the presence of the gene in the cell lines relative to 
the untransfected cell line (Figure 3.5). Note: experiment with MF3.1 was done 
separately from the other MF because of the difference in age of the constructs 
(the other MF had their constructs done a considerable time before that of 
pHD1336-TcoMF3.1). 
 
 
 
Figure 3.5.A: An example of a linearized plasmid (pHD1336) showing MF gene. 
 After linearization with NotI, the plasmid integrates in the RNA spacer (sprRNA). The 
expression of the gene is under the PARP promoter (pPARP). The MF DNA fragment is 
followed by 3’ Actin-PARP (3’ ACT-PARP) and 5’ Actin (5’ACT) and Blasticidin the antibiotic 
resistance gene. The green arrows indicate primers used for the amplification of the MF 
gene whilst the purple primers check for the integration of the plasmid into the trpanosome 
Figure 3.5.B: PCR confirmation of presence of TcoMF3.1. 
This was done using gDNA, the reverse primer (HDK548) of the gene and the forward primer 
of the plasmid pHD1336 (HDK429). 1.= Control (WT s427)), 2. =TcoMF3.1 in ISMR1, 
3.=TcoMF3.1 in B48 and 4= TcoMF3.1 in WT s427. Band size of ~1.4 kb in 2-4 shows MF3.1 
and lack of it in control. M= DNA ladder. The presence of all the constructs was confirmed 
by PCR. 
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3.3 Drug sensitivity assays of cells expression T. 
congolense MF3.1 gene in ISMR1, B48 and WT s427 
cell lines 
Drug sensitivity assays were performed with ISMR1 parasites expressing 
TcoMF3.1. untransfected ISMR1 was used as control. From the outcome of this 
test shown in Figure 3.6, Clone 1 of the parasites expressing TcoMF3.1 was seen 
to exhibit significant resistance to PEN but ~10-fold higher sensitivity to CpdA 
when compared with the control. There was no significant difference when SUR 
was used (Figure 3.6). 
However, expression of the T. congolense MF3.1 gene in B48 parasites did not 
show any significance difference in drug sensitivity to any of the compounds 
tested (Figure 3.7). 
Similarly, expression of T. congolense MF3.1 gene in WT s427 parasites did not 
result in any significant difference in drug sensitivity to any of the compounds 
tested (Figure 3.8). 
Amani S. Alhejely   Chapter 3,105 
 
 
Figure 3.6: Drug sensitivity assays of selected trypanocides against three ISMR1 clones 
expressing TcoMF3.1. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium,  
isometamidium, CpdA/NPD-001 and suramin. ISMR1 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells 
per well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours 
at 37 oC, and 5% CO2. From the results Clone 1 of the parasites expressing TcoMF3.1 
showed significant resistance to pentamidine but ~10-fold sensitive to CpdA when 
compared with the control cell line. Values are means derived from multiple (n=3 to 6) 
experiments + standard error of mean (SEM). Unpaired t-test showed significance indicated 
by *P<0.05; **P<0.01; ***P<0.001. RF=Resistance Factor defined as the ratio of EC50 of the 
transgene parasite to that of the control (ISMR1). 
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Figure 3.7: Drug sensitivity assays of selected trypanocides against three B48 clones 
expressing TcoMF3.1. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium,  
isometamidium, CpdA/NPD-001 and suramin. B48 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per 
well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 
oC, and 5% CO2. The result shows no significant differences between control and 
transfected cells. Values are means derived from multiple (n=3-6) experiments + standard 
error of mean (SEM). Unpaired t-test showed no significance, defined as P<0.05. 
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Figure 3.8: Drug test of parasites sensitivity to selected trypanocides. 
Three WTs427 clones expressing TcoMF3.1 were tested against pentamidine, diminazene, 
Ethidium, isometamidium, CpdA/NPD-001 and suramin. Phenylarsine oxide (PAO), a known 
poison was used as positive control. WTs427 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per 
well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 
oC, and 5% CO2. The result shows no significant differences between control and 
transfected cells. Values are means derived from multiple (n=3-6) experiments + standard 
error of mean (SEM). Unpaired t-test showed significance indicated by P<0.05; P<0.01; 
P<0.00 
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3.4 Result summary 
In this part of the study, T. congolense genes were expressed in isometamidium- 
(ISMR1) and pentamidine-resistant (B48) T. brucei cells and the susceptibilities 
of the resultant phenotypes tested against standard anti-trypanosomal drugs. 
Overall, a significant effect of the drugs on some cell lines was observed. From 
the initial series of 8 genes used, TcoMF5.2, TcoMF7.1 and TcoMF18.8 showed 
the most interesting effects of the drugs. For instance a significant resistance to 
pentamidine was observed when these genes were expressed in ISMR1. This 
phenomenon was not observed when the expression was in B48 (highly resistant 
to pentamidine: this is more likely to highlight transporters that increase 
pentamidine sensitivity) as appeared to be the case for MF2.2. Additionally, 
ISMR1 cells were significantly sensitised to CpdA when expressing TcoMF1.1, 7.1 
and 18.1. Thus, T. brucei orthologues comprising several of these genes 
[TbMF5.2 (Tb927.10.14090), TbMF7.1 (Tb927.5.470) and TbMF18.8 
(Tb927.8.5590)] were selected for genetic manipulation, in order to ascertain 
their effect, if any, on drug sensitivity and cAMP efflux in WT s427 parasites. 
TcoMF3.1 was sensitised to the anti-trypanosomal drugs but this was observed 
only when it is expressed in ISMR1 and not in either B48 or WT trypanosomes. 
One possible explanation for this observation might be that the homologous T. 
brucei transporter (Tb927.10.12400) is affected in the ISM-resistant line, 
consequently the characteristics of these cells are much more altered by the 
(re)-introduction of the MF3.1 transporter (from T. congolense). 
 
 
  
  
Investigation of TcoMF5.2 and TbrMF5.2 
transporters Expressed in T. brucei cell lines 
 
4.1 Genetic manipulation of TbrMF5.2 (Tb927.10.14090) in 
s427 and 2T1 cell lines 
 
As aforementioned in section 2.3, Mazurkiewicz and colleagues showed that 
bacterial (such as Gram-positive lactic acid bacteria) transporters have high 
affinity for ethidium bromide, which is structurally related to ISM (Mazurkiewicz 
et al., 2005). Consequently, Dr Delespaux at the Vrije Universiteit Brussel, 
Belgium performed further literature searches (Neyfakh, 2002; Couto et al., 
2008; Paixão et al., 2009; Coleman and Mylonakis, 2009; Lee et al., 2009) 
leading to the identification and generation of a list of several such transporters 
in the T. congolense genome (see appendix A.5). In this study, genes coding for 
these transporters were identified through data mining and a BLAST search of T. 
congolense genomic database. This was performed in 
https://tritrypdb.org/tritrypdb/ with these set of transporters (See Table 2.3 
for list of genes).  
In chapter 3, it was observed that expression of TcoMF5.2 in ISMR1 induced 
significant resistance to pentamidine. Consequently, TbrMF5.2 (Tb927.10.14090) 
was chosen for genetic manipulation in order to investigate its effect, if any, on 
drug sensitivity and cAMP efflux in T. brucei WT s427. The strategy to express 
the proteins in T. brucei cell lines was mainly informed by the fact that the 
genome of T. congolense is difficult to manipulate as it remains largely 
unamenable. Currently, some vectors for T. congolense are becoming available 
but at the beginning of the project, the culturing of T. congolense was still a 
major issue and its genetic manipulation in its infancy, at best. It therefore 
became necessary to choose a strategy of expressing the T. congolense 
transporter genes in T. brucei and deleting the homologous T. brucei genes in 
the process. TbrMF5.2 in the T. brucei s427 and 2T1 cell lines was therefore 
knocked out or knocked down, and the resultant cell lines were functionally 
characterized in terms of sensitivity to anti-trypanosomal drugs, cAMP 
mediation, growth patterns and general uptake of certain compounds. To rescue 
the TbrMF-/-, TbrMF-/B was generated in 2T1 parasites as described previously 
(section 2.3.4). The 2T1 cell line (Alsford et al., 2005) is ideal for the 
tetracycline (Tet) gene induction system which makes it possible to introduce an 
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ectopic copy of the gene in order to rescue the phenotype (but only in the 
presence of Tet) when both native genes have been deleted. This cell line (2T1) 
was also used for knockdown experiments which are herein described. 
4.1.0 Deleting TbrMF5.2 in the 2T1 cell line 
Firstly, TbrMF5.2 in WT s427 parasites was deleted, replacing each gene with 
antibiotic resistant cassettes. Heterozygote cells of TbrMF5.2 were obtained by 
replacing the gene with either blasticidin (Blast), neomycin (Neo) or hygromycin 
(Hyg). Integration of the constructs was confirmed with PCR; amplifying from 
the 5’UTR region and the reverse primer on the antibiotic and 3’UTR reverse 
primer and a forward primer from the antibiotic cassette (see Figure 4.1.a and 
b). 
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Figure 4.1 a: KO constructs designed with the various resistant cassettes to replace MF 
genes. 
The P(no.) corresponds to primer used to check for loss of gene and also the integration 
of construct into the genome of the parasite.  
Figure 4.1.b: Gel confirmation of PCR integration of antibiotic resistant cassettes. Using 
gDNA. TbrMF5.2+/- heterozygote cells of TbrMF5.2 were obtained by replacing the gene 
with the antibiotic. The right integration of the constructs was checked with PCR; 
amplifying from the 5’UTR forward primer (HDK926) and the reverse primer on the 
antibiotic and 3’UTR reverse primer (HDK927) and a forward primer from the antibiotic 
cassette. 
A. For the heterozygote cells of TbrMF5.2 with the hygromycin-resistance cassette 
TbrMF5.2+/- : 1. TbrMF5.2 Hyg 5’UTR (~1.4 kb) using 5’UTR forward primer HDK926 and 
reverse primer on the Hyg HDK1045; 2. s427 with primers in lane 1 ; 3. TbrMF5.2 Hyg 
3’UTR (~ 2kb) using 3’UTR reverse primer HDK927 and forward primer from the Hyg 
HDK1044 ; 4. s427 with primers in lane 3.  
B. For the heterozygote cells of TbrMF5.2 with the blasticidin-resistance cassette 
TbrMF5.2+/- : 1. TbrMF5.2 Blast 5’UTR (~ 1.7kb) by using 5’UTR forward primer HDK926 and 
reverse primer on the Blast HDK283 ; 2. TbrMF5.2 Blast 3’UTR (~ 2.5kb) by using 3’UTR 
reverse primer HDK927 and forward primer from the Blast HDK282 ;3. s427 with primers 
as in lane 1; 4. s427 with primers asin lane 2.  
C. For the heterozygote cells of TbrMF5.2 with the neomycin-resistance cassette 
TbrMF5.2+/- : 1. MF5.2 Neo 5’UTR (~ 1.9kb) by using 5’UTR forward primer HDK926 and 
reverse primer on the Neo HDK285 (; 2. TbrMF5.2 Neo 3’UTR (~ 1.9kb ) by using 3’UTR 
reverse primer HDK927 and forward primer from the Neo HDK284 ; s427 with primers as in 
lane 1; 4. s427 with primers as in lane 2. 
M= DNA Ladder. 
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4.1.1 Quantitative RT-PCR confirmation of heterozygote 
TbrMF5.2+/- (Tb927.10.14090) gene in WTs427 cell line 
Following PCR confirmation of TbrMF5.2 heterozygosity (TbrMF5.2+/-), gene 
expression level was determined using qRT-PCR. The expression level of the 
gene was expected to decrease. Replacement of a single TbrMF5.2 allele by 
antibiotics resulted in a significant decrease in TbrMF5.2 with the Neomycin 
resistance-expressing clone showing the highest decrease (Figure 4.2). The 
expression level of the clone with the neomycin construct was very low and may 
reflect the sometimes-unpredictable results obtained with the neomycin 
marker/selection. It is conceivable that the cells had been affected by the 
selecting antibiotic. 
 
Figure 4.2: Quantitative RT-PCR confirmation of heterozygote cells of TbrMF5.2(TbrMF5.2+/-). 
In this figure one allele was replaced with the corresponding antibiotic. 20 ng/µl cDNA was 
used as template DNA. Expression levels were quantified using the generated CT values. 4-
6 replica reactions were performed using the housekeeping gene GPI8 as control. 
Heterozygosity resulted in a significant loss of gene activity with Neomycin showing the 
highest loss of activity. Statistical significance was determined using a multiple 
comparisons ANOVA test with the PRISM 7.0 software package. *, P<0.05; **, P<0.01; ***, 
P<0.001, **** P<0.0001 
NB:TbrMF5.2 single knockout is herein referred to as heterozygote cells of TbrMF5.2 
(TbrMF5.2+/- ). 
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4.1.2 Creation of null TbrMF5.2-/- (Tb927.10.14090) WT s427 cell 
line 
Several attempts were made to knockout the second allele of the gene with any 
of the antibiotic resistance cassettes but this resulted in the production of non-
viable cells. Even when double-transfectant clones were obtained (i.e. resistant 
to two different antibiotics), TbrMF5.2 could still be amplified from these cells, 
indicating an incorrect integration of the construct and an apparent inability to 
correctly replace the second TbrMF5.2 allele (Figure 4.3). This strongly suggests 
that TbrMF5.2 is essential in T. brucei. In this method of gene deletion, the 
genes being deleted were to be replaced by resistant cassettes that require 
specific both 5’ and 3’ gene UTRs to guide their integration and hence gene 
deletion. However, it is possible that only the 3’ UTR could integrate without 
the 5UTR integrating and hence conferring resistance without gene deletion. 
Also in some cases, although there is proper integration and gene deletion, the 
gene itself may integrate randomly in the genome and may or may not 
expressed. They may also act as episomes in the cytoplasm and replicate 
independently of the parasite genome. In some species like Leishmania, some 
genes could be in triploid (trisomy) and hence have additional gene copy that 
may not have been annotated. However, based on similar methods we used in 
deleting other genes we believe that TbrMF5.2 is essential. 
 
 
 
 
 
1 M 2 3 
1. Kb 
Figure 4.3: Gel confirmation of the presence of null TbMF5.2 (Tb927.10.14090) parasites. 
This was done using gDNA. 1. TbrMF5.2 ORF of WT s427 used herein as positive control; 
2. Amplification of TbrMF5.2 null (TbrMF5.2-/-) in WT Tb s427; 3. No DNA, the negative 
control. M= DNA Ladder. Primers for the complete ORF (~ 1kb) were used: HDK1394, 
HDK1395. TbrMF5.2 could still be seen amplified from these cells in lane 2, indicating an 
incorrect integration of the construct and an apparent inability to correctly replace the 
second TbrMF5.2 allele). This is strong evidence that that TbrMF5.2 is essential in T. 
brucei. 
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4.1.3 Ribonucleic Acid Interference (RNAi) of TbrMF5.2  
In order to study the effect of TbrMF5.2 depletion on drug sensitivity and uptake 
of compounds whilst overcoming the issue of essentiality, primers were designed 
to generate an RNAi construct that will interfere with the expression of the 
TbrMF5.2 gene. The RNAi plasmid pGL2048 used was made using the GATEWAY 
Cloning method. The plasmid is a Donor Vector designed with attB sites (1 and 2) 
that through BP reaction receives section of the ORF. For the 5’ the attB1: 5’-
GGGG ACA AGT TTG TAC AAA AAA GCA GGC TNN followed by template specific 
sequence-3’ whilst attB2: 5’- GGGG ACA AGT TTG TAC AAA AAA GCA GGC TNN 
followed by template specific sequence-3’. PCR primers were designed with the 
attB sites in mind and synthesised for TbrMF5.2 (see section 2.3.5). In a single 
reaction a recombination in opposing directions into pGL2048 led to the 
generation of a stem loop RNAi construct (Jones et al., 2014). The TbrMF5.2 
RNAi plasmid was confirmed by restriction digest (Figure 4.4) before being 
transfected into T. brucei 2T1 cell lines. After transfection, correct integration 
of the plasmid into T. brucei 2T1, would be hygromycin and phleomycin 
resistant, which will remove the puromycin resistance from the cell line. This 
was used to generate an inducible plasmid. It must be noted that T. brucei 2T1 
cell line expresses TetR from the pHD1313 cassette integrated at the tubulin 
locus (Alsford et al., 2005).  
 
 
 
2 3 4 1 M 
1.5 Kb 
Figure 4.4: Double digest confirmation of TbrMF5.2 RNAi PGL2048 plasmid. 
1. BamHI XbaI ~1500bp and ~5000bp 2. AscI ~2600bp and ~3800bp 3. ClaI ~600bp and 
~5800bp 4. StuI ~600bp and ~5800bp. M= Ladder. 
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4.1.4 Quantitative RT-PCR confirmation of RNAi of TbrMF5.2 in 
2T1 cell line  
The addition of tetracycline to the 2T1 strain transfected with the TbrMF5.2 
RNAi construct led to a consistent decrease in the level of gene expression over 
time albeit not statistically significant. At 18 h MF5.2 levels decrease in the 
presence of tet but was not significant. At 24 h however, there was a significant 
decrease in MF5.2 levels in the presence of tet. Although levels of MF5.2 
increased at 18 h and 24 h without tet, that was not significantly different to 
that of MF5.2 in wildtype 2T1. Statistical analysis was re-performed using 
ordinary one-way Anova: Multiple comparison.  
  
 
 
 
 
 
Figure 4.5: Quantitative RT-PCR of TbrMF5.2 RNAi cells with and without tetracycline. 
20 ng/µl cDNA was used as template DNA. Expression level was quantified using the 
generated CT values. 3-4 replica reactions were performed, using the house keeping gene 
GPI8 as control. Addition of Tet significantly decreased the expression of TbrMF5.2 after 
24 h. Statistical significance was determined using a multiple comparisons ANOVA test 
with the PRISM 7.0 software package. *, P<0.05. 
 F
ol
d 
C
ha
ng
e 
of
 C
on
tro
l  
Amani S. Alhejely Chapter 4,117 
4.1.5 Growth pattern of RNAi cells confirms the essentiality of 
TbrMF5.2. 
To confirm the essentiality of TbrMF5.2 (Tb927.10.14090), 2T1 control cells and 
TbrMF5.2 RNAi cells were grown with and without tetracycline in a continuous 
culture and parasites counted every 12 h. 2T1 +/- tetracycline (A) and TbrMF5.2 
RNAi - tetracycline (B) were observed to grow over the period. However, the 
addition of tetracycline resulted in the death of TbrMF5.2 RNAi after 5 days 
in culture, even though growth was apparently not different from the ‘no-tet’ 
control up to that point (Figure 4.6 A-B). This observation seems to suggest 
that TbrMF5.2 is essential for the long-term survival of the parasite.  
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Figure 4.6: Growth curve of TbrMF5.2 RNAi parasites with/without tetracycline. 
 2T1 and TbrMF5.2 RNAi cells were grown in continuous culture with/without 
tetracycline and parasites counted every 12 h. Cells were passaged to starting 
concentrations of 2×104 in fresh medium whenever the density exceeded 1×106 
cells/ml which is approximately 48 h for all tested cell lines indicated by*. A.  2T1 -
Tet/2T1+Tet. B. TbrMF5.2 RNAi -/+ Tet. Only the culture of TbrMF5.2 RNAi +Tet 
died on day 5, i.e. they failed to grow after the second passage. All other cultures 
displayed only ‘normal’ cells in apparent log-phase of growth. N=3 
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4.1.6  Demonstration of essentiality of the TbrMF5.2 gene in the 
parasites 
To confirm the essentiality of the TbrMF5.2 gene to the parasites, a rescue 
plasmid was generated that includes the gene, expressed under a tetracycline 
promoter. Firstly, a single TbrMF5.2 allele was deleted to be replaced with a 
blasticidin cassette in the 2T1 cell line that can be regulated with tetracycline 
making TbrMF-/blasticidn (Figure 4.7.a). Confirmation of integration of blasticidin 
was done using PCR (Figure 4.7.b). The ORF of TbrMF5.2 was ligated into pRPa in 
order to express a TbrMF5.2-GFP tagged construct. This was then transfected 
into the heterozygote TbrMF-/blasticidin to integrate into the tubulin locus making a 
TbrMF-/blasticidin + TcoMF5.2 (Figure 4.7.b). To confirm the integration of 
pRPaTbrMF5.2, the plasmid primers (HDK535 and HDK713) were used (Figure 4.7.b). 
The second allele was then replaced with a neomycin resistance cassette making 
TbrMFblasticidin/neomycin whilst growing the parasites in the presence of tetracycline 
to ensure the survival of the parasite after the deletion of the second allele 
(Figure 4.7.a). Correct integration of the constructs to make heterozygote and 
null was confirmed with PCR as previously described in 4.1.1 c. 
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Figure 4.7 A.: Illustrates the stages involved in the creation of a double knock out 
with rescue copy.  
The first TbrMF5.2 allele will be replaced with blasticidin, then a rescue copy 
construct of TcoMF5.2 was added in an alternative location, followed by 
neomycin replacing the second TbrMF5.2 allele. 
Figure 4.7.B.: PCR confirmation of TbrMFS-/B-TcoMF5.2 parasites. This was done 
using gDNA .1. Clones 1-4 did not have integration of KiN plasmid; clone 5 
showed positive integration of KiN plasmid with primers HDK535 and HDK713. 
(band size ~ 1.5kb). M=Ladder. 
Figure 4.7.C.: PCR confirmation of TbrMFS-/-- parasites.  
1&2 heterozygote cells of TbrMF5.2  with the blasticidin-resistance cassette 
TbrMF5.2+/-   
1. TbrMF5.2 Blast 5’UTR (~ 1.7kb) by using 5’UTR forward primer HDK926 and 
reverse primer on the Blast HDK283;  
2. TbrMF5.2 Blast 3’UTR (~ 2.5kb) by using 3’UTR reverse primer HDK927 and 
forward primer from the Blast HDK282;  
3. Blank. 
4&5 heterozygote cells of TbrMF5.2 with the neomycin-resistance cassette 
TbrMF5.2+/- 
4. TbrMF5.2 Neo 5’UTR (~ 1.9kb) by using 5’UTR forward primer HDK926 and 
reverse primer on the Neo HDK285. 
5. TbrMF5.2 Neo 3’UTR (~ 1.9kb ) by using 3’UTR reverse primer HDK927 and 
forward primer from the Neo HDK284 
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4.1.7 Growth pattern of TbrMF5.2-/- + TcoMF5.2 in relation to 
proposed TbrMF5.2-/- and Wildtype 2T1 
As seen from the TbrMF5.2 RNAi experiment, the absence of MF5.2 causes the 
death of the parasite 96 h after knocking down the gene. Growth pattern of 
parental cell line 2T1 and TbrMF5.2-/- + TcoMF5.2 with/without tet predicts that 
the parasite is rescued by activating the expression of TcoMF5.2 by adding tet 
whereas in the absence of tet, the parasite dies due to the absence of the 
essential MF5.2 gene (Figure 4.8). 
 
 
 
 
Figure 4.8: Growth curve of wildtype 2T1 and rescue TbrMF5.2-/-+TcoMF5.2 with/without 
tet. 
WT 2T1 grows normally in media with/without tet. However, TbrMF5.2-/-+TcoMF5.2 is only 
able to grow without tet as it needs the expression of the gene to survive.  N=1 
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4.1.8 Expression of TcoMF5.2 in WT s427 parasites: 
The ORF was ligated into pHD1336 to make pHD1336-TcoMF5.2 in order to 
express the gene under a PARP promoter. This construct was transfected into 
wild-type T. brucei s427. Integration of the construct was confirmed using PCR 
(Figure 4.9). 
 
 
4.2 Susceptibility of MF5.2 knock-out, knock-in and RNAi 
cell lines to trypanocides. 
Sensitivity of heterozygote (TbrMF5.2+/hygromycin) and null TbrMF5.2 (TbrMF5.2-/-) 
parasites to selected trypanocides was investigated using the usual Alamar Blue 
Assay. As shown in the previous section, these cells survived and grew normally 
for 3-5 days after the withdrawal of tetracycline (see Figure 4.6). RNAi 
knockdown TbrMF5.2 in 2T1 cell line showed a significant increase in sensitivity 
to ISM and CpdA. It was also observed to be resistant to SUR. All the MF5.2 
genetically manipulated cell lines showed significant sensitivity to ISM indicating 
that this gene might be involved in the transport of ISM in to these cells (Figure 
4.10).  
 
 
1 M 2 3 4 5 
2 Kb 
Figure 4.9: Gel confirming the presence of pHD1336 TcoMF5.2 plasmid expressing the 
gene in WT s427. 
Using the forward primer for the plasmid (HDK429) and reverse primer of the gene 
(HDK1395). This was done using gDNA. 1. pHD1336 TcoMF5.2 Clone 1; 2. pHD1336 
TcoMF5.2 Clone 2; 3. pHD1336 TcoMF5.2 Clone 3; 4. WT s427 5. No DNA. M= DNA 
Ladder. (band size ~ 2kb) 
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Figure 4.10: Drug sensitivity assay of TbrMF5.2 RNAi and null TbrMF5.2 (TbrMF5.2-/- ) 
parasites. 
The trypanocides tested are pentamidine, diminazene, Ethidium and isometamidium, 
CpdA/NPD-001 and suramin. 2T1 was used as control cell line. Using the standard alamar 
blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) were 
incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, and 
5% CO2. The result shows showed that RNAi knocking down of TbrMF5.2 in the 2T1 cell line 
significanly increased sensitivity to ISM, and CpdA but resulted in significant resistance to 
SUR. All the MF5.2 genetically manipulated cell lines showed significant sensitivity to ISM. 
Values are means derived from multiple (n=3 to 6) experiments + standard error of mean 
(SEM). Unpaired t-test showed significance indicated by *P<0.05; **P<0.01; ***P<0.001. 
RF=Resistance Factor defined as the ratio of EC50 of the transgene parasite to that of the 
control (2T1) 
NB:TbrMF5.2 SKO=heterozygote TbrMF5.2 (one alelle replaced with one antibiotic) in the 
absence of tet; 
TbrMF5.2 dKO -tet= Null TbrMF5.2 parasite (with both allels deleted) in the absence of tet.  
TbrMF5.2 dKO +tet= Null TbrMF5.2 parasites with both alleles deleted but in the presence of 
tet.  
TbrMF5.2 RNAi=RNAi knockdown of TbrMF5.2 
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4.2.1 Susceptibility of TcoMF5.2 expressed cell lines to 
trypanocides. 
As previously reported in Chapter 3, TcoMF5.2 was expressed in B48 and ISMR1, 
and found to confer resistance to pentamidine in ISMR1. It was therefore 
decided to test the susceptibility of the Wild Type s427 cells expressing 
TcoMF5.2 to selected trypanocides. TcoMF5.2-expressing s427 cells showed small 
but significant sensitisation to PEN and DIM. There were no significant 
differences in response to the other trypanocides (Figure 4.11). This observation 
may be due to the already expressed identical TbrMF5.2 gene in the s427 cell 
line, or that the TcoMF5.2 mRNA in the transformed s427 were either broken 
down and never progressed to protein synthesis. As to the observation that a 
reduced expression of TbrMF5.2 increases ISM sensitivity, which may indicate 
that this gene is involved in ISM efflux or sequestration, no effect was observed 
with the overexpression of the equivalent T. congolense gene. It could therefore 
be hypothesised that either ISM is a substrate for the T. brucei transporter but 
not for the T. congolense one, or the efflux rate in the wild-type T. brucei is 
already substantial as demonstrated by Eze and colleagues (Eze et al., 2016) and 
that the contribution of the T. congolense gene does not further alter the EC50 
value.  
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Figure 4.11: Drug sensitivity assay. Drug sensitivity test of selected trypanocides against 
TcoMF5.2-expressing wild-type parasites. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium, CpdA/NPD-001 and suramin. Phenylarsine oxide (PAO), a known poison 
was used as positive control. WTs427 was used as control cell line. Using the standard 
alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) 
were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, 
and 5% CO2. The result shows TcoMF5.2-expressing s427 cells showed small but 
significant sensitisation to PEN and DIM and there were no significant differences to the 
other trypanocides. Values are means derived from multiple (n=3 to 6) experiments + 
standard error of mean (SEM). Unpaired t-test showed significance indicated by *P<0.05; 
**P<0.01; P<0. 001. RF=Resistance Factor defined as the ratio of EC50 of the transgene 
parasite to that of the control (WTs427) 
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4.3 Intracellular and extracellular Cyclic Adenosine 
Monophosphate (cAMP) levels in WT cells expressing 
TcoMF5.2. 
Expressing TcoMF5.2 in WT s427 parasites led to a significant decrease in cellular 
cAMP levels, when compared with s427WT, at basal (unstimulated) levels and 
when cAMP breakdown was inhibited by the PDE inhibitor CpdA at a 
concentration of 2x or 5x EC50. This observation may probably be due to 
elevated levels of cAMP in all cells treated with CpdA, but not as much in cells 
expressing TcoMF5.2. For the cells expressing TcoMF5.2 the increase in 
intracellular cAMP upon CpdA treatment was significantly less than in the 
corresponding cell lines without expression of TcoMF5.2. For the latter cells the 
dose-response appeared inverted, with the 2x CpdA-exposed cells displaying 
higher apparent levels than the 5x-exposed cells. However, both groups 
displayed massively increased levels compared to the untreated control cells, 
and the apparent discrepancy may be caused by the ELISA used for 
quantification being less reliable near its top end. It was observed that both 2x 
EC50 and 5x EC50 concentration of CpdA caused an increase in cAMP in the media 
(extracellular) of TcoMF5.2 (TcIL3000.10.11980) in WT s427 (Figure 4.12). 
However, only the 5x EC50 concentration of CpdA showed a significant increase in 
cAMP compared to WT s427 of the same concentration. It should be noted that 
the extracellular cAMP assay is less sensitive than the intracellular assay, due to 
the very much greater volume of the extracellular medium than the intracellular 
volume of the parasites, thus requiring a large amount of cAMP to significantly 
increase the concentration of cAMP. The observed increase in the presence of 
higher concentration of CpdA could be as a result of the high drug concentration 
pushing the levels of cAMP above a threshold that causes the parasite to attempt 
to release the cAMP into the extracellular medium. A plausible explanation is 
that TcoMF5.2 acts as a cAMP export mechanism. cAMP was measured in 
pmol/ml. Graphs are a plot of Mean and SE of 3 to 6 independent biological 
replicates 
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Figure 4.12: cAMP measurement in WT T. brucei s427 and cells expressing TcoMF5.2, and in 
the extracellular media, using an ELISA-based assay. cAMP was measured in pmol/ml. 
Cultures were exposed to either 2× or 5× the EC50 concentration of CpdA for 3 h. Statistical 
significance was determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001. Differences in intracellular and 
extracellular cAMP levels between the different cell lines at the fixed CpdA concentrations 
are shown. n=3 to 6  
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4.3.1 Intracellular and extracellular Cyclic Adenosine 
Monophosphate (cAMP) levels in TbrMF5.2 RNAi cells. 
Knock down of TbrMF5.2 by RNAi in 2T1 parasites caused a significant decrease 
in cAMP levels relative to the un-transfected 2T1 control cells. It must however 
be emphasised that this was observed only when CpdA was used at a 
concentration 5× that of its EC50value. In the media of MF5.2 RNAi parasites, 
incubation with either 2× or 5× EC50 concentration of CpdA for 3 hours caused a 
significant decrease in cAMP levels compared to 2T1 (Figure 4.13). In both cell 
types intracellular and extracellular cAMP concentrations were markedly and 
dose-dependently increased by CpdA. 
 
Figure 4.13: cAMP measurement in TbrMF5.2 RNAi cells and media. cAMP measurement in 
2T1 and TbrMF5.2 RNAi cells and and in the extracellular media, using an ELISA-based 
assay. cAMP was measured in pmol/ml. 
Cultures were exposed to either 2× or 5× the EC50concentration of CpdA 3 h. Statistical 
significance was determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001 
The significance difference was between the cell line and s427wt at the same cpdA 
concentration. n=3 to 6 
 
 
 
 
 
 
 
 
Amani S. Alhejely   Chapter 4,131 
 
4.4 Uptake of ISM by TbrMF5.2 RNAi cell lines. 
TbrMF5.2 RNAi cells were tested for their uptake of ISM and SUR. Knocking down 
MF5.2 resulted in an increase rate of net uptake of ISM over a 1 hour period 
(Figure 4.14), i.e. the combined accumulation as a result of uptake and efflux 
over time. This observation could be due to a reduction in the expression of 
TbrMF5.2 in this cell line, assuming TbrMF5.2 functions as an efflux mechanism 
for ISM, and is consistent with the RNAi knockdown of TbrMF5.2 causing 
hypersensitivity for ISM (section 4.2). 
 
Figure 4.14: Uptake assay of TbrMF5.2 RNAi parasites using ISM compared with 2T1 
control. 
A marked difference in uptake of ISM was observed between TbrMF5.2 RNAi 
parasites and the control cells. . n=3  
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4.4.1  Uptake of Suramin by TbrMF5.2 RNAi cell lines. 
Knocking down TbrMF5.2 using RNAi did not affect the uptake of [3H]-suramin in 
2T1 cells, measured at a single time point of 15 min. The accumulation of either 
a moderate concentration (25 µM) or a high concentration (100 µM) of suramin 
did not show any difference when compared with the 2T1 control (Figure 4.15).. 
As to the lack of effect on uptake of suramin, despite the apparent resistance to 
suramin shown in Fig 4.10 for the TbrMF5.2 knockdown strain, it would appear 
that (lack of) this transporter affects suramin sensitivity without changing its 
cellular accumulation, at least over 15 minutes. This can occur when the cellular 
distribution of the drug is altered away from its target. In the case of suramin it 
has been documented that an MFS-type transporter is instrumental in the release 
of the drug from the lysosomal system after receptor-mediated endocytosis 
(Zoltner et al., 2016), which fits the model well. However, the ISM and SUR data 
can only be reconciled by the gene product TbrMF5.2 being present both on the 
[plasma membrane (ISM) and the lysosomal/endosomal system.  
Figure 4.15: Uptake assay of TbrMF5.2 RNAi parasites using Suramin (SUR) 
compared with 2T1 control within 15 min. 
The vertical axis represents intracellular [3H]-suramin concentration (dpm) in the 
cells, while the horizontal axis is the cell line/ concentration of [3H]-suramin: 25 µM 
2T1, 100 µM 2T1 represents 25 µM and 100 µM [3H]-suramin in wild-type 2T1 cells 
respectively; and 25 µM TbrMF5.2, 100 µM TbrMF5.2 represents 25 µM and 100 µM 
[3H]-suramin in MF5.2 knock down in 2T1 cell line respectively. The values presented 
here are averages of two independent repeats and SEM. 
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4.5 Summary of the results: 
In order to begin to understand the function of the TbrMF5.2 gene in the 
metabolic activities and drug sensitivities of trypanosomes, the gene was 
manipulated and the resultant phenotype was assessed in terms of growth rate, 
ability to transport certain substrates, cellular cAMP levels and export, and their 
susceptibilities to selected trypanocides in vitro.  
Interestingly, the outcome showed that MF5.2 is essential for the long-term 
survival of bloodstream form T. brucei. Null MF5.2 T. brucei cell lines were not 
viable in long-term culture. It was observed that deletion of both alleles of the 
gene was only possible after the introduction of a copy of TcoMF5.2. Reduction 
of TbrMF5.2 transcript correlated with a significantly increased sensitivity to 
ISM, and CpdA. These cell lines were, however, significantly resistant to SUR. 
The increased sensitivity to ISM could indicate that the transport protein 
encoded by the MF5.2 gene could be involved in the efflux, rather than uptake, 
of ISM. This speculation was much enhanced by the observation that the rate of 
net ISM accumulation in 2T1 was markedly increased after knockdown of the 
TbrMF5.2 gene. 
The outcome of the test with CpdA could be interpreted in terms of its 
accumulation by the parasites. Thus, the 5-fold increase in sensitivity by 
TbrMF5.2 RNAi could indicate the loss of an efflux transporter for this compound 
in the parasite. This is perhaps against the report that this highly lipophilic PDE 
inhibitor diffuses quite freely through the membranes, although the active 
extrusion of lipophilic, diffusible drugs from cells, linked to resistance is well 
documented, for instance for tetracycline resistance (Grkovic et al., 2002). An 
alternative explanation could be that TbrMF5.2 functions as a cAMP efflux pump, 
and its knock-down or knockout causes the cellular cAMP levels to increase, 
leading to reduction in extracellular (medium) cAMP levels compared to control 
cells. The latter phenomenon, in particular, was highly significant when cAMP 
levels were pharmacologically elevated by inhibiting its breakdown with CpdA. 
However, although cellular cAMP levels were somewhat higher in the MF5.2 RNAi 
cells, in untreated cells or after treatment with 2× EC50 CpdA this was not 
significant, and a decrease in cellular cAMP was even seen when cells were 
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treated with 5× EC50. On the other hand, expression of TcoMF5.2 in T. brucei 
lowered both basal and CpdA-stimulated cAMP levels significantly, consistent 
with its perceived cAMP efflux mediation role, leading to a simultaneous 
increase in extracellular cAMP. More investigation is needed regarding this in 
order to draw a firm conclusion whether or not MF5.2 is definitely involved in 
cAMP efflux in trypanosomes. 
The 4-fold resistance to suramin in the TbrMF5.2 conditional knockout and RNAi 
strains was highly significant (P<0.001) and consistent. Previously, a different 
MFS transporter, Tb927.9.6380 (previously known as Tb09.v2.0030), has been 
implicated in suramin resistance in T. brucei. It is believed that this lysosomal 
MFS transporter aids the ‘escape’ of suramin from its endocytotic vesicle after 
receptor-mediated endocytosis (Alsford et al., 2012; Zoltner et al., 2016). MF5.2 
(Tb927.10.14090) was not detected in that genome-wide RNAi screen, but it 
could be argued that this could be related as it is apparently essential to the 
trypanosome, allowing short-term knockdown or conditional knockout, but not 
for the longer selection that is required for the RITseq strategy. 
  
  
Investigating the role of TcoMf7.1 and TbrMF7.1 in 
transport activities of T. brucei cell lines 
 
5.1  Introduction  
The uptake of nutrients and drugs into trypanosomes as well as the efflux of 
some compounds from the parasite has previously been demonstrated. However 
detailed mechanisms of some of these transport activities have not been well 
elucidated. This section of the study explored the possible role some of the 
genes, donated by a collaborator (Dr. Vincent Delespaux of Institute for Tropical 
Medicine in Antwerp) and listed in chapter 2 could play in the transport 
activities of the parasite. Specifically, the role of TcoMf7.1 and TbrMF7.1 in 
translocation of compounds in trypanosome was investigated. 
5.2 Genetic manipulation of TbrMF7.1 in the WT s427 cell 
line 
 In an attempt to unravel the role of MFs as transporters, TcoMF7.1 which was 
observed in chapter 3 in this thesis to induced resistance to pentamidine when 
expressed in ISMR was further investigated. To do that TbrMF7.1 was genetically 
manipulated in order to investigate its effect, if any, on drug sensitivity and 
cAMP efflux in T. brucei WT s427.  
The strategy to express the protein in T. brucei cell lines was mainly informed 
by the fact that the genome of T. congolense is difficult to manipulate as it 
remains largely unamenable. Currently, some vectors for T. congolense are 
becoming available but at the beginning of the project, the culturing of T. 
congolense was still a major issue and its genetic manipulation in its infancy, at 
best. We therefore chose a strategy of expressing the T. congolense transporter 
genes in T. brucei and deleting the homologous T. brucei genes. In order to 
ascertain the function of TbrMF7.1 (Tb927.5.470) in T. brucei WT s427, the gene 
was either knocked out or expressed after which it was functionally 
characterized. The generated phenotype’s response to cAMP and other 
compounds was investigated.  
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5.2.1 Constructing TbNeo, TbHyg, TbBlast, TbrMF7.1 (TbrMF7.1+/-) 
heterozygote lines 
To understand the possible role of TbrMF7.1 in the transport of substrate in T. 
brucei, firstly, each gene was sequentially deleted and replaced with a resistant 
antibiotic cassette through single homologous gene replacement method. 
Heterozygotes of TbrMF7.1 (TbrMF7.1+/-) were obtained by deleting each allele 
of the gene and replacing it with either Blasticidin (Blast), Neomycin (Neo) and 
hygromycin (Hyg). The success of the manipulations was confirmed with PCR 
amplification of the 5’UTR and 3’UTR regions using the reverse and forward 
primers respectively (Figure 5.1).  
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Figure 5.1.a: KO constructs designed with the various resistant cassettes to replace 
MF genes. 
The P(no.) corresponds to primer used to check for loss of gene and also the 
integration of construct into the genome of the parasite.  
Figure 5.1.b: Gel picture confirmation of PCR integration of antibiotic resistant 
cassettes. Using gDNA, heterozygote cells of TbrMF7.1 (TbrMF7.1+/-) were obtained 
by replacing the one allele with the antibiotic. Correct integration of the constructs 
was confirmed with PCR, amplifying from the 5’UTR forward primer (HDK937) and 
the reverse primer on the antibiotic and 3’UTR reverse primer (HDK938) and a 
forward primer from the antibiotic cassette.  
A. For the Heterozygote of TbrMF7.1(TbrMF7.1+/- ) with the blasticidin-resistance 
cassette: 1. TbrMF7.1+/- Blast 5’UTR (~ 1.6kb) by using 5’UTR forward primer HDK937 
and reverse primer on the Blast HDK283 ; 2. s427 with primers as in lane 1 ; 3. 
TbrMF7.1 Blast 3’UTR (~ 2kb) by using 3’UTR reverse primer HDK938 and forward 
primer from the Blast HDK282 ;4. s427 with primers as in lane 3. 
B. For the Heterozygote of TbrMF7.1(TbrMF7.1+/- ) with the hygromycin-resistance 
cassette: 1. TbrMF7.1+/- Hyg 5’UTR (~1.2 kb) by using 5’UTR forward primer HDK937 
and reverse primer on the Hyg HDK1045; 2. s427 with primers as in lane 1 ; 3. 
TbrMF7.1 Hyg 3’UTR (~ 2.4kb) by using 3’UTR reverse primer HDK938 and forward 
primer from the Hyg HDK1044 ; 4. s427 with primers as in lane 3.  
C. For the Heterozygote of TbrMF7.1 (TbrMF7.1+/- ) with the neomycin-resistance 
cassette: 1. TbrMF7.1+/- Neo 5’UTR (~ 2.2 kb) by using 5’UTR forward primer HDK937 
and reverse primer on the Neo HDK285 ; 2. s427 with primers as in lane 1; 3. MF5.2 
Neo 3’UTR (~ 900 bp ) by using 3’UTR reverse primer HDK938 and forward primer 
from the Neo HDK284 ; 4. s427 with primers assigned to lane 3. 
M= DNA Ladder 
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5.2.2 Generation of TbrMF7.1 null (TbrMF7.1-/-) cell lines  
After the deletion of the first gene to obtained Heterozygote of TbrMF7.1, the 
second allele was also knocked out, replacing it with an alternate antibiotic 
cassette to obtained null MF7.1 parasites. This was confirmed with PCR (Figure 
5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Gel picture confirmation the loss of TbrMF7.1 open reading frame in WT 
s427 parasites using gDNA. 
Primers for the complete ORF (HDK1396, HDK1397)  
1. TbrMF7.1 null Clone 1  
2. TbrMF7.1 null Clone 2  
3. TbrMF7.1 null Clone 3  
4. WT s427 (~ 1.2kb) 
5. No DNA. M= DNA Ladder 
1 2 3 M 4 5 
    1Kb 
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5.2.3 Quantitative RT-PCR confirmation of heterozygote and null 
TbrMF7.1 (Tb927.5.470) parasites.  
Confirmation of reduction in gene transcript abundance due to the deletion of a 
single TbrMF7.1 gene was assessed using qRT-PCR. All 3 heterozygote parasites 
with their genes replaced by antibiotic cassettes of hygromycin, blasticidin and 
neomycin showed a significant reduction in gene function (Figure 5.3). Two out 
of three clones picked from the double TbrMF7.1 gene deletion could not be 
detected by qRT-PCR confirming the complete loss of gene and thus the 
transcription into mRNA (Figure 5.3). 
 
 
Figure 5.3: Quantitative RT-PCR confirmation of heterozygote(TbrMF7.1+/- ) and null 
(TbrMF7.1-/- ) cells of TbrMF7.1. 
Heterozygote in this figure one allele was replaced with the corresponding antibiotic which 
resulted significant reduction of TbrMF7.1 in Null of TbrMF7.1 parasite expressing 2 different 
antibiotics which showed in Clone 1 and 2 no detection of mRNA confirming double gene 
deletion. 20 ng/µl cDNA were used and the house keeping gene was GPI8. The qRT-PCR 
presented here are data from 3 to 4 (n=3 to 4) independently generated cultures. Statistical 
significance was determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001, **** P<0.0001. 
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5.2.4 Complementation of null TbrMF7.1 (Tb927.5.470) parasites 
with TcoMF7.1 expressing parasite (Knock in) and 
expression of TcoMF7.1 (TcIL3000.5.90) in WT s427 
parasites. 
In order to investigate the effect of loss of function to TbrMF7.1 after both gene 
deletions, the null MF7.1 parasites were rescued with a pHD1336-TcoMF7.1 
plasmid. It was hypothesized that replacing the null TbrMF7.1 with the TcoMF7.1 
could somewhat reverse the effect of the loss of both genes of TbrMF7.1 due to 
their synteny. Confirmation of Knock In (KiN) was done by PCR using primers that 
amplify the open reading frame (ORF) of MF7.1 (Figure 5.4.A). The ORF of MF7.1 
(TcIL3000.5.90) was ligated into pHD1336 to make pHD1336-TcoMF7.1 
(TcIL3000.5.90), so as to express the gene under a PARP promoter. Integration of 
expressing construct was confirmed using PCR (Figure 5.4.B). 
Figure 5.4.A: An example of a linearized plasmid (pHD1336) showing MFS gene. 
After linearization with NotI, the plasmid integrates in the RNA spacer (sprRNA). The 
expression of the gene is under the PARP promoter (pPARP). The MFS DNA fragment is 
followed by 3’ Actin-PARP (3’ ACT-PARP) and 5’ Actin (5’ACT) and Blasticidin the 
antibiotic resistance gene. The green arrows indicate primers used for the amplification 
of the MFS gene whilst the purple primers check for the integration of the plasmid into 
the trypanosome. 
Figure 5.4.B: Confirming the presence of rescue copy (KiN) of TcoMF7.1 open reading 
frame in TbrMF7.1dko parasites, and the presence of pHD1336 TcoMF7.1 plasmid 
expressing the gene in WT s427 by Using gDNA. Panel A: 1. WT s427 (~ 1.2kb) 2. 
TbrMF7.1 dKO + TcoMF7.1 kIN 3. TbrMF7.1 dKO. 4. No DNA. M= DNA Ladder. Primers for 
the complete ORF(HDK1396,HDK1397).  
Figure 5.4.C: Gel confirmation of the presence of pHD1336 TcoMF7.1 plasmid expressing 
the gene in WT s427 by using the reverse primer of the gene (HDK1397 ) and the forward 
primer of the plasmid pHD1336 (HDK429 ). M. DNA Ladder. (1) TcoMF7.1 Kin. Clone 1;  
(2) TcoMF7.1 Kin. Clone 2; (3) TcoMF7.1Kin. Clone 3; (4) WT s427 5. No DNA. Band size 
of ~800 bp. Band size of ~800 bp by Using gDNA. 
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5.3 Drug sensitivity of heterozygote (TbrMF7.1+/-) and null 
(TbrMF7.1-/-) in WT s427. 
Heterozygote and null TbrMF7.1 parasites were tested in the presence of some 
trypanocides. Heterozygote of TbrMF7.1 was slightly but significantly resistant to 
DIM compared with WT s427; however parasites lacking TbrMF7.1 did not display 
any resistance to diminazene. This is an interesting outcome which we found 
difficult to explain. At best it could be speculated that the observed difference 
between the two might be spurious. This was the only explanation we could 
adduce to this data. No other significant differences were observed using this 
drug and cell lines (Figure 5.5). 
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Figure 5.5: Drug sensitivity assay of Heterozygote and null of TbrMF7.1 (Tb927.5.470) in WT 
s427. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium, CpdA/NPD-001 and Phenylarsine oxide, a known poison was used as 
positive control. WTs427 was used as control cell line. Using the standard alamar blue 
assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) were incubated 
with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, and 5% CO2. The 
result shows that heterozygote TbrMF7.1 cell lines were slightly but significantly resistant to 
DIM compared with WT s427 cell lines. Values are means derived from multiple (n=3 to 6) 
experiments + standard error of mean (SEM). Unpaired t-test showed significance indicated 
by *P<0.05; P<0.01; P<0.001. RF=Resistance Factor defined as the ratio of EC50 of the 
transgene parasite to that of the control (WTs427). n= 3 to 6 
NB:TbrMF7.1SKO=heterozygote TbrMF7.1 (one allele replaced with one antibiotic); 
TbrMF7.1dKO = Null TbrMF7.1 parasite (with both alleles deleted). 
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5.3.1 Drug sensitivity assay of null TbrMF7.1 + Kin of TcoMF7.1 
The T. congolense gene TcoMF7.1 was expressed in the null TbrMF7.1 (TbrMF7.1-
/-) strain in order to highlight its function in the absence of its T. brucei 
orthologue. Complementing TbrMF7.1 with TcoMF7.1 lead to a slight increase in 
resistance to Diminazene, and sensitisation to CpdA. However, none of these 
differences were significant (Figure 5.6). 
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Figure 5.6: Drug sensitivity assay of null of TbrMF7.1+Kin (Tco) in WT s427. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium, CpdA/NPD-001 and Phenylarsine oxide a known poison was used as 
positive control. WTs427 was used as control cell line. Using the standard alamar blue 
assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) were incubated 
with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, and 5% CO2. The 
result shows no significant differences were observed with any of the drugs tested. Values 
are means derived from multiple (n=3 to 6) experiments + standard error of mean (SEM). 
Unpaired t-test showed significance indicated by *P<0.05; P<0.01; P<0.001. RF=Resistance 
Factor defined as the ratio of EC50 of the transgene parasite to that of the control (WTs427). 
NB:MF7.1Kn+dko= TcoMF7.1 was expressed in the null TbrMF7.1 (TbrMF7.1-/-). 
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5.3.2 Drug sensitivity test of TcoMF7.1 in WT s427. 
In previous section (chapter 3), TcoMF7.1 was expressed in B48 and ISMR1, and 
found to confer resistance to pentamidine in ISMR1. Wild Type s427 cells 
expressing TcoMF7.1 were tested with some trypanocides. Expression of 
TcoMF7.1 in WT s427 parasites caused the parasites to be more sensitive to ETH. 
Although the resistance factor (RF) was only 0.6 (i.e. 40% sensitisation), this 
difference was strongly significant (P = 0.004) (Figure 5.7). No other significant 
differences were observed but it could be noted that sensitivity to the related 
phenanthridine drug ISM also increased upon expression of TcoMF7.1, by ~25%, 
although this did not attain statistical significance (P = 0.2). 
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Figure 5.7:, Drug sensitivity assays of selected trypanocides against TcoMF7.1-expressing 
wild-type parasites. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium and CpdA/NPD-001. WTs427 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells 
per well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours 
at 37 oC, and 5% CO2. The result shows TcoMF7.1 expressing s427 cells showed somewhat 
sensitized to ETH and there were no significant differences to the other trypanocides. 
Values are means derived from multiple (n=3 to 6) experiments + standard error of mean 
(SEM). Unpaired t-test showed significance indicated by *P<0.05; P<0.01; P<0.001. 
RF=Resistance Factor defined as the ratio of EC50 of the transgene parasite to that of the 
control (WTs427). 
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5.4 Uptake of isometamidium by genetically manipulated 
MF7.1 (Tb927.5.470) cell lines 
Knocking out both TbrMF7.1 (Tb927.5.470) alleles causes an apparent reduction 
in the uptake of ISM over time compared with WT s427 parasites (Figure 5.8). 
However, the scatter of points as seen in Figure 5.8 below makes it hard to 
judge the significance of this finding without more repeats, which are presented 
in section 7.2.1  
 
 
 
 
 
 
Figure 5.8: Uptake of ISM by null TbrMF7.1 (Tb927.5.470) WT s427. 
Null MF7.1 parasites showed reduced uptake of ISM compared with WT s427 
NB:MF7dko:Null TbrMF7.1 parasite (with both allels deleted) 
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5.4.1 Uptake of Diminazene by TcoMF7.1 expressing parasites in 
WT s427 parasites. 
Expressing TcoMF7.1 in wild-type T. brucei causes an increase in the uptake of 
DIM over time compared with WT s427 parasites. Figure 5.9 shows one of four 
identical but independent experiments, three of which displayed significantly 
uptake rates for the control and TcoMF7.1-expressing cells (F-test), whereas in a 
fourth experiment no significant difference was observed. This resulted in an 
overall average uptake rate for control cells of 0.0143 ± 0.0052 pmol/(107 cells)-
1s-1 versus 0.0195 ± 0.0041 pmol/(107 cells)-1s-1 for control and +MF7.1 cells, 
respectively (n=4, P = 0.068, Student’s paired t-test). 
 
 
 
Figure 5.9: Uptake of 0.4 µM [3H]-diminazene by parasites expressing TcoMF7.1 in WT s427. 
TcoMF7.1-expressing parasites take up more DIM compared with WT s427. An F-test 
showed that the slopes of the control and TcoMF7.1-expressing cell lines are significantly 
different: F = 10.43, P = 0.0121). n=4 
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5.5 Result summary 
The role of the MF7.1 gene in the transportation of various drugs and metabolic 
inhibitors of trypanosomes was interrogated by creation of knockout cell lines 
and expression of TcoMF7.1 gene in wild-type T. brucei. 
Apart from the pharmacological insights gained, these approaches helped to 
ascertain the function of the protein it encodes and also to determine its 
suitability as a target for novel anti-trypanosome compounds. It was observed 
that creation of heterozygote MF7.1 resulted in significant resistance to 
diminazene. However, null MF7.1 did not show any resistance to the drug. From 
this observation it can be deduced that MF7.1 gene encode a protein, which 
mediate the transport of diminazene and probably similar compounds. But care 
must be taken in interpreting this result, as the increased resistance to 
diminazene observed in the heterozygote line may be spurious. In support of 
this, three out of four transport experiments with [3H]-diminazene showed 
significant increase in uptake associated with the expression of TcoMF7.1. Thus 
it could be argued that TcoMF7.1 is an important diminazene transporter than 
the brucei homologue. However, an important argument against this is that the 
expression of this gene did not change the sensitivity to diminazene when 
introduced in the diminazene-resistant cell line B48.  
Under normal circumstances one would expect that null TcoMF7.1 parasites 
would rather exhibit significant increase in resistance to the drug. However, the 
contrary was observed in this study. For a possible explanation of this 
observation, we speculate that the disruption of the gene might have triggered 
an up-regulation of other genes which encode proteins with similar function(s) to 
compensate for the lost due to the knock out. Genetic compensation in response 
to a gene knockout was first reported in yeast in 1969. Since then, genetic 
compensation has been documented many times in a number of model 
organisms; however, our understanding of the underlying molecular mechanisms 
remains limited. It must be emphasized that the loss of one gene may be 
compensated for by another with overlapping functions and expression patterns.  
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It was also observed in this part of the study that disruption of the MF7.1 gene 
resulted in a reduced uptake of ISM when compared with uptake of the 
compound into the wild type (WT s427) parasites, which, if confirmed, would 
indicate that the protein encoded by this gene mediates, at least in part, the 
transport of the ISM, a phenanthridine aromatic amidine. The notion that 
isometamidium has multiple pathways for cell entry has not been proven but this 
is supported by the fact that extensive studies on ISM resistance, in T. brucei 
and in T. congolense have not identified mutations in a transporter gene 
encoding an important transporter. Rather, multiple studies have suggested that 
ISM resistance is associated with changes to the mitochondrial membrane 
potential, which provides a driving force for its uptake, as the cationic 
phenanthridine accumulates in the mitochondrion. 
It is important to note that ISM has been used both as a prophylactic and 
therapeutic trypanocidal agent in the field. There is the thinking that chemical 
alteration of this compound may allow it to be used to treat drug resistant 
strains of trypanosome. Expression of TcoMF7.1 in WT s427 parasites was 
observed to result in a significant increase in sensitivity to ETH, giving rise to the 
hypothesis that this transporter might mediate ethidium uptake. It is worth 
noting that another member of the MFS, Rv1410c from Mycobacterium 
tuberculosis, has been reported to transport ethidium bromide and other toxins, 
albeit in this case by efflux (Farrow et al., 2016). 
  
  
TcoMF18.8 and TbrMF18.8 in T. brucei cell lines 
sensitivity to trypanocides. 
 
6.1  Genetic manipulation of TbrMF18.8 (Tb927.8.5570) in 
WT s427 cell line 
From previous experiments carried out in this study, it was shown that one of 
the genes, TcoMF18.8, identified by our collaborator (referred to in chapter 3) 
induced significant resistance to pentamidine when expressed in ISMR1. In order 
to ascertain whether it also contributes to uptake of other anti-typanosoma 
drugs and cAMP efflux in T. brucei WT s427, TcoMF18.8 was genetically 
manipulated and the resultant phenotype interrogated regarding their transport 
role in the parasite. As previously stated, the decision to express the proteins in 
T. brucei cell lines was mainly due to the fact that the genome of T. congolense 
is not easily amendable. 
To carry out this objective, TbrMF18.8 (Tb927.8.5570) in was deleted in T. 
brucei WT s427 parasites, and the TcoMF18.8 (TcIL3000.8.5380) expressed in 
these cells. Parasite sensitivity to trypanocides and certain drugs were 
functionally characterized using the classical drug sensitivity and uptake assays. 
Effect of the deletion on cAMP  concentration in the transgenic parasites was 
also assessed. 
 
6.1.1 Construction of null TbrMF18.8 (TbrMF18.8-/-) parasite cells 
lines 
To understand the possible role of TbrMF18.8 (Tb927.8.5570) in transport of 
substrate in T. brucei, plasmids with 5’UTR and 3’UTRs of TbrMF18.8 
(Tb927.8.5570) and genes expressing resistance to Blasticidin (Blast) or 
hygromycin (Hyg) were transfected into WT s427 to replace the native genes 
(wild type). Generation of the TbrMF18.8+/- heterozygote was confirmed by PCR 
(see legend of Figure 6.1 for detailed description).  
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Figure 6.1.A: KO constructs designed with the various resistant cassettes to replace MF 
genes. 
The P(no.) corresponds to primer used to check for loss of gene and also the integration of 
construct into the genome of the parasite. 
Figure 6.1.B&C PCR confirmation of integration of antibiotic resistant cassettes. Using 
gDNA, TbrMF18.8+/- heterozygote cells of TbrMF18.8 were generated by replacing the gene 
with antibiotic cassette. Correct integration of the constructs was confirmed with PCR, 
amplifying from the pre-5’UTR forward primer (HDK1033) and the reverse primer on the 
antibiotic and post 3’UTR reverse primer (HDK1034) and a forward primer from the antibiotic 
cassette. 
Figure 6.1.B: For TbrMF18.8+/- heterozygote cells of TbrMF18.8 with the blasticidin-
resistance cassette: 1. TbrMF18.8 Blast 5’UTR (~ 1.7kb) using pre-5’UTR forward primer 
HDK1033 and reverse primer on the Blast HDK283 ; 2. s427 with primers as in lane 1 ; 3. 
TbrMF18.8 Blast 3’UTR (~ 1.8kb) using post 3’UTR reverse primer HDK1034 and forward 
primer from the Blast HDK282 ;4. s427 with primers as in lane 3. 
Figure 6.1.C: For TbrMF18.8+/- heterozygote cells of TbrMF18.8 hygromycin-resistance 
cassette: 1. TbrMF18.8 Hyg 5’UTR (~2.2 kb) using pre-5’UTR forward primer HDK1033 and 
reverse primer on the Hyg HDK1045; 2. s427 with primers as in lane 1 ; 3. TbrMF7.1 Hyg 
3’UTR (~ 2.5kb) using post 3’UTR reverse primer HDK1034 and forward primer from the Hyg 
HDK1044 ; 4. s427 with primers as in lane 3. M= DNA Ladder 
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6.1.2 Generation of null TbrMF18.8 (TbrMF18.8-/-) cell lines 
After the deletion of the first gene allele which generated the TbrMF18.8+/- 
heterozygote cells, the second allele of TbrMF18.8 gene was also deleted to 
obtain a null TbrMF18.8 parasites. This was confirmed with PCR (Figure 6.2). 
 
 
Figure 6.2: Gel picture confirmation of the loss of TbrMF18.8 open reading frame in WT s427 
parasites using gDNA. 
Primers for the complete ORF were HDK1398 and HDK1399. 1. Null TbrMF18.8 (TbrMF18.8-/-) 
2. WT s427 (~ 1.4kb )3. No DNA. M= DNA Ladder 
 
6.1.3 Quantitative RT-PCR confirmation of heterozygote and null 
TbrMF18.8 parasites.  
Confirmation of fold decreases of gene mRNA due to the deletion of a single 
TbrMF18.8 gene was assessed using qRT-PCR. Parasites that have lost one 
TbrMF18.8 gene did not show any significant decrease in gene expression level 
probably to be due to the ability of the single allele to compensate for the loss 
of homozygosity (Figure 6.3). However, all three clones of the null TbrMF18.8 
cell line could not be detected by qRT-PCR confirming the total loss of mRNA 
transcription and hence lack of the gene (Figure 6.3). 
 
1.5 Kb  
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Figure 6.3: Quantitative RT-PCR confirmation of heterozygote and null cells of TbrMF18.8. 
In the heterozygote only one allele was replaced with the corresponding antibiotic with no 
change in expression level. Deletion of the second allele of TbrMF18.8 gene resulted in the 
generation of null of TbrMF18.8 parasites. All clones showed no detection of mRN with Null 
TbrMF18.8 parasites, confirming double alleles deletion. 20 ng/µl cDNA was used as 
template DNA, Expression level was quantified using the generated CT values. 4-6 replica 
reactions were performed. The house keeping gene GPI8 was used as control. Statistical 
significance was determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001, **** P<0.0001. n=3 to 6 
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6.1.4 Expression of TcoMF18.8 (TcIL3000.8.5380) in WT s427 
parasites. 
The ORF of TcoMF18.8 was ligated into pHD1336 to make pHD1336-TcoMF18.8 in 
order to express the gene under a PARP promoter. Integration of expression 
construct was confirmed using PCR (Figure 6.4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4.A: An example of a linearized plasmid (pHD1336) showing MFS gene. 
After linearization with NotI, the plasmid integrates in the RNA spacer (sprRNA). The 
expression of the gene is under the PARP promoter (pPARP). The MFS DNA fragment 
is followed by 3’ Actin-PARP (3’ ACT-PARP) and 5’ Actin (5’ACT) and Blasticidin the 
antibiotic resistance gene. The green arrows indicate primers used for the amplification 
of the MFS gene whilst the purple primers check for the integration of the plasmid into 
the trypanosome. 
Figure 6.4.B: Gel picture confirming the presence of pHD1336 TcoMF18.8 plasmid 
expressing the gene in WT s427. The reverse primer of the gene (HDK1398) and the 
forward primer of the plasmid pHD1336 (HDK429) were used. This was done using 
gDNA. 1. TcoMF18.8 Kin Clone 1; 2. TcoMF18.8 Kin Clone 2; 3. TcoMF18.8 Kin Clone 3; 
4. WT s427; 5. No DNA. M= DNA Ladder. Expected band size is~800 bp. 
Amani S. Alhejely   Chapter 6,158 
 
6.1.5 Quantitative RT-PCR confirmation of the expression of 
TcoMF18.8 parasites in WT T. brucei.  
Messenger RNA levels were measured using qRT-PCR to confirm expression of 
MF18.8 gene. However, the primers used also recognised the T. brucei MF18.8 
gene (TbrMF18.8), causing a high background in the WT control cells. Three 
clones were selected after transfection and mRNA levels measurement. All three 
selected clones showed increased mRNA levels, but only one of them, designated 
clone 3, showed a significant increase in MF18.8 expression (Figure 6.5). 
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Figure 6.5: Quantitative RT-PCR of TcoMF18.8 expression in WTS427. 
20 ng/µl cDNA was used as template DNA. It was quantified using the generated CT values. 
4-6 replica reactions were performed, the house keeping gene GPI8 was used as control. All 
three clones showed a significant increase with clone 3 showing a significant increase in 
gene expression. Statistical significance was determined using a multiple comparisons 
ANOVA test with the PRISM 7.0 software package. *, P<0.05; **, P<0.01; ***, P<0.001. n=3 to 6 
 
 
 
6.2 Drug sensitivity assay of heterozygote and null 
TbrMF18.8 WT s427. 
Single (heterozygote) and double KO (null) TbrMF18.8 parasites were tested in 
the presence of several trypanocides. Only null TbrMF18.8 showed significantly 
lower sensitivity to ISM with an EC50 value 30% higher than the control. (Figure 
6.6). Both single and null parasites of MF18.8 showed some sensitisation to 
CpdA. However, this was not significantly different from that of the WT parasite. 
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Figure 6.6: Drug sensitivity assay of Heterozygote and null TbrMF18.8 WT s427. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium and 
isometamidium, CpdA/NPD-001 and Phenylarsine oxide, a known poison used as positive 
control. WTs427 was used as control cell line. Using the standard alamar blue assay, the 
cells (2x105 cells per mL corresponding to 2x104 cells per well) were incubated with serially 
diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, and 5% CO2. Only null 
TbrMF18.8 cell lines showed significantly lower sensitivity to ISM; the EC50 value was only 
30% higher than the control. Statistical analysis showed that there was no significant 
difference between the heterozygote and null cell lines when compared with WT s427. This 
result indicates that deletion of the TbrMF18.8 did not influence parasite’s sensitivity to 
cpdA. 
Values are means derived from multiple (n=3-6) experiments + standard error of mean 
(SEM). Unpaired t-test showed significance indicated by *P<0.05; P<0.01; P<0.001. 
RF=Resistance Factor defined as the ratio of EC50 of the transgene parasite to that of the 
control (WTs427). 
NB:TbrMF18.8 SKO=heterozygote TbrMF18.8 (one alelle replaced with one antibiotic); 
TbrMF18.8 dKO = Null TbrMF18.8 parasite (with both allels deleted).  
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6.2.1 Drug sensitivity test of WT T. brucei s427 expressing 
TcoMF18.8 in WT s427. 
In a previous section (chapter 3), TcoMF18.8 was expressed in B48 and ISMR1, 
and found to confer resistance to pentamidine. Here, the gene was expressed in 
WT s427. The parasite expressing TcoMF18.8 was observed to be resistant to ISM 
and CpdA ( Figure 6.7).  
Amani S. Alhejely   Chapter 6,161 
 
 
Figure 6.7: Drug sensitivity assays of selected trypanocides against wild-type parasites 
expressing TcoMF18.8. 
The trypanocides tested in this work are pentamidine, diminazene, Ethidium, 
isometamidium and CpdA/NPD-001. WTs427 was used as control cell line. Using the 
standard alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per 
well) were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 
oC, and 5% CO2. The result shows Expression of TcoMF18.8 caused significant resistance 
to ISM and CpdA . Values are means derived from multiple (n=3-6) experiments + standard 
error of mean (SEM). Unpaired t-test showed significance indicated by *P<0.05; P<0.01; 
P<0.001. RF=Resistance Factor defined as the ratio of EC50 of the transgene parasite to that 
of the control (WTs427). 
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6.3 Determination of intracellular and extracellular levels 
of Cyclic Adenosine Monophosphate (cAMP) in WT, 
null (TbrMF18.8-/-)and WT+TcoMF18.8 cells lines. 
Deleting both genes (dKO) of TbrMF18.8 (TbrMF18.8-/-) causes a significant 
decrease (1.7 fold) in intracellular levels of cAMP. The decrease in the 
intracellular cAMP in the absence of MF18.8 probably suggests that MF18.8 plays 
a role in regulating steady-state cAMP levels, perhaps through an ability to allow 
the distribution of cAMP within the parasite, bringing PDEs other than the 
TbrPDEB isoforms inhibited by CpdA into play. The observation that the internal 
cAMP levels are no different from control when TbrPDEB1 is inhibited seems to 
indicate that the effect on basal cAMP levels is the result of an adaptation in the 
null cells that does not affect the acute surge in intracellular cAMP resulting 
from PDE inhibition. 
Surprisingly, overexpressing Tco MF18.8 in WT s427 also caused a significant 
decrease in the intracellular concentration of cAMP in these parasites (Figure 
6.8). This is a very surprising result which is quite difficult to explain. A possible 
far-fetched explanation might be that since Tb MF18.8 and Tco MF18.8 show 
some synteny, overexpressing Tco MF18.8 in WT s427 which still have both 
alleles of Tb MF18.8 disrupts cAMP signalling pathway affecting the feedback 
loop. This resulted in a decrease in cAMP levels possibly due to 
overcompensation. 
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Figure 6.8: Determination of extracellular and intracellular cAMP levels in WT T. brucei s427, 
null TbrMF18.8 cells lines and cells expressing TcoMF18.8 using an ELISA-based assay. 
Cultures were exposed to either 2× or 5× the EC50 concentration of CpdA for 3 hours. Result 
shows in the absence of TbrMF18.8 causes a significant decrease in intracellular levels of 
cAMP and expressing TcoMF18.8 in the WTs427 cells resulted in a significant decrease in 
intracellular cAMP levels in the unchallenged parasites, whilst both 2x and 5x EC50 
concentration of CpdA. Using 2× EC50 concentration of the PDE inhibitor, statistical 
significance was determined using a multiple comparisons ANOVA test with the PRISM 7.0 
software package. *, P<0.05; **, P<0.01; ***, P<0.001. n=3 to 6 
NB:TbrMF18.8 dKO = Null TbrMF18.8 parasite (with both alleles deleted).  
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6.4 Transport of Diminazene into null TbrMF18.8 
(Tb927.8.5570) WT s427 
Knocking out both TbrMF18.8 alleles (TbrMF18.8-/-) did not significantly influence 
the uptake of DIM compared with WT s427 parasites. However, in 3 out of 4 
repeats a small increase in diminazene accumulation (22-28% versus control) was 
observed, whereas in 1 repeat there was virtually no difference between the 
dKO and WT control groups (Figure 6.9). Table 6.1 summarises the rate of 
uptake for the 4 experiments.  
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Figure 6.9: Uptake of DIM by null TbrMF18.8 (Tb927.8.5570) parasites in WT s427. 
The two graphs are representative of four independent repeats. Slopes for all four 
experiments are shown. F-test showed no difference between the two slopes in the upper 
panel, but a significant difference (P<0.05) for the lower panel. 
NB: MF18.8 dKO = Null TbrMF18.8 parasite (with both alleles deleted).  
 
Amani S. Alhejely   Chapter 6,165 
 
 
Table 6.1: Uptake rates of [3H]-diminazene by WT and TbrMF18.8 null (dKO) cells. 
Rates were derived from linear regression of 5 points taken over 10 minutes as shown in 
Figure 6.9 and are expressed as pmol(107 cells)-1s-1. 
 
 
6.4.1 Uptake of isometamidium by TbrMF18.8-/- strain. 
Knocking out both TbrMF18.8 (Tb927.8.5570) alleles causes a highly significant 
(P<0.0001, F-test) increase in the uptake of ISM over time compared with WT 
s427 parasites (Figure 6.10). In three independent repeats the increase in 
intracellular ISM accumulation was consistently highly significant between the 
two lines, and overall the comparison between the control and TbrMF18.8-/- line 
was significant by paired t-test (Table 6.1). 
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Figure 6.10: Uptake of ISM by s427 strain from whichTbrMF18.8 (Tb927.8.5570) had been 
deleted. 
Double KO MF18.8 (null) parasites showed increase uptake of ISM compared with WT s427 
that was significantly different by F-test (F = 136.2; P <0.0001). 
 
 
 
 
Table 6.2: Overview of three identical but independent experiments measuring the rate of 
uptake of ISM in Tb427WT and the derived TbrMF18.8 knockout strain. 
The right-hand column gives an intra-experimental comparison between the slope of the 
two lines. The bottom two rows give the outcomes of paired and unpaired Student’s t-test 
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6.5 Result summary 
The emergence of trypanosome species resistant to the standard trypanocides 
has prompted the search for novel anti-trypanosome agents to ameliorate the 
situation. The unique metabolic pathway of the parasite could be a good drug 
target. The transport system of the parasite and the cAMP pathways, which are 
involved in signal transduction, could be investigated and considered in this 
regard. In facts, reports have already suggested the validation and exploitation 
of Phosphodiesterases (PDEs) as possible drug targets, since inhibitors of these 
enzymes prevent cAMP degradation with a consequent adverse outcome (Shakur 
et al., 2011; de Koning et al., 2012; Blaazer et al., 2018). Other components of 
the cAMP signal transduction system that could be interrogated and validated as 
drug target in trypanosomes include adenylate cyclase and protein kinase A 
(Gould and de Koning, 2011). GAF-domains have been identified in the N-
terminus of several different Trypanosoma phosphodiesterases (Oberholzer et 
al., 2007; de Koning et al., 2012), and could provide targets for more specific 
PDE inhibitors that avoid the highly conserved catalytic domain, bearing in mind 
the effects on the host homologues (de Heuvel et al., 2019). However, one 
major limitation concerning the effective use of PDE inhibitors is the efflux of 
the cAMP (counteracting the effectiveness of inhibiting its degradation). The up-
regulation of cAMP efflux has been suggested as a likely cause of parasite 
resistance mechanisms (T. Seebeck, personal communication). Therefore the 
role of TcoMF18.8 and TbrMF18.8 in cAMP efflux was investigated in this part of 
the study. 
Although many different transporters of nutrients such as TbAT1, HAPT and LAPT 
have been thoroughly investigated, the functions of transporter families such as 
MFS and MATE are yet to be properly examined in trypanosomes. Thus, a major 
objective of this study was to identify and clone MFS, MATE and similar 
transporters in trypanosomes, and investigate their role in drug sensitivity and 
cAMP efflux. By creating heterozygous and homozygous null mutants for the gene 
encoding these transporter proteins, this objective was pursued. 
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Trypanosomes lacking one of the MFS genes were created through a single or 
double KO of the MF18.8 gene in the parasite. Null MF18.8 genes parasites were 
tested in the presence of some trypanocides.  
Interestingly, these same TbrMF18.8-null cells displayed a much-increased rate 
of ISM accumulation when ISM uptake was measured using its intrinsic 
fluorescence. This effect was much more pronounced and significant than the 
relatively small increase in EC50 had suggested. This phenomenon has been 
observed before in our laboratory and it highlights a limitation in the standard 
drug sensitivity assay based on a 48-h incubation with the test compound before 
the addition of resazurin (Alamar blue); a change in the rate of ISM accumulation 
may not greatly impact whether the cells are dead in 48 h - they may die faster 
but ther indicator dye is only added after 48 h. In contrast, the transport assay is 
conducted on a scale of minutes. From the outcome of the ISM transport 
experiments it can be deduced that TbrMF18.8 plays a role in the efflux of ISM, 
leading to a higher net accumulation in the null mutant. Consistent with that 
result, expressing TcoMF18.8 in Tb427WT rendered these cells significantly less 
sensitive to ISM (and ethidium), which might also indicate a capacity to extrude 
phenanthridine drugs from the cells.  
Expressing TcoMF18.8 in Tb427WT also slightly sensitised the parasites to 
diminazene (P<0.05). When uptake of [3H]-diminazene was assessed, there was a 
trend showing a higher net accumulation in the TbrMF18.8-null cell line, but it 
amounted to an increase of only 15% in the knockout strain, a difference that 
was ultimately not significant over 4 repeats. We thus concluded that MF18.8 
does not make a major contribution to diminazene import or efflux. Indeed, it 
has previously been reported that the majority of diminazene uptake in 
bloodstream form T. brucei is mediated by the TbAT1/P2 aminopurine 
transporter (de Koning et al., 2004). However, the High Affinity Pentamidine 
Transporter (HAPT1), now known to be identical to TbAQP2 (Munday et al., 
2014), is also capable of some diminazene uptake, which becomes clear in the 
absence of TbAT1, as demonstrated in procyclic cells (Teka et al., 2011), that do 
not express the P2 transporter (de Koning et al., 1998). That leaves the 
possibility that TcoMF18.8 is able to transport diminazene even when TbrMF18.8 
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is not. However, the data presented in Chapter 3, when TcoMF18.8 was 
expressed in T. brucei B48, do not support this interpretation.  
Another interesting observation with MF18.8 was that the wild-type T. brucei 
s427 expressing TcoMF18.8 were two-fold less sensitive to CpdA (P<0.01). Since 
CpdA is a classical inhibitor of PDEs (de Koning et al., 2012) this result should be 
discussed in terms of cAMP breakdown and cAMP cellular concentrations, and we 
therefore measured cAMP content in the TcoMF18.8-expressing cells. These cells 
displayed a reduced basal cAMP level (P<0.01) in the absence of a PDE inhibitor, 
but not significantly so when the cells were treated with CpdA. However, both 
2× and 5× EC50 concentration of CpdA caused a highly significant increase in 
cAMP in the media of the parasites expressing TcoMF18.8 compared with WT 
s427 (P<0.01 and P<0.001, respectively). This dose-dependent increase in the 
extracellular cAMP content is as expected if TcoMF18.8 mediates cAMP efflux, 
the breakdown of which is inhibited by CpdA. 
If the TbrMF18.8 were to have a similar role, the knockout of the gene should 
potentiate the effect of CpdA as cAMP would no longer be disposed of as 
efficiently and thus attain deleterious levels sooner. Indeed, an increase in 
sensitivity to the PDE inhibitor was observed in both single and double knockout 
clones, but the effect was not statistically significant, nor was a clear and 
consistent effect observed on cAMP levels and we conclude that TbrMF18.8 does 
not play a significant role in cAMP metabolism in T. brucei, although TcoMF18.8 
is certainly a candidate for playing such a role in T. congolense. 
  
Deleting more than one TbrMF gene in the same 
parasite 
 
7.1 Deleting more than one TbrMFS gene in the same 
parasite. 
One possible reason for the marginal effects of some of the transporter 
knockouts on drug sensitivity may be that drugs may be recognized by multiple 
transport proteins hence deletion (or introduction) of one efflux or import 
transporter alone may not result in a large difference in flux. In an attempt to 
further understand the possible role of MF genes in the transport of 
trypanocides, TbrMF5.2 was deleted from TbrMF7.1 dKO parasites to generate a 
dKO MF7.1+sKO MF5.2 cell line, whilst a single MF7.1 allele was deleted from 
dKO MF18.8 to generate dKO MF18.8+sKO MF7.1 parasite.  
Attempts to knockout TbrMF7.1 alleles from the TbrMF18.8 dKO strain were 
problematic, as it was observed that most of emerged clones that were screened 
were not correctly integrated (false knockouts). Only 1 genuine sKO clone for 
TbrMF7.1 could be obtained in the TbrMF18.8 dKO background. Attempts to 
achieve a double knockout of both TbrMF7.1 alleles in this strain were 
unsuccessful after many attempts (using transfection of s427 as an internal 
control for the procedure), even though the same constructs were used as 
previously obtained (a TbrMF7.1 dKO in the wild-type s427). We thus concluded 
that the simultaneous deletion of TbrMF7.1 and TbrMF18.8 is not viable. 
Similarly, the deletion of both TbrMF5.2 alleles was not possible, as already seen 
in the wild type T. brucei strain (see Chapter 4). Validation of the constructs 
was done using PCR (Figure 7.1). 
A drug sensitivity assay was undertaken on the multiple MF mutant parasites. 
Deleting a single TbrMF5.2 gene from a dKO TbrMF7.1 parasite causes these 
parasites to be significantly resistant to DIM and ISM with a Resistance Factor 
(RF) in one clone reaching 6.04 for ISM. Similarly, deleting a single TbrMF7.1 
allele from TbrMF18.8 dKO parasites led to the EC50 of ISM reaching 
approximately 3.5-fold of that of the WT s427. None of the other compounds 
tested showed any significant differences (Figure 7.2).  
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Figure 7.1: A. Gel confirmation of TbrMF7.1-/- (dKO).   
A- Gel picture confirmation of the loss of TbrMF7.1 open reading frame in WT s427: 
This was done using gDNA. Primers for the complete ORF (HDK1396, HDK1397): 
M: DNA Ladder 
1: TbrMF7.1 null 
2: WT s427 (~ 1.2kb) 
3: No DNA 
 
B. Confirmation of deletion of one allele of TbrMF5.2  and replacement with the blasticidin-
resistance cassette in TbrMF7.1-/- (dKO) background.  
B- TbrMF7.1-/- (dKO) + TbrMF5.2+/- 
M:DNA ladder 
1:MF5Blast 5UTR 
MF5.2 Blast 5’UTR (~ 1.7kb) by using 5’UTR forward primer HDK926 and reverse primer on 
the Blast HDK283 
2: WT . s427 with primers as in lane 1 
3: MF5.2 Blast 3’UTR (~ 2.5kb) by using 3’UTR reverse primer HDK927 and forward primer 
from the Blast HDK282 
4:WT s427 with primers as in lane 3.  
C. Gel confirmation of TbrMF18.8-/- (dKO).   
M:DNA ladder 
1: Null TbrMF18.8 (TbrMF18.8-/-) 
2: WT s427 (~ 1.4kb ) 
3: No DNA 
D. Confirmation of deletion of one allele of TbrMF7.1  and replacement with the neomycin-
resistance cassette in TbrMF18.8-/- (dKO) background 
D- For the Heterozygote of TbrMF7.1 (TbrMF7.1+/- ) with the neomycin-resistance cassette:  
M:DNA ladder 
1:TbrMF7.1+/- Neo 5’UTR (~ 2.2 kb) by using 5’UTR forward primer HDK937 and reverse 
primer on the Neo HDK285 
2: s427 with primers as in lane 1 
3:TbrMF7.1 Neo 3’UTR (~ 900 bp ) by using 3’UTR reverse primer HDK938 and forward 
primer from the Neo HDK284 
4: s427 with primers assigned to lane 3. 
    M        1      2       3     4  
1 KB 
1.5 KB 1.5 KB 
    M     1       2      3 A.     M     1     2     3     4  B. 
1.5 KB 
    M     1      2        3  C. D. 
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Figure 7.2: Drug sensitivity assay of MF mutant paras. 
The trypanocides tested in this work are pentamidine (PEN), diminazene (DIM), Ethidium 
(ETH) and isometamidium, (ISM). WTs427 was used as control cell line. Using the standard 
alamar blue assay, the cells (2 x 105 cells per mL corresponding to 2 x 104 cells per well) 
were incubated with serially diluted drugs in a 96 well plate for a total of 72 hours at 37 oC, 
and 5% CO2. The result shows deleting a single TbrMF5.2 gene from a dKO TbrMF7.1 
parasite causes these parasites to be significantly resistant to DIM and ISM with a 
Resistance Factor (RF) in one clone reaching 6.04 for ISM. Similarly, deleting a single 
TbrMF7.1 allele from TbrMF18.8 dKO parasites drives the ISM EC50 to approximately 3.5-fold 
the value of WT s427. None of the other compounds tested showed any significant 
differences. Values are means derived from multiple (n=3 to 6) experiments + standard error 
of mean (SEM). Unpaired t-test showed significance indicated by *P<0.05; P<0.01; P<0.001. 
RF=Resistance Factor. 
NB:MF18.8dko/ MF7.1 sko= TbrMF7.1 heterozygot in TbrMF18.8 null cell line. 
MF7.1 dko/ MF5.2 sko= TbrMF5.2 heterozygot in TbrMF7.1 null cell line. 
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7.1.1 Gene expression of TbrMF5.2 in MF7.1 and MF18.8 mutant 
parasites. 
Expression of TbrMF5.2 in MF7.1 and MF18.8 genetically manipulated parasites 
was performed. Appropriate primers were used to determine the expression of 
TbrMF5.2 in these parasites. TbrMF5.2 expression was observed to have been 
significantly reduced in all the genetically manipulated MF7.1 parasites, 
including the strain expressing TcoMF7.1 (Figure 7.3). Surprisingly, all these 
transgenic parasites displayed a very similar expression level for MF5.2, whether 
the MF7.1 transporter was expressed or deleted. These results appear 
contradictory but may be an indication of interaction, at the level of 
transcription or mRNA stability, between the two T. brucei transportetrs, but 
not between T. brucei MF5.2 and the T. congolense MF7.1. It should be noted 
that MF5.2 and MF7.2 genes belong to the MFS and that functional overlap is a 
real possibility.  
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Figure 7.3:  Quantitative RT-PCR of genetically manipulated MF7.1 in WTS427 using MF5.2 
primers. 
20 ng/µl cDNA was used as template DNA, it was quantified using the generated CT values, 
4-6 replica reactions were performed, the house keeping gene GPI8 was used as control .All 
cell lines showed significant decrease in MF5.2 gene expression in these parasites. 
Statistical significance was determined using a multiple comparisons ANOVA test with the 
PRISM 7.0 software package. *, P<0.05; **, P<0.01; ***, P<0.001. n=3 to 6 
NB:TbrMF7.1 SKO=heterozygote TbrMF17.1 (one alelle replaced with one antibiotic); 
TbrMF7.1 dKO = Null TbrMF7.1 parasite (with both allels deleted).  
 
 
There were no significant differences in the expression of MF5.2 in MF18.8 
parasites including sKO TbrMF7.1 in dKO TbrMF18.8 parasite (Figure 7.4). 
TbrMF18.8 is of an unknown transporter family. 
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Figure 7.4: Quantitative RT-PCR of genetically manipulated MF18.8 using MF5.2 primers. 
20 ng/µl cDNA was used as template DNA, it was quantified using the generated CT values, 
4-6 replica reactions were performed, the house keeping gene GPI8 was used as control .All 
cell lines showed no significant differences in MF5.2 gene expression in these parasites. 
n=3 to 6. 
NB:TbrMF18.8 SKO=heterozygote TbrMF18.8 (one alelle replaced with one antibiotic); 
TbrMF18.8 dKO = Null TbrMF18.8 parasite (with both alleles deleted).  
 
 
 
 
 
 
 
 
 
 
 
 
 
W
T  
s 4
2 7
T b
rM
F 1
8 .
8 s
K O
T b
rM
F 1
8 .
8 d
K O
T c
o M
F 1
8 .
8  
K i
n
T b
rM
F 1
8 .
8 d
k o
+ T
b r
M
F 7
.1
s k
o
0
1
2
3
4
5
F
o
ld
 C
h
a
n
g
e
 o
f 
C
o
n
tr
o
l
E x p re s s io n  o f  M F 5 .2  in  M F 1 8 .8 /M F 7 .1  c e ll l in e s
Amani S. Alhejely   Chapter 7,177 
 
7.1.2 Gene expression of MF18.8 in MF7.1 and MF5.2 mutant 
parasites. 
Deleting MF5.2 in a dKO MF7.1 parasites causes a significant increase in 
resistance of clone 3 of dKO MF7.1+sKO MF5.2 (Figure 7.5). 
 
 
Figure 7.5:  Quantitative RT-PCR of genetically manipulated MF18.8 using MF5.2 primers. 
20 ng/µl cDNA was used as template DNA, it was quantified using the generated CT values, 
4-6 replica reactions were performed, the house keeping gene GPI8 was used as control .All 
cell lines showed no significant differences in MF5.2 gene expression in these parasites. 
Statistical significance was determined using a multiple comparisons ANOVA test with the 
PRISM 7.0 software package. *, P<0.05; **, P<0.01; ***, P<0.001. n=3 to 6 
NB:TbrMF5.2SKO=heterozygote TbrMF5.2 (one alelle replaced with one antibiotic); 
TbrMF7.1 dKO = Null TbrMF7.1 parasite (with both allels deleted).  
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7.2 Uptake assays with dKO TbrMF7.1+sKO TbrMF5.2 
mutant parasites.  
Drug uptake was performed in dKO TbrMF7.1+sKO TbrMF5.2 using [3H]-
diminazene. The results showed that deleting both TbrMF7.1 alleles as well as 
deleting 1 allele of TbrMF5.2 in the MF7.1 null strain led to a reduction in uptake 
of DIM in these parasites (Figure 7.6). The average of three independent repeats 
showed that this difference was statistically significant, both by a paired and an 
unpaired t-test. However, there was no difference at all between the deletion of 
the two TbrMF7.1 allele and the additional deletion of the MF5.2 allele. 
 
Figure 7.6:  Uptake of DIM by dKO MF7.1 and dKO MF7.1+sKO MF5.2 parasites in WT s427. 
Deleting both MF7.1 genes and also deleting MF5.2 from these dKO MF7.1 parasites causes 
a sharp decline in the uptake of DIM. n=3 
NB: dkoMF7.1+sKO MF5.2=heterozygote TbrMF5.2 (one alelle replaced with one antibiotic) 
in Null TbrMF7.1 parasite (with both allels deleted) cell line; MF7.1 dKO = Null TbrMF7.1 
parasite (with both allels deleted).  
 
 
7.2.1 Uptake of isometamidium of dKOTbrMF7.1+sKO TbrMF5.2 
mutant parasites. 
Both TbrMF7.1 double knockout strain and the clone with additional Tbr5.2 sKO 
appeared to display a lower rate of isometamidium uptake than the Tb427WT 
cells. However, the experiment was performed only once, making it impossible 
to draw definitive conclusions from it, especially since the linear regression of 
the wild-type data yielded a rather poor correlation coefficient on this occasion. 
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However, if taken at face-value, it appears that again there was little extra 
value in the deletion of the TbrMF5.2 allele over the deletion of the TbrMF7.1 
alleles. 
 
 
Figure 7.7: Uptake of ISM by dKOTbrMF7.1+sKO TbrMF5.2. 
Both TbrMF7.1 double knockout strain and the clone with additional Tbr5.2 sKO appeared to 
display a lower rate of isometamidium uptake than the Tb427WT cells. n=3 
NB: dkoMF7.1+sKO MF5.2=heterozygote TbrMF5.2 (one alelle replaced with one antibiotic) ; 
TbrMF7.1 dKO = Null TbrMF7.1 parasite (with both allels deleted). 
 
7.3 DISCUSSION: 
In order to understand and assess the complementary role of some of the genes 
encoding proteins in the MFS, TbrMF5.2 was deleted from TbrMF7.1 dKO 
parasites to generate a dKO MF7.1+sKO MF5.2 cell line, whilst a single MF7.1 
allele was deleted from dKO MF18.8 to generate dKO MF18.8+sKO MF7.1 
parasite. Such permutation of gene deletions is important as it permits the 
assessment and understanding of gene complementarity or supplementation 
within the parasite. In gene complementation, one gene could be dominant as it 
can express itself. The second gene could also be dominant but may expresses 
itself only when it is supported by the presence of the first gene.  
TbrMF5.2 expression was significantly reduced in all genetically manipulated 
MF7.1 parasites, including the strain expressing TcoMF7.1. Surprisingly, all these 
manipulated lines displayed a very similar expression level for MF5.2, whether 
the MF7.1 transporter was expressed or deleted. It can be deduced from these 
observations that the genes do not require each other in order to be expressed.  
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In Chapter 5 it was postulated that TcoMF7.1 might have some capacity for 
diminazene uptake. Here we show a strain from which both TbrMF7.1, and one 
TbrMF5.2 alleles were deleted was 5-to-6-fold resistant to diminazene, and 
displayed a significantly reduced [3H]-diminazene uptake rate. Further 
investigations as to how the dKO+sKO clones became so resistant to diminazene 
will be required, however, as the minor reduction in diminazene uptake rate 
does not seem to account for it. It can be speculated that, more than changing 
the net diminazene uptake rate, the MF transporters change the distribution of 
diminazene in the cell.  
The same cell lines also displayed both isometamidium resistance (3.5 - 6-fold) 
as well as apparently reduced isometamidium uptake. If the effects on both 
diminazene and isometamidium sensitivity can be confirmed in T. congolense, 
this would constitute a breakthrough in our understanding of cross-resistance for 
these essential animal trypanosomiasis drugs.  
  
  
General Discussion 
8.1 General Discussion 
Although the incidence of trypanosomiasis is reported to be declining (Simarro et 
al., 2011), yet the disease still remains a problem in the tropical regions of the 
world, and animal trypanosomiasis remains a problem and is spreading outside 
the tsetse belt (Giordani et al., 2016). Currently, in addition to the toxicity 
associated with the difficult to administer anti-trypanosome drugs, there is the 
report of the emergence and spread of drug resistant parasites (Simarro, P. P., 
Franco, J., Diarra, A., Postigo, J. A. and Jannin, 2012; Baker et al., 2013). For 
now, due to the antigenic variation of the surface glycoproteins of the parasite, 
vaccines are unlikely to be developed for the control of trypanosomiasis 
(McCulloch, 2004). To successfully control trypanosomiasis and possibly 
eliminate its presence in Africa therefore requires the search for novel, 
efficient, non-toxic anti-trypanosome drugs. There is an urgent need for novel 
drug target discovery, especially those that are involved in the unique metabolic 
pathways of the parasites. Drug targets could best be identified through 
increased and sustained effort to understand the cell biology of the 
trypanosomes at the molecular level. In this regard, among the more interesting 
and important drug targets to consider are the parasite’s transport proteins and 
signal transduction mechanisms. This is because, transport proteins in the 
parasites are not only involved in the translocation of nutrients from 
extracellular sources into the parasite for use but may also participate in the 
influx and efflux of chemical substances such as drugs, as well as in signal 
transduction. 
In an attempt to understand the drug transport system in trypanosomes, so as to 
exploit it for delivery of drugs and/or understand the mechanisms of drug 
resistance, eight genes (MF1.1, MF 2.2, MF 3.1, MF 4.1, MF 5.2, MF 6.3, MF 7.1, 
MF 18.8) encoding transporter proteins in the parasite were studied. These genes 
were originally identified in bacteria or fungi and later found to be present in 
many other organisms including T. congolense and T. brucei. The T. congolense 
genes were cloned, sequenced and successfully expressed in several drug-
sensitive and drug-resistant T. brucei cell lines, including the ISM and 
pentamidine-resistant T. brucei strains ISMR and B48 previously described by the 
group of de Koning (Bridges et al., 2007; Eze et al., 2016). The strategy to 
express the proteins in T. brucei cell lines was mainly informed by the fact that 
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the genome of T. congolense is difficult to manipulate as it remains largely 
unamenable. Currently, some vectors for T. congolense are becoming available 
but at the beginning of the project, the culturing of T. congolense was still a 
major issue and its genetic manipulation in its infancy, at best. We therefore 
chose a strategy of expressing the T. congolense transporter genes in T. brucei 
and deleting the homologous T. brucei genes as necessary. 
It must be emphasised once again that animal trypanosomiasis caused by T. 
congolense has a serious impact on livestock in sub-Saharan Africa. Currently, 
management of the disease is through the administration of drugs. 
Chemotherapy and chemoprophylaxis of African animal trypanosomiasis make 
use of three compounds, namely: diminazene, an aromatic diamidine; 
homidium, a phenanthridine; and isometamidium, a phenanthridine aromatic 
amidine hybrid (Leach and Roberts, 1981; Wilkes et al., 1995). Unfortunately, all 
of these drugs have toxic side effects in addition to reduced efficacy due to the 
evolution and spread of resistant parasites. Although, the mechanism of 
resistance and uptake of these drugs have been thoroughly studied, they are not 
fully understood, especially in T. congolense and other veterinary trypanosomes 
such as T. vivax. Some transporter proteins have been reported to play major 
role in the mediation of anti-Trypanosoma compounds (Carter and Fairlamb, 
1993; Geiser et al., 2005; Schumann Burkard et al., 2011; Baker et al., 2011). 
However, there is the suspicion that other transporter proteins such as the MFS 
and MATE play important role in compounds translocation, as is the case in other 
single-celled and multi-cellular organisms. Therefore, detailed knowledge of the 
role, if any, played by these transporter proteins in terms of the compounds 
they mediate within the parasites and the role they play in signal transduction 
may give proper insight and inform whether they could be considered as targets 
for anti-trypanosomal drugs. 
A major aim of this study was therefore to establish the expression levels of the 
proteins encoded by the selected genes and identify the permeates they 
mediate within the parasite as well as their involvement in regulating 
camp efflux, which has been observed to occur in trypanosomes (de 
Koning, unpublished observations; T. Seebeck, personal communication). 
Controlled disruption of genes encoding these membrane transporter 
proteins will enable 
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proper assessment of the suitability of the protein to deliver certain drugs into 
the cells. An organism's genes can be removed using genetic knockout 
techniques. Studying the differences between the phenotype emerged from the 
knockout and the wild type can give an insight into the function of the gene. 
Using similar technique, two alleles can be simultaneously knocked out in an 
organism (double knockout). It must be emphasised that delivery of drugs into 
cells is an important determinant of therapeutic efficacy of drugs. Since the 
genome of T. congolense is not easily amenable to manipulation, the selected 
genes investigated in this study were rather expressed in isometamidium- (ISMR) 
and pentamidine-resistant (B48) T. brucei cells lines for the investigations. 
These were chosen so as to more easily detect introduced genes that could 
restore sensitivity to isometamidium and diminazene, respectively. Meanwhile, 
transporters that cause resistance to ISM and DIM would be highlighted by 
expression in the ISM-sensitive B48 and in the wild-type s427 strains. To 
ascertain the roles of the MFS and MATE transporters in cAMP modulation, CpdA, 
a pharmacological inhibitor of T. brucei phosphodiesterase B1 and B2 
(TbPDEB1/2) was used to induce a decrease in cAMP breakdown in the cell, 
which is reported to result in elevated levels of cAMP in the cell and 
extracellular medium, causing cell death after 2-3 rounds of attempted but 
faulty cell division (de Koning et al., 2012). 
From observations made in this study, we can confirm that some of the genes 
investigated, especially MF5.2, are essential for the long-term survival of the 
parasites, as it was impossible to knock this gene out until an inducible ‘rescue 
copy’ was introduced. This finding is important as it implies that depriving the 
parasite of the protein encoded by this gene could results in its death. We 
speculate that this gene encodes a transporter protein that mediates the uptake 
and/or cellular distribution of essential nutrient(s) which are urgently required 
by the parasite for survival. Parasites lacking the MF5.2 gene also showed 
increased sensitivity to ISM and CpdA but resistance to SUR (see Figure 8.1). 
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Some transporters mediate the efflux rather than the uptake of the drugs, and in 
this case their expression can contribute to drug resistance. This phenomenon 
could explain some of the observations made here. Responses to CpdA whether 
negative or positive implies that the protein participates in the regulation of 
cAMP in the parasite. In most organism cAMP plays an important fundamental 
role as a second messenger in cellular responses to many hormones and 
neurotransmitters. The presence of cAMP in trypanosomes, and the regulation of 
its cellular concentration during the course of infection, have been recognized 
and reported since 1975 (Strickler and Patton, 1975). Emerging evidence 
suggests that cAMP plays significant roles in the development of the parasites. 
For instance, cAMP signaling cascade is reportedly involved in the differentiation 
of long-slender bloodstream T. brucei to the non-replicating stumpy form 
(Garcia et al., 1995; Van Den Abbeele et al., 1995; Vassella et al., 1997). 
Generally, production of cAMP in most organisms is initiated by the stimulation 
of Adenylyl Cyclases (ACs), whilst cyclic nucleotide PDEs degrade the 
phosphodiester bond in cAMP thus abrogating signal transduction (Dorsey et al., 
Figure 8.1: summary figure showing what each drug is transported by and includes MF 
transporters data from this work. 
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2010). Since in the current study, MF5.2 null parasites showed increased 
sensitivity to CpdA, a compound reported elsewhere in this thesis as an inhibitor 
of T. brucei phosphodiesterase, it is correct to say that the transporter protein 
encoded by MF5.2 gene appears to play a crucial role in signal transduction of 
the parasite. Even the cellular localization of the protein is consistent with them 
acting as modulators of that process, possibly through the efflux of cAMP.  
An interesting observation made in this study is that single knock out of some of 
the genes, for instance, TbrMF7.1 resulted in significant resistance to 
diminazene but that the parasite with double knockout of the gene did not show 
any resistance to the drug. A plausible reason for the difference in response to 
the drug could be that a ‘better fit parasite’ emerged after the double knock out 
of the gene through overexpression of proteins encoded by other genes so as to 
compensate for the lost genes. A single or double knockout of MF7.1 gene 
resulted in a significant reduction in the uptake of ISM indicating that the 
protein mediates in the transport of this compound. An expression of TcoMF7.1 
in WT s427 parasites resulted in a significant increase in sensitivity to ETH 
implying that this compound, closely related to the other phenanthridine drug, 
isometamidium, is also a likely substrate for the transporter protein. From these 
observations it can firmly be deduced that the protein encoded by the gene 
mediates the transport of probably many compounds including some anti-
trypanosomal drugs of the phenanthridine class (see Figure 8.1). 
Knocking out both alleles of TbrMF18.8, which was found to be localized on the 
cell surface of the parasite, did not significantly influence the uptake of DIM. 
However, it resulted in a significant decrease in intracellular levels of cAMP. 
This observation seems to suggest that compounds such as DIM are not the 
normal substrate for this protein. However the protein appears to play some role 
in the regulation of the concentration of cAMP. This assertion is supported by 
the fact that expressing TcoMF18.8 in the WT cells resulted in a significant 
decrease in intracellular cAMP levels in the unchallenged parasites, whilst both 
2× and 5× EC50 concentration of CpdA causes a significant increase in cAMP in the 
media of parasites expressing MF18.8. CpdA could therefore be a substrate for 
the transporter protein, or the transporter mediates cAMP efflux (see Figure 
8.1).  
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One possible reason for the relatively marginal effects of some of the 
transporter knockouts on drug sensitivity may be that drugs may be recognized 
by multiple transport proteins (and trypanosome genomes contain hundreds of 
transporter genes) and that the deletion (or introduction) of one efflux or import 
transporter alone may not result in a large difference in flux. In an attempt to 
further understand the possible role of MF genes in the transport of 
trypanocides, TbrMF5.2 was deleted from TbrMF7.1 dKO parasites to generate a 
dKO MF7.1+sKO MF5.2 cell line, whilst a single MF7.1 allele was deleted from 
dKO MF18.8 to generate dKO MF18.8+sKO MF7.1 parasite. Deleting a single MF5.2 
gene from a dKO MF7.1 parasite causes these parasites to be significantly 
resistant to DIM and ISM with a Resistance Factor (RF) in one clone reaching 6.04 
for ISM. Similarly, deleting a single MF7.1 allele from MF18.8 dKO parasites 
increases the ISM EC50 to approximately 3.5-fold the value of WT s427. 
The first population genomic study of T. congolense was reported in 2017 by 
Tihon and colleagues (Tihon et al., 2017). The study which examined genomics 
of parasites from ten African countries reported the existence among the 
population of a significant number of single nucleotide polymorphisms (SNPs), 
small insertions/deletions (indels) and gene deletions. 
A group of parasites from Zambia were found to be enormously diverse, 
exhibiting substantial number of heterozygous SNP and indel sites compared to 
T. congolense parasites from nine other countries. The group demonstrated in 
Genomewide 5-kb phylogenetic analyses that these parasites were the product 
of hybridization between phylogenetically distinct T. congolense lineages. Such 
findings bring to the fore the role of hybridization in spreading genes for drug 
resistance, pathogenicity and virulence.  
Bringing this at par with observations made in the current study one could be 
right to suggest that in considering novel drugs for treating the disease in 
endemic areas as well as in disease management, an important factor to 
consider is the existence of enormous genetic diversity among the parasite 
population. This comes in the light of several reports indicating that  knowledge 
of T. congolense life cycle, population biology and genetic diversity in the wild 
remains very poor (Tait et al., 2011; Autyi et al., 2015; Morrison et al., 2016). 
This discussion probably reflects the findings of a preceding report by Peregrine 
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et al of a significant variation in resistance to isometamidium among subclones 
derived from a drug-resistant Trypanosoma congolense stock (IL 2856) and 
characterized in mice for their sensitivity to isometamidium chloride and 
diminazene aceturate (Peregrine et al., 1991). 
This work is the first to discover, describe and confirm the activity of any MFS, 
MATE or similar gene product as a transporter for important compounds or drugs, 
used in the current treatment of both human and animal trypanosomiasis and 
previously un-discovered basis of resistance to these compounds. Finally, we 
describe here the first protozoan transporter/symporter for cAMP, which is 
potentially very important (if a suitable inhibitor can be developed) in the quest 
to apply the use of Phosphodiesterases (PDEs) as new therapies in the treatment 
of trypanosomiasis. This will allow the possibility of the application of 
combination therapy as well as recognize possible sources of resistance.  
All put together, it can be said that some members of the Major Facilitator 
Superfamily play important roles in transport and signal transduction in 
trypanosomes. This study constitutes the first attempt to determine functions 
for some of the MFS and MATE transporters expressed by trypanosomes. 
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APPENDICES 
Appendix A  
Table A.1: PCR mix for Phusion polymerase was prepared in 50 μl as follows: 
10 μl 5X Phusion GC buffer (contains MgCl2; final buffer conc. = 1X)  
2 μl 10mM dNTP (final dNTP conc. 0.2mM)  
2 μl primer 1 (taken from a 10 μM stock solution; 0.5 μM final conc.)  
2 μl primer 2 (taken from a 10 μM stock solution; 0.5 μM final conc.)  
0.5 μl Phusion polymerase  
1 μl genomic DNA (conc. to be 50 to 250 ng/50 μl PCR reaction)   
32.5 μl dH2O 
(Control PCR reaction contained an extra μl of H2O in place of the template) 
 
 
 
Table A.2: The PCR conditions for Phusion polymerase: 
Hot lid On 112 
Temperature step 98°C for 30 seconds  
Cycle starts 35 cycles: 
Temperature step 98°C for 10 seconds  
Temperature step α °C for 20 seconds (α depends on primer) 
Temperature step 72°C for β minutes (β is 30 sec/kb of DNA ofinterest) 
Cycle ends   
Temperature step 72°C for 10 minutes  
Storage: at 10°C 
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Table A.3: PCR mix for Go Taq polymerase was prepared in 20 μl: 
4 μl 5 x Go Taq Reaction buffer  
1 μl 10mM dNTP (final dNTP conc. 0.5mM) 
0.75 μl primer 1 (taken from a 10 μM stock solution) 
0.75 μl primer 2 (taken from a 10 μM stock solution) 
0.2 μl Go Taq polymerase 
13.3 μl dH2O 
Control PCR reaction contained an extra μl of H2O in place of the 
template. 
 
Table A.4: PCR mix for Go Taq polymerase was prepared in 20 μl: 
Hot lid on 112 
Temperature step: 95°C for 3 minutes 
Cycle starts 35 cycles: 
Temperature step 95°C for 30 seconds 
Temperature step 55°C for 30 seconds 
Temperature step 
72°C for 1.5 minutes (1 min/kb of DNA 
of interest) 
Cycle ends   
Temperature step 72°C for 5 minutes  
Storage at 10°C 
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Table A.5: Genes List 
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Appendix B  
Table B.1: Primers used in research methodology in this thesis 
Primer What used for Sequence  
HDK 687 MF7.1 5UTR F TAGCGGCCGCGTCGTTGACATTACGTGG 
HDK 688  MF7.1 5UTR R GCGCTCTAGAGCTTTTCTTCTTCTTTCCG 
HDK 689 MF7.1 3UTR F GCATGCATGAGGGGAAAGTATAATAAAAAG 
HDK 690 MF7.1 3UTR R GCCTCGAGCACCCATTTCAAACACTAATT 
HDK 547 MF 3.1 F ACAAGCTTATGACGCCAGAGGCCTCAACACCATGGAA 
HDK 548 MF 3.1 R GCGGATCCTCATACTTTGTTAAGCAGGGTTTTCTCCTCGTCC 
HDK 833 MF5.2 F 5' UTR GCGGCCGCCGCTTTCGCCCTACTCCTTT 
HDK 834 MF5.2 R 5' UTR TCTAGATCACTACTGTAGTCGAAAA 
HDK 835 MF18.8 F 3' UTR ATGCATCTTTCCTCTCT 
HDK 836 MF18.8 R 3' UTR CTCGAGATCCGTCTCACGAAT 
HDK 944 MF5.2 F 5UTR CGGCGGCCGCGTTGCTGAAACCCTTACAA 
HDK 945 MF5.2 R 5UTR CGTCTAGATCACTACTGTAGTCGAAAAAA 
HDK 945 MF5.2 F 3UTR CGATGCATCTTTCCTCTCTTGAAGGGAT 
HDK 945 MF5.2 R 3UTR CGCTCGAGCGTTTGTTTCTTGAACACG 
HDK 948 MF18.8 5UTR F CGGCGGCCGCGTCGCTCGTGGAAAAAC 
HDK 949 MF18.8 5UTR R CGTCTAGACTTCGGTTGTCAGTGCC 
HDK 950 MF18.8 3UTR F CGATGCATCCTGCAAATTAAGATATACAG 
HDK 951 MF18.8 3UTR R CGCTCGAGCTCTCCTTCCGTGATTATA 
HDK 926 MF5.2 PRE 5' UTR GGGTAACGTAATTATCTCCTCTC 
HDK 927 MF5.2 POST 3' UTR TCTGGTGAGTTTCGATAACAGCCC 
HDK 928 MF18.8 PRE 5' UTR TAGTGTGGGTGGCGTTGATGAGTT 
HDK 929  MF18.8 POST 3' UTR TTGCACTCTCTGTGTTGCCGAATC 
HDK 937 MF7.1 PRE 5' UTR GCCCGTTTTTTCTGTCCGAAAGCAT 
HDK 938 MF7.1 POST 3' UTR GAGGCATTTTGGGATAATTCGGG 
HDK 1029 MF5.2 PRE5' UTR F CACGACTTGCCAAGCACAAGGTGCAAACTTC 
HDK 1030 MF5.2 POST 3' UTR R GGCAGTACGACTCCTGGAGCTCCAACAGTC 
HDK 1031 MF18.8 PRE 5' UTR F CGAGCGAATTTTGGTAGTGTGGGTGGCGTTG 
HDK 1032 MF18.8 POST 3' UTR R CTACACTAAACTGCAGCACCTGTAAGGGCCC 
HDK 1033 MF7.1 PRE 5' UTR F CTTAACTTTCTTTGAACAAAACAAATTAAC 
HDK 1034 MF7.1 POST 3' UTR R TAAAAAAAAAAAATTATGTTTACTCGAGCAC 
HDK 931 MF5.2 XbaI – F FOR CT CGTCTAGAATGTCAGCTGAGGTACAAAG 
HDK 932 MF5.2 BamHI-R FOR CT CGGGATCCAAATACTGGCCTCACTGC 
HDK 1118 MF5.2 FOR qRT-PCR -F GCGATTTCCCGTCACCAA 
HDK 1119 MF5.2 FOR qRT-PCR -R TCCTCTCGAGAAGGCATTGTC 
HDK 1120 MF7.1 FOR qRT-PCR -F GTTTCCCTCCATAACGGCAAT 
HDK 1121 MF7.1 FOR qRT-PCR -R GGTGACAGCCCCAACGAA 
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Primer What used for Sequence  
HDK 1122 MF18.8 FOR qRT-PCR -F TGTCAACGGAGAGAGGGAAGA 
HDK 1123 MF18.8 FOR qRT-PCR -R TCCAAGCGCTCAAGGACATC 
HDK 1394 MF5.2 Gene – Con- F CATTGCCGGTTGTTTAGTCG 
HDK 1395 MF5.2 Gene – Con- R CCATGCGCCGGACATCC 
HDK 1396 MF7.1 Gene – Con- F CGCCGCGAACATTTATGTTG 
HDK 1397 MF7.1 Gene – Con- R CTTGCATGGGAGGTGCC 
HDK 1398 MF18.8 Gene – Con- F CGCCGCTCTTATCGTGG 
HDK 1399 MF18.8 Gene – Con- R CTTTCGAGGATCAGTGGC 
HDK 1440 MF7.1 XBI_F CAGTCTAGAATGCTTCCAAGTTTCACCCG 
HDK 1441 MF7.1 BamHI_R CAGGGATCCTCACATAATCTCAACAAGTTTTGT 
HDK 1442 MF18.8 XBI_F CAGTCTAGAATGATCGCCGACGCGGT 
HDK 1443 MF18.8 BamHI- R CAGGGATCCTCATCTAACTATATAAATTGACAACC 
HDK455  V19CI1.1 qt-pcr F CGAGGCGGATCATTTGCT 
HDK456 V19CI1.1 qt-pcr R GCACAACGGTTCGCACTTC 
HDK457 V24CI2.2 qt-pcr F CGCTCTCGGTATGATGAATGC 
HDK458 V24CI2.2 qt-pcr R CCAGGGCGCCACATACAC 
HDK459 V34CI4.1 qt-pcr F GGACTTCAACGTGGTGCAAA 
HDK460 V34CI4.1 qt-pcr R CAGCCGCTTCCTTCTCTTCA 
HDK461 V44CI5.2 qt-pcr F GATTTCCCATCCCCGACACT 
HDK462 V44CI5.2 qt-pcr R CGGCAGCCTTTTGAGAACA 
HDK463 V54CI7.1 qt-pcr F CTGGCGTTTGGTCGAAGCTA 
HDK464 V54CI7.1 qt-pcr R CATGCAGAATCCAATGATGCA 
HDK465 V59CI8.8 qt-pcr F CTTGGCGTCTTTGTCAGCTTT 
HDK466 V59CI8.8 qt-pcr R CAGTACGCCACCAACAAATAGG 
HDK0535 Forward  CGGACAGGTATCCGGTAAGC 
HDK0713 Reverse ATGCAAGCTAGGCCACACCT 
HDK429 Forward  TTCGAGTTTTTTTTCCTTTT  
Hdk 335 Reverse CGTGGAGCAGCTGAAGGACA  
Hdk 282 Blasticidin forward  CGAA TTCA TGGCCAAGCCTTTGTCT  
Hdk 283  Blasticidin reverse  CGAATTCTTAGCCCTCCCACACATA  
Hdk 284  Neomycin forward  GTTCTCGAGTGCAAGCGGA T  
Hdk 285  Neomycin reverse  CACAA TGCGGTCAAACTGCA  
Hdk 1045  Hygromycin forward  CTATTCCTTTGCCCTCGGACGAGTGCTGAG 
Hdk 1044  Hygromycin revers e  CTGAACTCACCGCGACGTCTGTCGAGAAG 
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Table B.2: Plasmids generated for genetic manipulation of trypanosomes. 
 
 
 
 
 
 
 
Plasmid 
Name 
Description of plasmid  Propose to use in this project  
pHD1336 To do genes expression, 
with PARP promoter  
Over expression of TcoMF 
1.1,2.2,3.1,4.1,5.2,6.3,7.1,18.8 
in B48, ISMR and 
TbrMF3.1,5.2,7.1,18.8 in 
s427WT. 
(Biebinger et 
al., 1997; 
Munday et al., 
2013; Munday 
et al., 2015)  
pRPaGFP
 
 To do gene expression and 
has the Tet-promoter for 
tetracycline induction  
The MF5.2 plasmid was 
transfected into the TbrMF5.2-
/- to integrate into the tubulin 
locus making a TbrMF5.2-/--
TcoMF5.2e  
(Alsford et al., 
2005)  
pGL2084 For RNAi To generate a loop that will 
interfere with the expression 
on the TbrMF5.2 
(TbrMF5.2RNAi) 
(Jones et al., 
2014). 
PGL2308-C-
Terminal 
This is a c-terminal 6x 
hemmaglutinin (HA) tagged 
6xHA tag was added to the C-
terminus of TcoMF5.2, 7.1 and 
18.8 expressed in B48 
(TcoMF6HA) 
Donated from 
Jeremy 
Mottram 
group. 
 
MB95  The plasmid was used to 
knockout the gene and 
replaced with blasticidin 
resistance marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
based on 
pTBT (Cross 
et al., 2002),  
MB96  The plasmid was used to 
knockout the gene and 
replaced with hygromycin 
as a resistance marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
based on 
pTBT (Cross 
et al., 2002), 
MB97  The plasmid was used to 
knockout the gene and 
replaced with neomycin as 
a resistance marker  
Delete the MF5.2,7.1 and18.8 
from T. brucei WT s427. 
TbrMF+/- and TbrMF-/- 
 
based on 
pTBT (Cross 
et al., 2002), 
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Table B.3: Cell lines made generated from genetic manipulation of trypanosomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Plasmid source Cell line created 
TcoMF 1.1,2.2,3.1, 
4.1,5.2,6.3,7.1,18.8  
pHD1336  B48 TcoMFoe, ISMRTcoMFoe 
TcoMF 5.2,7.1,18.8 pHD1336 WT s427 TcoMFoe 
TcoMF 5.2,7.1,18.8 PGL2308-C- 
Terminal 
WT s427 TcoMF6HA 
TbrMFs,7.1,18.8 MB95 H MB96 B 
MB97 N 
TbrMF-/- 
 TbrMF5.2 MB95 
MB96 
MB97 
TbrMF5.2+/- 
TbrMF5.2    
 
MB95 
MB96 
MB97 
TbrMF5.2+/- 
TcoMF5.2    pRPaGFP TbrMF5.2-/--TcoMF5.2e 
TbrMF5.2 
 
MB95 
MB96 
MB97 
TbrMF5.2-/- 
TbrMF5.2 pGL2084  TbrMF5.2RNAi 
TcoMF7.1 pHD1336 TbrMF7.1-/-- TcoMF7.1e 
TbrMF5.2 MB95 
MB96 
MB97 
TbrMF7.1-/-- TbrMF5.2-/- 
TbrMF 7.1 MB95 
MB96 
MB97 
TbrMF18.8-/-- TbrMF7.1-/- 
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Appendix C  
C.1: Making of competent cells for transformation 
 
Keep the cells as cold as possible throughout this procedure, to ensure the cells are as 
competent as possible. 
 
• Streak out E. coli XL-1 blue cells on a LB agar plate containing 10 µg/ml tetracycline. 
• Incubate overnight at 37°C. 
• Use one colony to inoculate 5 ml of LB broth with 10 µg/ml tetracycline. Incubate 
overnight at 37°C. 
• Dilute overnight culture 1:100 in LB broth to give 200 ml of culture. 
Grow at 37°C until OD=0.6 (at 600 nm). 
• Transfer cells to 50 ml tubes and incubate on ice for 15 min. 
• Centrifuge at 2000 rpm for 15 min at 4°C. 
• Resuspend cell pellets in 16 ml of RF1 buffer / 50 ml pellet. Resuspend by slow 
vortexing and incubate on ice for 15 min. 
• Centrifuge the suspension for 15 min at 1800 rpm at 4°C. 
• Resuspend cell pellet, with careful pipetting, in 4 ml of RF2 (per original 50 ml). 
Incubate on ice for 1 hour (no precision required). 
• Aliquot heat-shock competent cells and deep-freeze with dry ice. 
• Store aliquots at -80°C. Don’t refreeze aliquots once defrosted. 
 
 
RF1 buffer 
      For 1 litre   For 100 ml 
100 mM rubidium chloride   12 g    1.2 g 
50 mM MnCl2.4H2O    9.9 g    0.99 g 
30 mM potassium acetate   30 ml of 1 M stock  0.293 g 
10 mM calcium chloride   1.5 g    0.15 g 
15% glycerol     150 ml   15 ml 
 
pH to 5.8, adjusted with 0.2 M acetic acid. 
Do this very carefully, as rubidium chloride precipitates easily if pH too low. 
Filter sterilise. Store at 4°C 
 
 
RF2 buffer 
      For 1 litre:   For 100 ml 
 
10 mM MOPS pH 6.8   20 ml of 0.5 M stock  2 ml of 0.5 M stock 
10 mM rubidium chloride   1.2 g    0.12 g 
75 mM calcium chloride   11 g    1.1 g 
15% glycerol     150 ml   15 ml 
 
pH to 6.8, adjusted with NaOH. 
Filter sterilise. Store at 4°C 
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